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Protein misfolding diseases (PMDs) are a broad group of disorders including 
Alzheimer’s, Parkinson’s and prion diseases. They are characterised by the presence 
of aggregated, misfolded host proteins which are thought to cause cell death.  
Prion diseases are associated with misfolded prion protein (PrPSc), which has a 
tendency to form fibrillar aggregates. By contrast, Alzheimer’s disease (AD) is 
associated with misfolded amyloid beta (Aβ), which aggregates to form 
characteristic Aβ plaques. A feature which is common across PMDs is that small 
assemblies (oligomers) of the misfolded proteins are thought to be the important 
neurotoxic species, and it has been proposed that there may be a shared mechanism 
leading to cell death across PMDs caused by oligomers.  
In this study, the toxicity of different misfolded forms of recombinant PrP (recPrP) 
and recombinant Aβ (recAβ) and the mechanisms leading to cell death were 
investigated using a primary cell culture model. In addition, the importance of the 
disulphide bond in recPrP in relation to oligomer formation was explored using size 
exclusion chromatography and mass spectrometry, the toxicity of the different 
resulting oligomer populations were also investigated. 
Both recPrP oligomers and fibrils were shown to cause toxicity to mouse primary 
cortical neurons. Interestingly, oligomers were shown to cause apoptotic cell death, 
while the fibrils did not, suggesting the activation of different pathways. By 
contrast, recAβ fibrils were shown to be non-toxic to cortical neurons, Aβ oligomers, 
however, were shown to cause toxicity. Similar to recPrP, my data showed that it is 
likely that recAβ 1-42 oligomers also cause apoptosis. However, by contrast this 
seemed to be caused by excitotoxicity, which was not found to be the case for 
recPrP. Additionally, I have shown that the presence or absence of the disulphide 
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bond in PrP has a profound effect on the size of oligomers which form. RecPrP 
lacking a disulphide bond leads to the formation of larger oligomers which are 
highly toxic to primary neurons.  
Findings from this study suggest that structural properties such as the disulphide 
bond in PrP can affect the size and toxicity of oligomers, furthermore, whilst 
oligomers have been shown to be important in both AD and prion diseases, they 





Diseases such as Alzheimer’s (AD) are prevalent in the modern world and put a 
large economic and social burden on society. There are currently no effective 
treatments for diseases such as AD, therefore, research into understanding these 
diseases is imperative for developing therapies.  
AD falls into a group of disorders known as protein misfolding diseases (PMDs).  
As well as AD, this group of diseases includes Parkinson’s disease, Amyotrophic 
lateral sclerosis and prion diseases. All of these disorders are caused by proteins 
found in the body, which ordinarily carry out a variety of functions. However, for 
reasons largely unknown these proteins can misfold into an abnormal structure, 
which not only stops them from carrying out their normal functions but can also be 
toxic. These toxic proteins have a tendency to clump together and form large 
structures known as plaques, which are commonly seen in the brains of individuals 
affected by these diseases. Additionally, they can form much smaller assemblies 
often referred to as oligomers. Therefore, while the PMDs mentioned previously are 
caused by different proteins, once the proteins have misfolded they can behave in a 
similar manner. This has led to the theory that there may be a common toxic 
structure formed by misfolded proteins, which may cause toxicity and death to cells 
in the brain by activating common pathways.   
In this study I have investigated which misfolded structures are the most toxic, and 
how they cause toxicity. To do this, I have produced proteins known to be involved 
in AD and prion diseases and refolded them into different conformations to try and 
mimic those seen in disease. I have then tested the toxicity of these proteins using 
neuronal cells; a type of cell found in the brain. Additionally I have investigated 
how the misfolded proteins cause toxicity, in the hope that if we can understand 
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which pathways are activated by these proteins then blocking them may lead to 
successful treatments.   
I found that the small assemblies formed from either the Alzheimer’s protein or the 
prion protein were toxic to neurons. However, it seemed that they may not be 
activating the same pathways. This may mean that therapies developed for one 
PMD may not be effective in treating other PMDs. Furthermore, I found that large 
aggregates of the misfolded proteins were not comparatively toxic. Large aggregates 
of the prion protein were found to be extremely toxic to neurons; however, large 
aggregates of the Alzheimer’s protein were not shown to cause any toxicity. This 
may suggest the end stage of the misfolding process, which is thought to be the 
large insoluble aggregates, may play different roles in different diseases. In prion 
diseases the large aggregates may contribute to toxicity and cell death, while in AD 
formation of the large aggregates may be a protective mechanism to sequester the 
smaller more toxic protein assemblies.  
The data from this study would suggest that while there are many similarities 
between PMDs, it is also likely that there are some important differences which may 
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1.1 Protein misfolding diseases (PMDs) 
 
1.1.1 What are protein misfolding diseases and why study them? 
Protein misfolding diseases (PMDs) are a broad group of disorders that are 
characterised by the misfolding of native host proteins. Once misfolded these 
proteins are prone to accumulation and aggregation, leading to the cellular toxicity 
seen in these diseases. Well characterised PMDs include Alzheimer’s (AD), 
Parkinson’s, Huntington’s and prion disease. The impact of PMDs on society today 
is huge, with an estimated 25 million people suffering from AD (Mancuso and 
Gaetani, 2014) worldwide and between 7-10 million with Parkinson’s disease 
(Bhimani, 2014). The prevalence of both these diseases is set to more than double by 
2030 and this is not accounting for the large number of other PMDs. This is a 
massive problem facing both the western and developing world, since it will cause 
both an economic burden to society and an emotional burden for family and friends 
of those affected. Therefore, it is imperative to better understand the disease 
mechanisms of PMDs in the hope that effective treatments may be developed.  
The misfolded proteins associated with PMDs, for example the prion protein (PrP) 
in prion diseases, and amyloid-β (Aβ) in AD, are prone to aggregation leading to 
the formation of large insoluble fibrillar aggregates (Bucciantini et al., 2002, 
Caughey and Lansbury, 2003, Knowles et al., 2014, Braak et al., 2003). For many 
years it was thought that these aggregates caused the neurodegeneration seen in 
these diseases, however, in more recent years it has been suggested that it is 
intermediates during the aggregation process which cause neuronal toxicity (Kuo et 
al., 1996, Lue et al., 1999, Naslund et al., 2000, McLean et al., 1999, Mucke et al., 
2000a, Walsh et al., 2002, Quist et al., 2005, Kristiansen et al., 2007, Simoneau et al., 
2007, Volles et al., 2001). Small soluble assemblies composed of the misfolded 
protein, often termed oligomers, which have a high β-sheet content have repeatedly 
been found to be neurotoxic in many PMDs (Kuo et al., 1996, Lue et al., 1999, 
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McLean et al., 1999, Mucke et al., 2000a, Walsh et al., 2002, Quist et al., 2005, 
Kristiansen et al., 2007, Simoneau et al., 2007, Volles et al., 2001, Winner et al., 2011, 
Caughey and Lansbury, 2003, Zhang et al., 2010, Kayed et al., 2003, Bucciantini et 
al., 2002). Evidence for this has come from many types of studies, including those 
which have used human tissue, animal models or in vitro cell systems. Studies 
which have used human tissue have correlated the presence of soluble Aβ 
oligomers with disease and found the concentration of soluble Aβ to be significantly 
higher in AD patients’ brains than in age matched controls (McLean et al., 1999, Lue 
et al., 1999, Kuo et al., 1996). Studies using animal models have allowed the toxicity 
of oligomers and fibrils to be tested directly, rather than looking at correlations 
between concentration of oligomers and severity of disease in humans. These 
studies have shown that Aβ oligomers are highly toxic in vivo, which supports the 
findings from human studies (Mucke et al., 2000b, Walsh et al., 2002, Winner et al., 
2011). Additionally, many studies have shown oligomers to be cytotoxic using in 
vitro systems. These studies have directly tested the toxicity of different 
conformations of misfolded proteins, including Aβ, PrP and α-synuclein 
(Kristiansen et al., 2007, Volles et al., 2001, Zhang et al., 2010, Kayed et al., 2003, 
Bucciantini et al., 2002). The combined evidence from a wide array of studies, which 
suggest that oligomers are the important toxic species in PMDs, is very compelling. 
Furthermore, this has led to the hypothesis that oligomeric forms of misfolded 
proteins may induce similar mechanisms of toxicity across PMDs (Glabe, 2006, 
Kayed et al., 2003, Haass and Selkoe, 2007, Quist et al., 2005).  
 
1.1.2 Transmissible spongiform encephalopathy (prion disease) 
Prion diseases are a group of fatal neurodegenerative disorders, which affect a 
variety of mammals. They are also known as the transmissible spongiform 
encephalopathies (TSEs) (Collinge, 2001). Well characterised TSEs include bovine 
spongiform encephalopathy (BSE) in cattle (Hope et al., 1988), scrapie in sheep and 
goats (Greig, 1950, Parry, 1962, Brotherston et al., 1968) and chronic wasting disease 
4 
 
in deer and elk (Williams and Young, 1980, Williams and Miller, 2002). In addition, 
kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker (GSS) 
disease and fatal familial insomnia (FFI) affect humans (Collins et al., 2001, 
Goldgaber et al., 1989). At post-mortem, prion-infected brains of humans and other 
mammals have spongiform degeneration in addition to astrocytic gliosis (Prusiner, 
1998b). According to the protein-only hypothesis, prion disease is caused by 
misfolding of the normal cellular prion protein (PrPC) to a conformationally 
different species referred to as PrPSc. This form is prone to aggregation and is likely 
to represent the cause of neuronal toxicity and cell death seen in prion diseases 
(Prusiner et al., 1998, Prusiner, 1998a, Prusiner, 1998b, Wang et al., 2010). This will 
be discussed further in section 1.2.1. 
 
1.1.2.1 Animal prion diseases 
The most well studied animal prion disease is scrapie, which affects sheep and 
goats. Scrapie has been endemic in the UK sheep flock for over 200 years (Greig, 
1950); symptoms include pruritus and progressive ataxia (Greig, 1950). However, it 
wasn’t until the 1960’s that it was recognised as a prion disease when similarities 
were drawn between scrapie and kuru, a human prion disease (discussed in section 
1.1.3.3). The first inoculation of scrapie into a mouse model was in 1961, when 
infected brain from a scrapie infected sheep was inoculated into a mouse and found 
to cause neurodegeneration (Chandler, 1961). Histological analysis of the mouse 
showed vacuolation, resembling that seen in sheep with scrapie(Chandler, 1961). 
This showed that the agent causing scrapie was transmissible to other species.  
In the 1980’s a new form of prion disease emerged, which affected approximately 
170,000 cattle (Pattison, 1998). This prion disease, referred to as BSE, was traced back 
to the consumption of contaminated food stuffs, which contained meat and bone 
meal (MBM) (Pattison, 1998). The banning of MBM in animal feed in 1988, led to a 
rapid decline in the number of cases (Pattison, 1998). The outbreak of BSE also led to 
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the emergence of a new human prion disease, variant CJD, which will be discussed 
further in section 1.1.2.3. Symptoms of cattle affected with BSE include nervousness, 
heightened reactivity and difficulty moving (Pattison, 1998). Vacuolation and 
astrocytosis is seen in the brains of cattle affected with BSE(Bradley, 1991). 
Another important animal prion disease is chronic wasting disease (CWD), which 
affects deer, elk and moose (Baeten et al., 2007, Williams et al., 2002). CWD is the 
only known prion disease to affect free-ranging animals, it has been endemic in 
Northern America for over 20 years but the prevalence has increased over the last 
decade (Williams et al., 2002). CWD is thought to be transmitted between deer and 
elk in the environment through saliva, faeces and other bodily fluids (Mathiason et 
al., 2006, Safar et al., 2008). It is not yet known whether CWD poses a threat to 
humans, but evidence so far suggests that the risk to humans is low (Race et al., 
2014, Kong et al., 2005).  
Genetic variations within the Prnp gene can increase susceptibility or resistance to 
prion disease. This has been extensively investigated in sheep and it has been 
shown that polymorphisms found at codons 136, 154 and 171 are important in 
dictating susceptibility to scrapie(Elsen et al., 1999, Baylis et al., 2004). Sheep which 
are homozygous for alanine at codon 136 and are homozygous for arginine at codon 
154 and 171 (known as ARR genotype) show resistance to scrapie, alternatively, 
those who are homozygous for valine at codon 136, homozygous for arginine at 
codon 154 and homozygous for glutamine at 171 (VRQ) are highly susceptible to 
scrapie (Elsen et al., 1999, Baylis et al., 2004). Understanding which genotypes are 
more resistant to scrapie means that sheep can be selectively bred for resistance.  
Back in the early 2000s a new type of scrapie was discovered, which was termed 
atypical scrapie (Saunders et al., 2006). Atypical scrapie cases tested positive in a 
standard immunoassay but they were negative when analysed for 
immunohistochemistry(Saunders et al., 2006). It is now possible to confirm atypical 
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cases by immunohistochemistry and it seems that it is a novel strain of the disease 
(Saunders et al., 2006). The polymorphisms within the Prnp gene which confer 
susceptibility to classical scrapie vary for atypical scrapie. For atypical scrapie a 
homozygous or heterozygous combination of ARR, ARQ or AHQ seems to confer 
susceptibility, however, the most susceptible genotype is conferred by 
phenylalanine (F) at position 141 (AF141RQ)(Saunders et al., 2006, Gesine et al., 2007).  
 
1.1.2.2 Familial human prion diseases 
The prion protein in humans is encoded by the PRNP gene; familial or genetic forms 
of human prion disease are caused by mutations in this gene. These include familial 
CJD, GSS disease and FFI (Collins et al., 2001, Goldgaber et al., 1989). They are 
associated with approximately 37 point mutations in the PRNP gene (Rossetti et al., 
2011) and are inherited in an autosomal-dominant manner. The mutations all result 
in the production of misfolded PrP, which accumulates in the brain. Common 
symptoms include rapidly progressive dementia (Ironside et al., 2005), ataxia 
(Collinge, 2001) and a short clinical phase (Ironside et al., 2005, Collinge, 2001). 
However, symptoms vary widely depending on the causative mutation(Collinge, 
2001, Gambetti et al., 2003).  
Whilst prion diseases are associated with a short clinical phase, relative to other 
PMDs, the incubation period or pre-clinical phase is long, often lasting for decades 
(Imran and Mahmood, 2011). A polymorphism found at codon 129 in the PRNP 
gene, in which an individual can have a methionine or a valine residue, can alter the 
phenotype of many prion diseases. For example, a person with the D178N mutation 
will have FFI if this is combined with a methionine residue at codon 129, and those 
who are homozygous for methionine generally have more severe symptoms (Imran 
and Mahmood, 2011). However, if a person has the D178N mutation and they are 
homozygous for valine at the 129 codon then they present with a familial CJD 
phenotype (Imran and Mahmood, 2011). The presentation of prion disease causing 
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mutations vary geographically (Kovács et al., 2005). More common mutations such 
as the E200K mutation are found in most countries, however, others are only found 
in specific communities (Kovács et al., 2005). Genetic forms of prion disease account 
for only 10-15 %(Mastrianni, 2010, Prusiner and Hsiao, 1994) of cases the remaining 
85-90% are sporadic or acquired forms of the disease, with the majority being 
sporadic(Mastrianni, 2010).  
 
1.1.2.3 Sporadic and acquired forms of human prion disease 
Sporadic forms of prion disease are the most common with sporadic CJD (sCJD) 
being most prevalent (Imran and Mahmood, 2011). However, with that said, sCJD is 
still very rare, with 1-2 in a million cases per year(Imran and Mahmood, 2011, Mead 
et al., 2003). Sporadic prion diseases, like genetic prion diseases, are associated with 
the production of PrPSc in the brain (Prusiner and Hsiao, 1994). The cause of 
sporadic prion disease is still unknown, with a spontaneous event leading to the 
production of pathogenic PrPSc (Prusiner and Hsiao, 1994).  
Acquired forms of human prion disease include variant CJD (vCJD), iatrogenic CJD 
(iCJD) and Kuru. The BSE crisis in the 1980s was linked to the emergence of a new 
human prion disease, vCJD, first described in the mid-1990s (Will, 2003). It was 
traced to the consumption of beef products contaminated with BSE (Will, 2003). At 
the height of the crisis many thousands of people were thought potentially to be 
infected (Will, 2003). To date, only 177 cases in the UK actually presented with the 
disease (Diack et al., 2014). Susceptibility to vCJD is also affected by the 129 codon, 
with almost all cases of vCJD having the 129MM genotype (Diack et al., 2014). 
 In addition to vCJD, prion infection has also been passed on through the use of 
contaminated surgical equipment (Belay et al., 2013), blood transfusion 
(McCutcheon et al., 2011, Llewelyn et al., 2004, Peden et al., 2004, Head et al., 2009), 
dura matter grafts (Brown et al., 2000, Thadani et al., 1988) and contaminated 
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human growth hormone (hGH) (Will, 2003, Brown et al., 2000, de Villemeur et al., 
1994). However only vCJD and Kuru are systemic infections, caused by oral 
consumption and prion infection throughout the lymph system, and therefore 
present a risk for passing on the infection by blood transfusion. The sporadic event 
which causes sCJD occurs in the brain and the misfolded protein is therefore not 
present throughout the body, meaning it could not be transmitted by blood. vCJD 
and sCJD could both potentially be transmissible through surgical procedures if the 
surgical equipment came into contact with infected tissue (the brain in sCJD)(Will, 
2003, Head et al., 2009, de Villemeur et al., 1994). It is possible to transmit prions by 
surgical equipment, since prions are resistant to normal surgical sterilisation 
procedures (Belay et al., 2013). In the case of hGH, before the advent of recombinant 
hGH, it was derived from the pituitary gland of cadavers (de Villemeur et al., 1994). 
One cadaver could provide the hormone for many recipients; it is thought that one 
or more of the cadavers used must have had a prion infection, which resulted in 
over 100 people acquiring iCJD (Will, 2003, de Villemeur et al., 1994).  
Kuru was a prion disease discovered in the 1950s in the Fore tribe of Papua New 
Guinea (Mead et al., 2003, Collinge et al., 2006). This population of people were 
isolated from the wider population and still practiced cannibalistic rituals, which 
were thought to be the cause of the widespread prion infection present in the tribe 
(Mead et al., 2003). It was thought that at some point in the past a member of the 
tribe had developed a prion infection, which was passed on through the 
cannibalistic rituals (Mead et al., 2003). The individuals which consumed the 
infected brain then developed prion disease often decades later and the process 
would have then been repeated, with their remains consumed by members of the 
tribe (Collinge et al., 2006). Those with the 129MM genotype were found to have 
shorter incubation periods than those who were heterozygous (Mead et al., 2003, 
Collinge et al., 2006). This is a characteristic example of how prion disease can be 




1.1.3 Alzheimer’s disease  
AD is a fatal neurodegenerative disorder of humans. Clinical symptoms tend to 
include progressive memory loss, confusion and changes in mood and personality 
(Selkoe, 2001). Pathologically, AD is characterised by atrophy of certain areas of the 
brain, particularly the cortex and hippocampus (Braak and Braak, 1991, Thal et al., 
2002). Within these regions extracellular senile plaques are found, which are 
comprised of aggregates of Aβ. Aβ is a small peptide formed from the processing of 
the amyloid precursor protein (APP, see section 1.2.2). Additionally, neurofibrillary 
tangles (NFT) made up of hyperphosphorylated tau (Braak and Braak, 1991, Thal et 
al., 2002, Selkoe, 2001) are found intracellularly. For many years it was thought that 
Aβ plaques were causing the cellular toxicity and cell death seen in AD. However, it 
was noted that plaque density did not correlate with cognitive impairment, and so 
was perhaps not the sole cause of neuronal loss (Selkoe, 2001, Hardy and Selkoe, 
2002). During the process of plaque deposition Aβ likely exists as smaller 
assemblies, or oligomers, which are thought to be important in causing toxicity. Aβ 
is formed by processing of the APP, which is cleaved by either α- or β-secretase. If it 
is cleaved by β-secretase then cleavage by the γ-secretase complex will follow, 
giving rise to Aβ peptides. The γ-secretase complex includes presenilin proteins; 
mutations in presenilin genes can cause genetic forms of AD (Borchelt et al., 1996, 
Price et al., 1998, Shepherd et al., 2009) (see section 1.1.3.1), the γ-secretase complex 
can cleave the APP at multiple sites, giving rise to Aβ peptides of varying length 
(for further details of Aβ formation and APP processing see section 1.2.2.1). The 
most common forms of Aβ tend to terminate at either Val40 or Ala42 giving rise to 
two main forms known as Aβ 1-40 and Aβ 1-42. The latter fragment has been shown 
to be more neurotoxic and prone to aggregation, however, the presence of both Aβ 
1-40 and Aβ 1-42 in a soluble form correlates more closely with the degree of 
cognitive decline than the number of senile plaques (Hardy and Selkoe, 2002, 
Naslund et al., 2000). The Aβ cascade hypothesis, which speculates that misfolded 
Aβ is the cause of AD, is the most extensively studied theory behind what causes 
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the neuronal loss seen in AD (Hardy and Higgins, 1992). Other theories include the 
importance of tau in causing toxicity in AD (Mandelkow and Mandelkow, 1998), 
since NFT deposits correlate better with the severity of AD symptoms than Aβ 
plaques (Treusch et al., 2009). However, it is thought that Aβ deposition precedes 
NFT formation (Hardy and Selkoe, 2002). 
 
1.1.3.1 Familial forms of Alzheimer’s disease 
Approximately 5 % of AD cases are caused by autosomal dominant mutations (Price 
et al., 1998). These mutations tend to occur in either the APP gene, in presenilin 1 
(PSEN1) or presenilin 2 (PSEN2) (Price et al., 1998). Mutations in the PSEN genes are 
the most common cause of familial AD (Kumar-Singh et al., 2006) (FAD), with 
mutations in PSEN1 accounting for 18-50% of FAD (Rogaeva et al., 2001, Cruts and 
Van Broeckhoven, 1998). Mutations in the APP gene are thought to affect the 
cleavage of APP and increase the production of Aβ (Price et al., 1998, Shepherd et 
al., 2009, Tamaoka et al., 1994) (see Aβ processing in section 1.2.2.1). The presenilin 
genes encode subunits of the γ-secretase protein complex, which cleaves APP. 
Mutations in these genes lead to increased production of Aβ 1-42 (Borchelt et al., 
1996, Price et al., 1998, Shepherd et al., 2009). FAD tends to be early onset (before the 
age of 60) and often clinical signs occur when an individual is in their 40’s or 50’s 
(Price et al., 1998, Shepherd et al., 2009). Once clinical symptoms develop they are 
similar to those of late onset AD (Price et al., 1998). The pathology of FAD is similar 
to that of late-onset AD, but in FAD there is a higher concentration of plaques and 
soluble Aβ made up of Aβ 1-42 (Shepherd et al., 2009, Tamaoka et al., 1994, Kumar-
Singh et al., 2006).  
 
1.1.3.2 Late onset Alzheimer’s disease 
Late onset AD (LOAD) is the most common cause of dementia worldwide, 
accounting for 60-80% of cases (Barnes and Yaffe, 2011). Like FAD, LOAD is 
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associated with Aβ plaques and NFT. LOAD differs from FAD in several ways, 
clinical onset occurs in people over the age of 65 and the incidence increases with 
increasing age (Naj et al., 2014, Fratiglioni et al., 1999). LOAD is a genetically 
complex disease and while there are polymorphisms that convey an increased or 
decreased risk of LOAD, the disease does not follow a Mendelian pattern of 
inheritance. The biggest genetic risk factor for LOAD is the apolipoprotein E (apoE) 
ε4 allele, which is found on chromosome 19 and has been shown to increase the 
chances of developing LOAD (Corder et al., 1993). Those with no ε4 allele have a 20 
% risk of developing LOAD, one ε4 allele increases that risk to 47 % and with two ε4 
alleles the risk goes up to 90 % (Corder et al., 1993). This means that those who are 
homozygous for the ε4 allele have an 8-fold increased risk of developing LOAD by 
the time they are 80 (Corder et al., 1993). The presence of the ε4 allele also decreases 
the age of onset in LOAD, with the average age decreasing to 68 with two copies as 
opposed to 84 with no ε4 allele (Corder et al., 1993).  
In recent years, with the advent of genome wide association studies, which allow 
millions of single nucleotide polymorphisms (SNPs) to be screened and compared 
between healthy individuals and those with LOAD, polymorphisms in many genes 
have been uncovered which are associated with the disease. These include: BIN1, 
PICALM and clusterin (Hu et al., 2011, Wijsman et al., 2011, Harold et al., 2009, 
Carrasquillo et al., 2010). At the present time it is difficult to predict whether an 
individual will develop LOAD before the onset of clinical symptoms. However, in 
the future it is possible that a panel of polymorphisms that increase the risk of 
developing LOAD will be able to highlight at risk individuals.  
In addition to genetic risk factors, there are also various environmental factors 
which have been shown to increase the chances of an individual developing LOAD. 
These include smoking, obesity and lack of physical activity (Scarmeas et al., 2009, 
Barnes and Yaffe, 2011, Luchsinger et al., 2012). Those who made healthy life style 
choices, such as a Mediterranean-style diet, had a decreased risk of LOAD 
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(Scarmeas et al., 2009, Devanand et al., 2013). When this was combined with regular 
physical activity the risk of LOAD decreased further (Scarmeas et al., 2009, 
Devanand et al., 2013). Additionally, it has been shown that individuals with higher 
intelligence have a decreased risk of LOAD (Devanand et al., 2013).  
 
1.1.4 Commonalities between PMDs 
In the past, diseases such as AD, Parkinson’s, Huntington’s and prion disease were 
all thought to be distinct neurodegenerative conditions. However, once it was 
established that they all were caused by misfolded proteins, similarities between 
them became more apparent. The important toxic species in these diseases is 
thought to be soluble oligomeric forms of misfolded protein, which may cause 
toxicity by a variety of mechanisms (Kuo et al., 1996, Lue et al., 1999, Naslund et al., 
2000, McLean et al., 1999, Mucke et al., 2000a, Walsh et al., 2002, Quist et al., 2005, 
Kristiansen et al., 2007, Simoneau et al., 2007, Volles et al., 2001). It is possible that 
pathways activated by oligomeric forms of these misfolded proteins may be the 
common link between PMDs (Glabe, 2006, Kayed et al., 2003, Haass and Selkoe, 
2007, Quist et al., 2005). 
The transmissible nature of prion disease has set it apart from other PMDs, 
however, these difference may be less defined than first thought. There have been 
studies which show injection of Aβ into the brains of rhesus monkeys (Ridley et al., 
2006) or transgenic mice (Kane et al., 2000, Walker et al., 2002) causes Aβ plaque 
deposition, showing that injection of Aβ may accelerate the process of Aβ 
accumulation (Aizenstein et al., 2008). Prion disease is likely to be the only PMD 
that is truly transmissible through an oral route or in the environment, but the 
disease progression and spread within an organism may be “prion like” in other 
PMDs (Guo and Lee, 2014, Luk et al., 2009, Danzer et al., 2009, Clavaguera et al., 
2009, Masuda-Suzukake et al., 2013). Seeds of misfolded proteins have been shown 
to recruit normal protein and, through a templating process, convert the normal 
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protein to a misfolded form (Guo and Lee, 2014). In transgenic AD mice, injected Aβ 
can be seen to spread between axonally connected regions in a “prion like” manner 
(Jucker and Walker, 2011). Additionally, in non-transgenic mice after intrastriatal 
inoculation of synthetic α synuclein fibrils, cell to cell transmission was seen 
accompanied by Parkinson’s-like pathology in interconnected brain areas including 
Lewy body deposition, loss of substantia nigra neurons and impaired motor 
coordination (Luk et al., 2012). Tau has also been shown to spread by similar 
mechanisms, with injection of tau fibrils into wild type tau expressing mice 
resulting in fibrillar deposition and spread to other brain regions (Clavaguera et al., 
2009). All these studies demonstrate that misfolded proteins likely propagate 
themselves by a similar process and spread throughout the brain by related 
mechanisms.  
1.2. Proteins associated with PMDs 
 
1.2.1 The prion protein 
 
1.2.1.1 PrPC structure and function 
PrPC is a ubiquitously expressed, membrane- bound glycoprotein (Millhauser, 2007). 
It is located on the outside of the cellular membrane where it is attached by a 
glycosylphosphatidylinositol (GPI) anchor via its C-terminus (Millhauser, 2007). The 
C-terminal region in PrPC has a globular structure consisting mainly of α- helices 
with just one two stranded β-sheet and a disulphide bond (Millhauser, 2007) (figure 
1.1). The N-terminal region, conversely, is largely unstructured in solution but has 
an octarepeat domain, which consists of tandem repeats of the sequence 
PHGGGWGQ. Most mammals have four or five repeats of this sequence 
(Millhauser, 2007).  
14 
 
The exact function of PrPC is still to be determined. It was thought that by knocking 
out PrPC, clues to its function may be uncovered. However, PrP0/0 null mice have no 
overt phenotype, although disturbances in circadian rhythms (Tobler et al., 1996, 
Tobler et al., 1997) have been noted along with a potential role in modulating 
neuronal excitability (Maglio et al., 2006, Maglio et al., 2004, Mallucci et al., 2002, 
Curtis et al., 2003), additionally, PrPC has been shown to be important in 
maintaining the integrity of peripheral myelin sheaths (Bremer et al., 2010). The 
subtle phenotypes associated with PrP0/0 null mice suggest that PrPC may have 
various roles possibly associated with neuroprotection. Furthermore, other studies 
have shown PrPC to be involved with cellular signalling or apoptosis (Westergard et 
al., 2007, Roucou and LeBlanc, 2005, Petrakis and Sklaviadis, 2006, Caetano et al., 
2008). The octarepeat domain in PrPC is highly conserved between species, 
therefore, probably has an important functional role; it has been shown to bind 
copper ions and there is some evidence to suggest it plays a neuroprotective 







Figure 1.1 Schematic diagrams of PrPC  
A) Ribbon diagram of human PrP, residues 120-230, courtesy of AC Gill. The 
disulphide bond is shown in purple and is highlighted by the green arrow. The blue 
residues show Asn180 and Asn196 where glycans would be attached. B) Schematic 
of the domains found in PrPC, from Millhauser el al (Millhauser, 2007).  
 
1.2.1.2 Processing of PrPC in the cell 
Since PrPC is located on the cell surface, it is expressed as part of the secretory 
pathway. As such, PrPC is translated on ribosomes attached to the endoplasmic 
reticulum (ER). The ER has a high concentration of chaperone proteins to assist in 
folding proteins into their correct tertiary structure (Kleizen and Braakman, 2004). 
This includes oxidising components to support disulphide bond formation (Kleizen 
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and Braakman, 2004), which is an important component of PrPC (the importance of 
the disulphide bond will be discussed in chapter 5). Other post-translational 
modifications to PrPC are also made, such as cleavage of the N-terminal signal 
peptide (Harris, 2003), attachment of the GPI anchor and addition of core N-linked 
glycans to residues 180 and 196 in the murine amino acid sequence (Wiseman et al., 
2005). In vivo, the site of glycan occupancy is variable; the protein can be un-, mono- 
or di- glycosylated. The glycosylation is thought to be important for stability of the 
protein but as yet it has not been proven to play a causative role in conversion of 
PrPC to PrPSc, or in propagation of PrPSc (Wiseman et al., 2005, Tuzi et al., 2008). 
Following on from the modifications made in the ER, the protein is transported to 
the Golgi apparatus where the N-linked glycans are modified to contain sialic 
acid(Harris, 2003). PrPC relocates to the cell membrane once it leaves the Golgi and 
then cycles continuously between the plasma membrane and endocytic 
compartments (Harris, 2003), this may be an important mechanism during 
conversion of PrPC to PrPSc.  
 
1.2.1.3 Conversion of PrPC to PrPSc 
The disease-associated form of PrP, namely PrPSc, is produced when PrPC undergoes 
a conformational change, leading to a tertiary structure where the mainly α-helical 
conformation of PrPC, is replaced by a structure consisting principally of β-sheets 
(Pan et al., 1993). PrPC is soluble in mild detergents and is completely digested by 
proteinase K, however, PrPSc is only partially digested, with the main site of 
cleavage being around residue 90 leaving the C-terminal region intact (Hayashi et 
al., 2005, Kocisko et al., 1995). This protease resistant region is very difficult to 
degrade, methods used for destroying nucleic acids fail to have any effect on PrPSc 
concentration and infectivity (Alper et al., 1967, Giles et al., 2008, Peretz et al., 2006). 
Interestingly, the presence of PrPC is needed to propagate prion disease since PrP 0/0 
null mice are resistant to prion infection (Bueler et al., 1993, Weissmann, 2004). By 
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mechanisms largely unknown PrPSc seems to “replicate” by converting PrPC into the 
misfolded conformation and so without PrPC the disease cannot occur.  
So far misfolded recombinant PrP (recPrP) alone has not been sufficient to cause 
disease in wild type animals. However, recombinant prions which were first 
refolded into amyloid or β-sheet rich structures have caused disease in transgenic 
mice overexpressing PrP (Legname et al., 2004, Colby et al., 2009). When recPrP is 
combined either with brain homogenate (Makarava et al., 2010) or with components 
such as RNA and lipids it has the ability to cause prion infection in wild type 
animals (Wang et al., 2010, Deleault et al., 2012). It is not yet understood how these 
cofactors allow the prion protein to cause disease, it has been proposed that they 
may stabilise the PrPSc conformation (Deleault et al., 2012).  
The site of conversion for PrPC to PrPSc is yet to be determined. Small quantities of 
abnormal PrP have been found to accumulate within the cell, so it is possible that 
PrP conversion may take place intracellularly (Ma et al., 2002). Potentially this could 
take place in the ER (Beranger et al., 2002) and the retention of misfolded PrPSc by 
the ER may play a role in the disease process (Beranger et al., 2002, Torres et al., 
2010), or the misfolding may take place after PrP has exited the ER. However, most 
aggregates of PrPSc in vivo tend to be extracellular (Jeffrey et al., 2000) and since PrPC 
is membrane bound it is likely that PrPSc conversion takes place at the cell surface. 
Lipid rafts are thought to be potentially important sites for conversion (Goold et al., 
2011, Wadia et al., 2008), along with endocytic vesicles (Dimcheff et al., 2003, Wadia 
et al., 2008). It is also possible that the endosomes, which endocytic vesicles fuse 
with, may be another possible site for conversion (Shyng et al., 1994, Lakhan et al., 
2009).  
 The exact mechanisms which lead to the formation of small assemblies of PrPSc 
(oligomers) and larger insoluble aggregates with a fibrillar structure are unknown, 
but it is believed that a nucleation process must take place to form a small “seed” 
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(Harper and Lansbury, 1997), which may be two or more PrPSc molecules. This 
nucleation and formation of a seed is known as the primary nucleation event 
(Knowles et al., 2014, Knowles et al., 2009). The protein aggregate can then increase 
in size by the ends of existing filaments recruiting soluble protein molecules, this 
results in a templated linear growth phase (Knowles et al., 2014, Knowles et al., 
2009). The aggregates can then multiply by a secondary nucleation event, such as 
fragmentation, when a fibril fragments the broken filaments can then begin to 
recruit soluble molecules by the same process as in the primary nucleation event 
(Knowles et al., 2014, Knowles et al., 2009). This process can lead to many fibrillar 
deposits in PMDs. It has been shown that the size of the most infectious PrP 
assembly is made up of 14-28 PrP molecules (Silveira et al., 2005). It is likely that 
such infectious particles are a product of secondary nucleation events.  
 
1.2.1.4 Strains of prion disease 
There are multiple strains of prion disease, which can exhibit different incubation 
periods, symptoms and pathology within the same species (Gambetti et al., 2011). 
These differences were noted when prion infected brain homogenates were injected 
into transgenic mice and strain properties were stable with repeated passage 
(Gambetti et al., 2011). The incubation period of a strain can be affected by the 
conformation of the prion particle and genetic components in the mouse (Collinge 
and Clarke, 2007). In addition to the incubation period which can be indicative of a 
specific strain, the pathological changes seen in the brain can also be very specific 
for different strains (Bruce, 2003). For example, the extent of vacuolation in certain 
brain areas is indicative of strain, along with the amount and type of PrP deposition 
(fibrillar, diffuse fibrils or very little deposition) (Bruce, 2003).  
Strains such as BSE and scrapie can be characterised though proteolytic digestion of 
isolated PrPSc, showing different fragment patterns suggesting differences in protein 
conformation. In addition to this, the glycoform ratios; the ratio of un- mono- or di- 
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glycosylated protein, vary between strains but remain stable through passage. 
Therefore, glycoform ratios can also be used for “strain typing”(Collinge and 
Clarke, 2007).  
The occurrence of “strains” would normally be associated with viruses or bacteria, 
in which strain differences would be encoded in nucleic acid sequences. Prions are 
unusual since it is thought that the differences between strains are due to different 
conformations of PrPSc (Toyama et al., 2007, Tanaka et al., 2006, Collinge and Clarke, 
2007). It is thought that a PrPSc molecule with a particular conformation interacts 
with a PrPC molecule and acts as a template to propagate that conformation or 
“strain”(Collinge and Clarke, 2007). This propagation can be affected when TSEs 
attempt to cross the species barrier, with much longer incubation times, this is 
thought to be because of differences in PrP sequence and structure which affects the 
conversion of PrPC to PrPSc (Aguzzi et al., 2007, Collinge and Clarke, 2007).  
If different strains of prion disease can be caused by differences in PrPSc structure 
this could also be applicable to other PMDs, since other misfolded proteins could 
also have different conformational forms (Aguzzi et al., 2007, Guo et al., 2013, 
Bousset et al., 2013). α synuclein, which is associated with Parkinson’s disease, has 
been shown to exhibit different strains with different structural conformations and 
different propagation properties in vitro (Bousset et al., 2013, Guo et al., 2013). It is 
hypothesised that this ability to propagate different “strains” may account for 
differences between α- synucleinopathies (Bousset et al., 2013). However, further 
studies are needed to study this in vivo and in patient tissue to show whether 
different strains really do account for the heterogeneity seen in synucleinopathies. 
Additionally, it is thought that strains of Aβ may also exist which have different 





1.2.2 Amyloid β (Aβ) 
 
1.2.2.1 Formation and processing of Aβ 
The amyloid precursor protein (APP) is translated at the ER, following post-
translational modifications, a small proportion is then transported to the cell 
membrane while the majority localises to the Golgi (Thinakaran and Koo, 2008). The 
APP is thought to be involved in neurite growth (Tyan et al., 2012), along with other 
potential roles in metal ion binding and cell adhesion (Thinakaran and Koo, 2008). 
When APP is localised to the cell membrane it is initially cleaved by α-secretase 
(ADAM10) or β-secretase (BACE1) and then further cleaved by the γ-secretase 
complex (Kaden et al., 2012) (figure 1.2). Cleavage by both β- and γ-secretases leads 
to the production of Aβ peptides, which are associated with AD (Kaden et al., 2012). 
Interestingly, cleavage of APP by α-secretase creates a soluble secreted form of APP 
(sAPPα) which is thought to have neuroprotective properties (Kaden et al., 2012, 
Furukawa et al., 1996, Mattson, 1997). Some mutations in APP that cause familial 
AD result in increased β-secretase cleavage and reduced cleavage by α-
secretase(Furukawa et al., 1996). The down regulation of sAPPα is thought to 
contribute to neurodegeneration in AD, since lower levels of sAPPα mean the 
neurons are more vulnerable to toxicity (Mattson, 1997, Furukawa et al., 1996). 
Additionally, sAPPα is thought to act as a growth factor for many cell types and 
promote neuritogenesis, therefore, the loss or down regulation of this protein could 
contribute to disease (Gralle and Ferreira, 2007).  
Aβ peptides are formed when the APP is cleaved by β-secretase and again by the γ-
secretase complex (figure 1.2C). At low levels they are thought to be involved in 
synaptic homeostasis, potentially acting as regulators of a negative feedback loop 
for synaptic transmission (Kamenetz et al., 2003). However, when levels of Aβ 
increase this ability to depress synaptic transmission is detrimental (Kamenetz et al., 
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2003). This is thought to be important in early pathological signs of AD (Kamenetz 
et al., 2003).  
As shown in figure 1.2, once the APP has been cleaved by β-secretase, the γ-
secretase complex can cleave at multiple sites, producing Aβ peptides which range 
in length from 38 to 43 amino acids (Thinakaran and Koo, 2008). Approximately 
90% of Aβ produced is the Aβ 1-40 form, with less than 10 % being the longer Aβ 1-
42 species (Thinakaran and Koo, 2008). Mutations in the APP gene can lead to an 
increased prevalence in cleavage at the 42 residue leading to increased production 





Figure 1.2 Processing of APP 
Schematic diagram to show the proteolytic processing of APP, from Thinakaran and 
Koo(Thinakaran and Koo, 2008). A) Shows the major cleavage sites of the APP. Β-
secretase normally cleaves at residue 1 but can also cleave at residue 11. When β-
secretase cleaves the APP, this is followed by cleavage with γ-secretase giving rise 
to Aβ peptides. APP can also be cleaved by α-secretase, giving rise to sAPPα. α-
secretase cleaves the protein between residues 16 and 17, which prevents the 
formation of Aβ peptides. B) Shows cleavage by α- and γ-secretase, giving rise to 
non-amyloidogenic peptides. C) Shows cleavage of APP by β- and γ-secretase, 
giving rise to Aβ. AICD: Amyloid precursor protein intracellular domain and CTF: C-
terminal fragment.  
 
 
1.2.2.2 Aβ in disease 
As mentioned in section 1.2.2.1, there are two main forms of Aβ formed in the brain; 
Aβ 1-40 and Aβ 1-42. The shorter species, Aβ 1-40 is most abundant whilst Aβ 1-42 
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is more prone to aggregation (Thinakaran and Koo, 2008). The ratio of these two 
isoforms is thought to be important in AD, with higher concentrations of Aβ 1-42 
being associated with toxicity and disease (Hansson et al., 2007). In early AD, 
cerebral spinal fluid levels of Aβ 1-42 are reduced while Aβ 1-40 is increased which 
is thought to be due to Aβ 1-42 aggregating in the brain (Hansson et al., 2007, van 
Oijen et al., 2006). Aβ has a tendency to self-aggregate and form fibrillar plaques 
which are hallmark features of AD. Soluble assemblies of Aβ referred to as 
oligomers or protofibrils also form, possibly through different pathways or on the 
way to becoming fibrils. Soluble oligomers have been found at much higher 
concentrations in AD brains, sometimes up to 70-fold higher, than in those who are 
unaffected (Gong et al., 2003). The concentration of soluble oligomers correlates 
better with cognitive decline than the density of Aβ plaques (Lue et al., 1999, Zhang 
et al., 2011, Tomic et al., 2009) and they have been shown both in vivo and in vitro to 
be highly toxic (Kuo et al., 1996, Naslund et al., 2000, McLean et al., 1999, Mucke et 
al., 2000a, Manzoni et al., 2011, Haass and Selkoe, 2007, El-Agnaf et al., 2000, Cleary 
et al., 2005, Texido et al., 2011). Aβ oligomers are, therefore, thought to be important 
in causing cell death and neurodegeneration.  
 
1.2.2.3 Tau and its relationship to Aβ 
Another pathological feature of AD is intracellular neurofibrillary tangles (NFT), 
which are aggregates of the protein tau. Tau is a microtubule associated protein, 
which functionally stabilises microtubules (Mandelkow and Mandelkow, 1998). Tau 
is normally phosphorylated, but under disease conditions such as in AD tau 
becomes hyperphosphorylated (Mandelkow and Mandelkow, 1998) and detaches 
from the microtubules, which causes instability and altered cellular processes 
(Medina and Avila, 2014). Aggregated deposits of tau are not specific to AD, they 
fall into a group of diseases often referred to as the tauopathies (Medeiros et al., 
2011, Medina and Avila, 2014). These include Pick's disease, progressive 
supranuclear palsy and corticobasal degeneration. Additionally, mutations in the 
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microtubule associated protein tau gene, MAPT, have been found to cause fronto-
temporal dementia with Parkinsonism (FTD) (Medeiros et al., 2011, Medina and 
Avila, 2014). This demonstrates that dysfunction of tau can cause 
neurodegeneration. In AD it is likely that tau pathology may also be important in 
causing cell death and degeneration. Several studies have shown than Aβ pathology 
precedes tau deposition and that Aβ may cause tau hyperphosphorylation 
(Medeiros et al., 2011, Oddo et al., 2006, Oddo et al., 2004, Lewis et al., 2001, Oddo et 
al., 2007). On the other hand, tau does not seem to affect Aβ production; when tau is 
down-regulated it has no effect on levels of Aβ (Medeiros et al., 2011, Oddo et al., 
2007).  
1.3 Toxic species in PMDs and potential mechanisms leading to cell 
death 
 
1.3.1 In vivo studies  
In order to understand the disease mechanisms underlying PMDs it is essential to 
identify the toxic protein species and understand how and why a conformationally 
different protein structure can cause neuronal toxicity and cell death. There is much 
conflicting evidence in the literature, but recent studies appear to support the idea 
that a prefibrillar, oligomeric protein species is potentially the most toxic of the 
various protein assemblies (Simoneau et al., 2007, Zhang et al., 2010, Caughey and 
Lansbury, 2003, Kayed et al., 2003, Kuo et al., 1996, Lue et al., 1999, Naslund et al., 
2000, McLean et al., 1999, Mucke et al., 2000a, Walsh et al., 2002, Quist et al., 2005, 
Kristiansen et al., 2007, Volles et al., 2001, Bucciantini et al., 2002).  
Animal studies using transgenic APP over expressing mice have shown the earliest 
behavioural changes precede detectable fibrillar protein aggregation (Moechars et 
al., 1999, Hsia et al., 1999), and the presence of prefibrillar oligomers causes synaptic 
loss and precedes a behavioural phenotype (Caughey and Lansbury, 2003, Mucke et 
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al., 2000a). This supports the hypothesis that it is a prefibrillar protein species that 
causes the initial toxicity in AD.  
In vivo studies of prion disease have been useful for understanding the different 
stages of neurodegeneration, since the starting point of the disease is defined by 
when the animals are inoculated with PrPSc. By examining animals at a pre-clinical 
phase, it is possible to uncover early changes in the disease process. Studies that 
have involved such experiments have shown that early stages of pathology include 
synaptic dysfunction and dendrite loss and these pathological changes seem to 
occur prior to neuronal cell death (Fuhrmann et al., 2007, Cunningham et al., 2003). 
Although fibril accumulation seems to occur around the same time as these 
pathological changes (Cunningham et al., 2003), it is still not clear whether the fibrils 
are causing the toxicity or if soluble oligomeric forms of PrP cause the damage prior 
to aggregation.  
Genetic disorders can act as useful in vivo models for investigating certain aspects of 
the disease process. People with Down’s syndrome have three copies of 
chromosome 21 meaning that they have three copies of the APP gene, which is the 
precursor for Aβ. This results in large quantities of Aβ being produced and 
generally an AD phenotype is seen by the time most individuals are in their fourth 
or fifth decade (Caughey and Lansbury, 2003, Lemere et al., 1996). The analysis of 
Down’s syndrome patients’ brains has highlighted that, in adults, there are dense 
Aβ plaques and NFT. Prior to this in the brains of children with Down’s syndrome, 
accumulation of non-fibrillar Aβ can be seen which precedes plaque formation and 
AD phenotype (Lemere et al., 1996, Caughey and Lansbury, 2003).  
Previous studies have suggested that it is only a subpopulation of fibrillar deposits 
with a β-sheet structure, which stain with dyes such as thioflavin-S, which are toxic 
to neurons (Caughey and Lansbury, 2003, Urbanc et al., 2002). Therefore, the β-sheet 
content of either fibrils or prefibrillar oligomers is an important factor in dictating 
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toxicity. In vivo studies show evidence for oligomers being important in the disease 
process of PMDs, however, since the pathology of the brain can only be analysed at 
set time points, it is difficult to show a definite cause and effect between misfolded 
protein species and neuronal toxicity. Therefore, in vitro studies can be used to look 
more closely at the mechanisms underlying neuronal loss.  
 
1.3.2 In vitro studies 
To date, in vitro studies have employed the use of a variety of cell lines as well as 
primary cell culture models (Novitskaya et al., 2006, Torres et al., 2010, Zhang et al., 
2010, Ma et al., 2002). PrP oligomers have consistently been shown to be neurotoxic 
to a variety of cells (Novitskaya et al., 2006, Simoneau et al., 2007, Caughey and 
Lansbury, 2003), although, some variation has been seen. This variability may be 
due to differences in cell membrane composition of different cell types (Zhang et al., 
2010), or differences in oligomer size or structure. When cells are incubated, in vitro, 
with fibrillar aggregates and assayed for toxicity the results have been variable 
(Novitskaya et al., 2006, Novitskaya et al., 2007, Quist et al., 2005, Simoneau et al., 
2007, Kristiansen et al., 2007, Dahlgren et al., 2002, Ahmed et al., 2010). Some studies 
have suggested that the formation of fibrils may be protective since they sequester 
small soluble forms of misfolded protein (Haass and Selkoe, 2007, Treusch et al., 
2009), or fibrils may just be the end point in the protein misfolding pathway 
(Caughey and Lansbury, 2003, Silveira et al., 2005, Soto, 2003, Ross and Poirier, 
2004, Dobson, 2003). Other studies, however, have shown fibrils to be just as toxic as 
oligomers (Novitskaya et al., 2006, Novitskaya et al., 2007); these discrepancies may 
be due to differences in the structure of the fibrillar aggregates. Generally, protein 
preparations are often not extensively characterised prior to incubation with cells in 
vitro, therefore, differences in protein conformation may account for these 
inconsistencies. Presently, it is still not clear which protein species primarily causes 
neuronal cell death in PMDs.  
27 
 
The mechanisms associated with how misfolded proteins cause toxicity are also not 
well defined. Several studies have shown misfolded proteins to cause apoptotic cell 
death (Novitskaya et al., 2006, Simoneau et al., 2007, Youssef et al., 2008, Yang et al., 
2009), while others have shown excitotoxicity to be important (Molinuevo et al., 
2005, Esposito et al., 2013, Di et al., 2010, Dong et al., 2009, Tabrizi et al., 1999, 
Chiarlone et al., 2014, Muller et al., 1993, Sassoon et al., 2004, Thellung et al., 2013). 
Additionally, ER stress (Lindholm et al., 2006, Yoshida, 2007) and autophagy 
(Levine and Kroemer, 2008, Martinez-Vicente and Cuervo, 2007, Wong and Cuervo, 
2010, Heiseke et al., 2010) have also been shown to be potential pathways leading to 
cell death after activation by misfolded proteins. Membrane disruption by 
oligomers, which affects the calcium levels within the cell triggering the apoptotic 
pathway (Simoneau et al., 2007, Zhang et al., 2010) has also been highlighted as a 
possible mechanism. It is thought that oligomers may insert into the phospholipid 
membrane, which causes a disruption in membrane potential (Kayed et al., 2004). 
This may provide another link between PMDs, since in some the misfolded protein 
accumulates inside the cell, while in others they accumulate in the extracellular 
space. Therefore, if it is the membrane which is affected this could be a plausible 
mechanism of toxicity for both intra and extracellular misfolded proteins.  
Most in vitro studies of prion toxicity have been performed with recPrP or short 
fragments of recPrP, but studies have also been carried out using the yeast prion 
protein Ure2. Protofibrils of Ure2 were found to be toxic to neuronal cells in a dose 
dependent fashion (Zhang et al., 2010), whilst fibrils were also found to be toxic but 
to a lesser extent. Changes in conductivity and calcium levels leading to apoptosis 
were observed, which correlate with findings from mammalian recPrP studies 
(Zhang et al., 2010).  
Many studies have also been undertaken using fragments of PrP, in particular the 
fragment corresponding with human residues 106-126. This fragment has been 
shown to fibrillise very quickly, particularly under slightly acidic conditions, and 
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has a β- sheet rich structure (Selvaggini et al., 1993). Additionally, it shows some 
resistance to proteinase K digestion as has been shown for PrPSc (Selvaggini et al., 
1993). The size of the fibrils which it forms are thought to consist of approximately 
6000 PrP molecules (Selvaggini et al., 1993). However, even in this fibrillar 
conformation PrP 106-126 has repeatedly been shown to be toxic to cells in vitro 
(O'Donovan et al., 2001, Jobling et al., 1999, Brown et al., 1996, Forloni et al., 1993). 
This may suggest that a fibrillar form of PrP can be toxic, and that perhaps toxicity 
is dependent on the structure or conformation of the fibrils.  
The importance of PrPC seems to be poorly defined in these in vitro studies; some 
show that the absence of PrPC seems to attenuate the toxicity of oligomers and fibrils 
(Novitskaya et al., 2006), whilst other studies show that the toxicity of oligomers or 
fibrils seems to be unaffected by PrPC expression (Simoneau et al., 2007). This adds 
another layer of complexity to the mechanisms which underlie neuronal toxicity in 
prion disease. 
Most studies which have investigated the toxicity of Aβ in vitro have generally 
shown Aβ fibrils to be less toxic than oligomers (Dahlgren et al., 2002, Ahmed et al., 
2010, Lesné et al., 2008). However, it has been proposed that fibrillar plaques may 
act as a reservoir of smaller oligomeric forms of Aβ, which can form a halo around 
the fibrillar plaque (Koffie et al., 2009). By contrast, Aβ oligomers have repeatedly 
been shown to be toxic (Manzoni et al., 2011, El-Agnaf et al., 2000). Various 
pathways have been shown to be activated by Aβ oligomers both in vitro and in 
vivo, including apoptosis (Youssef et al., 2008, Yang et al., 2009, Shimohama, 2000), 
excitotoxicity (Dong et al., 2009, Li et al., 2009, Alberdi et al., 2010, Li et al., 2011, 
Rammes et al., 2011, Rönicke et al., 2011), autophagy (Mizushima et al., 2008, 
Martinez-Vicente and Cuervo, 2007) and ER stress (Lindholm et al., 2006, Yoshida, 
2007). All may be important under different conditions or for oligomers with 
different structures. Clinical trials are underway targeting some of these pathways; 
it remains to be seen whether any will reverse or slow disease progression.  
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1.4 Main objectives 
To date, there is still uncertainty surrounding whether oligomers formed from 
different misfolded proteins cause cell death by similar mechanisms. Additionally, it 
is still unclear whether fibrils are inert and non-toxic or if they also play a role in 
causing disease. It has been hypothesised that oligomers composed of different 
disease associated misfolded proteins are toxic to neuronal cells and activate 
common intracellular pathways to cause cell death. In this thesis, I have tried to 
address these questions: 
 Can recPrP and recAβ be produced in sufficient yield to allow them to be 
refolded into different disease associated structures and characterised? 
I have produced recPrP and recAβ and refolded them into disease associated 
conformations, including fibrils and oligomers. I have characterised these misfolded 
species in order to clearly define links between structure and toxicity.  
 Which misfolded species are most toxic? And is the toxic species the same 
for different proteins? 
I have investigated the toxicity of the disease associated isoforms of recPrP and 
recAβ using murine primary cortical cells. This allowed me to establish the 
important toxic species associated with these diseases and compare their relative 
toxicities. This has brought new insights into how these misfolded isoforms may be 
involved in disease pathogenesis in two PMDs. As part of these investigations, I 
have explored how the disulphide bond in recPrP may be important in misfolding 
and associated toxicity. I found that the presence or absence of the disulphide bond 
was critically important in determining the size of oligomers which form and their 
associated toxicity.  
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 What pathways are activated by misfolded proteins? Do oligomers of recPrP 
and recAβ activate the same mechanisms? 
Lastly, once I had established which of the misfolded proteins species were toxic I 
investigated the mechanisms and pathways that are activated by these misfolded 
proteins and lead to cell death. This work highlighted the complexity of these 
diseases and suggests that oligomers formed from different misfolded proteins may 
not cause cell death by activating the same pathways. Furthermore, fibrils may not 
be the same in all PMDs and may in some cases be involved in causing cellular 




Chapter 2: Materials and Methods 





2.1 General protein analysis 
 
2.1.1 Denaturing SDS-PAGE  
All SDS-PAGE analysis was carried out using the Novex NuPAGE SDS-PAGE gel 
system (Invitrogen). Protein samples were denatured with NuPAGE LDS sample 
buffer (4X) at a 3:1 ratio, the samples were heated at 100 °C for 10 minutes. The 
samples were centrifuged at 16100 g for 1 minute prior to loading to remove 
condensation. Samples were loaded onto a pre-cast NuPAGE Bis-Tris gel 
(Invitrogen), along with SeeBlue Plus2 pre-stained protein standard (Invitrogen). 
Proteins were resolved by electrophoresis at 180 V for 1 hour or until the lowest 
protein marker had reached the bottom of the gel. Gels were then analysed by 
coomassie, silver staining or western blotting.  
 
2.1.2 Coomassie staining 
To coomassie stain an SDS-PAGE gel, the gel was incubated with approximately 20 
ml of InstantBlue (expedeon). Protein bands were left to develop for 2-24 hours. The 
gel was washed with MilliQ H2O before being imaged with a flatbed scanner.  
 
2.1.3 Silver staining 
The gel was fixed for 1-24 hours (fixative: 30 % (v/v) ethanol, 10 % (v/v) acetic acid 
in MilliQ H2O). Following fixation the gel was sensitised for 1 hour (sensitising 
solution (in a 100 ml final volume): 30 % ethanol, 0.2 % (w/v) sodium thiosulphate, 
0.83 mM sodium acetate & 0.5 ml of 25% glutaraldehyde solution). The gel 
underwent 4 X 15 minute washes with MilliQ H2O and was stained with silver 
nitrate for 1 hour (silver nitrate solution: (final volume 100 ml) 15 µM silver nitrate 
made up in MilliQ H2O with 100 µl of 37 % formaldehyde solution). This was 
followed by two 1 minute washes with MilliQ H2O, the gel was developed 
(developing solution: (final volume 100 ml) 0.24 mM sodium carbonate & 40 µl 
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formaldehyde) until the bands could be clearly seen. Once the bands were resolved 
the reaction was stopped with the stopping solution (50 µM EDTA). The gel was left 
in stopping solution for 1-24 hours and then washed in MilliQ H2O before being 
imaged using a flatbed scanner.  
  
2.1.4 Western blotting 
Following SDS-PAGE the gel was transferred onto an Immobilon-P PVDF 
membrane using a semi dry transfer system (Invitrogen). Briefly, eight pieces of 
filter paper were cut to approximately 9 cm x 8 cm and soaked in transfer buffer (0.1 
M tris, 0.19 M glycine, 5 % methanol (v/v)); a piece of PVDF membrane was cut to 
the same size and soaked in 100 % methanol. The semi-dry transfer stack was set up 
with four pieces of filter paper on the anode plate, the methanol soaked membrane 
was rinsed in transfer buffer and placed on top of the filter paper using tweezers. 
The SDS-PAGE gel was rinsed in transfer buffer and stacked on top of the 
membrane, the remaining four pieces of soaked filter paper were placed on top of 
the gel. A roller was used to push out any bubbles. The top cathode plate was 
placed on top of the stack and the screws fastened. The gel was transferred at 180 
mA for 1 hour for 1 gel, or at 280 mA for 1 hour for 2 gels. The membrane was 
transferred to blocking solution: 5 % Marvel (w/v) made up in 1X TBS-T (0.01M tris, 
0.14 M NaCl, 0.05 % tween (v/v)), for 1 hour or overnight. Once the membrane had 
been blocked, the blocking solution was replaced with the primary antibody which 
was diluted in 1 % Marvel (w/v) in TBS-T. The membrane was incubated with the 
primary antibody either for 1 hour at room temperature with agitation or overnight 
at 4 °C. The membrane was subjected to 3 X 15 minute washes in TBS-T with gentle 
agitation. The secondary antibody was applied, this was also diluted into 1 % 
Marvel (w/v) in TBS-T. The membrane was incubated with the secondary antibody 
for 1 hour at room temperature. The membrane was again subjected to 3 X 15 
minute washes in TBS-T. Once the final wash was removed, the membrane was 
incubated with ECL western blotting detection reagent (GE Healthcare) for 2 
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minutes. The membrane was dried and exposed to Amersham Hyperfilm ECL for 
varying lengths of time. The film was developed using a Curix 60 processor 
(AGFA).  
 
2.1.5 Native- PAGE  
To analyse proteins in their native form, I used the Novex NativePAGE system 
(Invitrogen). Protein samples were mixed 1:3 with NativePAGE sample buffer (4X, 
Invitrogen) and not heated. Samples were loaded onto NativePAGE Novex 4-16% 
Bis-Tris protein gels, along with the NativeMark unstained protein standard. 
NativePAGE anode and cathode buffers were made according to manufacturer’s 
guidelines (Invitrogen). Proteins were resolved by electrophoresis at 150 V for 105 
minutes. Gels were fixed for 1-2 hours in fixative (40 % ethanol (v/v), 10 % (v/v) 
acetic acid), this was removed and replaced with more fixative for 8-16 hours, 
finally this was removed and fresh fixative was applied for a further 2 hours. The 
gel was silver stained either with the protocol outlined in section 2.1.3, or using 
SilverQuest silver staining kit (Invitrogen).  
 
2.1.6 Determining protein concentration by spectroscopy 
Protein concentration was determined by spectroscopy at 280 nm using a NanoDrop 
spectrophotometer. Before analysing the concentration of a protein, a reading was 
taken of the protein buffer which acted as the blank. Approximately 2 µl of the 
protein sample was loaded onto the NanoDrop and an absorbance reading at 280 
nm was acquired. The molecular mass (MW) of the protein was then divided by the 
extinction coefficient (EC) and multiplied by the 280 nm absorbance reading to give 
the concentration of the protein in mg/ml. To obtain the molar concentration, the 280 
nm absorbance reading was divided by the EC. The EC was calculated as shown in 
Gill and von Hippel(Gill and von Hippel, 1989). The MW and EC used for PrP was 
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MW: 23113 and EC: 61000. For Aβ 1-40, MW: 4329.8 and EC: 1490 and for Aβ 1-42, 
MW: 4514.1 and EC: 1490. For TEV MW: 28600, EC: 32290.  
2.2 Expression of recombinant proteins  
 
2.2.1 Expression of recombinant PrP  
Full length recombinant murine PrP (recPrP) encompassing residues 23-230 was 
expressed in Rosetta Escherichia coli (Novagen). The Rosetta E.coli carrying the 
plasmid containing the mouse prnp gene were grown on selective plates containing 
ampicillin (100 μg/ ml) and chloramphenicol (50 μg/ ml) and left to grow overnight 
at 37 °C. A single colony was picked from the plate and grown in a 10 ml Luria 
broth (LB, Sigma) overnight culture containing ampicillin (100 μg/ ml) and 
chloramphenicol (50 μg/ ml). Approximately 3 ml of the overnight culture was 
added to 400 ml of terrific broth (TB, Sigma) containing ampicillin (100 μg/ ml) and 
chloramphenicol (50 μg/ ml) the culture was grown to an optical density with 
absorbance at 600 nm of 0.6- 1. Protein expression was induced using 1 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) and left for 16 hours. The cultures 
were transferred to 250 ml sorvall flasks the next day and centrifuged at 10 K rpm 
for 10 minutes (SLA-1500 rotor), the supernatant was disposed of and the pellets 
were frozen at -20° C for a minimum of 4 hours before lysis.  
 
2.2.2 Expression of recombinant Aβ 1-40 and Aβ 1-42 fusion proteins 
Plasmids for human recombinant Aβ 1-40 or Aβ 1-42 (recAβ 1-40 or recAβ 1-42) 
fusion proteins were obtained from Prof. Glockshuber’s group(Finder et al., 2010). 
The fusion proteins consisted of a soluble polypeptide with 19 repeats of the amino 
acids NANP followed by the TEV recognition sequence ENLYFQ and then either 
the Aβ 1-40 or Aβ 1-42 sequence (a schematic of the fusion protein is shown in 
figure 3.8). The plasmids contained a T7 promoter and ampicillin resistance cassette. 
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The plasmids were transformed into BL21 (DE3) bacteria and selected for using 
ampicillin containing plates. A single colony containing either the recAβ 1-40 fusion 
protein plasmid or the recAβ 1-42 fusion protein plasmid were selected and grown 
in 10 ml LB overnight cultures containing ampicillin (100 μg/ ml). Approximately 3 
ml of the overnight cultures was added to 400 ml TB cultures containing ampicillin 
(100 μg/ ml). The cultures were grown to an optical density (absorbance 600 nm) of 
0.6- 1. Protein expression was induced using 1 mM IPTG and left for 16 hours. The 
cultures were transferred to 250 ml sorvall flasks the next day and centrifuged at 10 
K rpm for 10 minutes (SLA-1500 rotor). The supernatant was disposed of and the 
pellets were frozen at -20° C for a minimum of 4 hours before purification.  
 
2.2.3 Expression of recombinant tobacco etch virus (TEV) protease 
Bacteria containing a plasmid encoding TEV protease and pLysS, (which decreases 
background expression of target genes) were available in the Gill group. Using a 
miniprep kit according to the manufacturer’s protocol (Qiagen), I extracted the 
plasmids and transformed them into ArcticExpress competent cells (Agilent 
technologies) following the manufacturer’s protocol. The transformed cells were 
grown on selective plates containing kanamycin (30 µg/ml), to select for the TEV 
plasmid. The cells were left to grow at 37 °C for 16 hours. Single colonies were 
selected and grown in 10 ml LB overnight cultures containing kanamycin (30 μg/ 
ml), gentamycin (20 μg/ ml, to select specifically for the arctic express bacteria) and 
chloramphenicol at (50 μg/ ml, to select for pLysS), the cultures were left to grow at 
37 °C for 16 hours. Approximately 3 ml of the overnight culture was added to 250 
ml of LB containing no antibiotics. The culture was grown to an optical density 
(absorbance 600 nm) of 0.6-1 at 30 °C at 225 rpm. The temperature was then reduced 
to 12 °C and left for 30 minutes to allow the bacteria to acclimatise. Protein 
expression was induced using 1 mM IPTG and left for 24 hours. The bacteria 
underwent centrifugation at 8 K rpm for 10 minutes (SLA-1500 rotor), the 
supernatant was then discarded and the cell pellet was suspended in TEV lysis 
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buffer (50 mM HEPES pH 7.5, 1 M NaCl, 10 % glycerol (v/v), 10 mM imidazole) 3 ml 
per gram of cells and snap frozen. The lysed bacteria were stored at -20 °C. 
2.3 Bacterial cell lysis 
 
2.3.1 RecPrP bacterial cell lysis  
The cell pellets were re-suspended in lysis buffer (50 mM Tris, 1 mM EDTA, 100 
mM NaCl pH 8), 9 ml per gram of cell pellet. Lysozyme was added to a final 
concentration of 0.2 mg/ml, this was left at 4 °C for 1 hour with stirring. Sodium 
deoxycholate was added to a final concentration of 1 mg/ml, this was left to stir at 
room temperature for 1 hour. DNAse was added to a final concentration of 4 µg/ml 
with MgCl2 to a final concentration of 40 mM, this was left to stir at room 
temperature for a further 40 minutes. The inclusion bodies were pelleted by 
centrifugation at 12 K rpm for 15 minutes at 4 °C (SLA-1500 rotor). The inclusion 
body pellets were frozen at -20 °C for up to six months.  
 
2.3.2 recAβ 1-40 and recAβ 1-42 fusion protein bacterial cell lysis  
The frozen bacterial pellets were re-solubilised in 6 M guanidine hydrochloride 
(GdnHCl) pH 8.0 (10 ml per gram of cells) and mixed using a 10 ml pipette and 
stirred for 90 minutes at 4 °C. Cell debris was removed by centrifugation at 15 K 
rpm for 30 minutes at 4 °C (SLA-1500 rotor). The supernatant was collected and 
used for purification.  
 
2.3.3 TEV bacterial cell lysis 
See expression of TEV, section 2.2.3. Following storage at -20 °C the bacteria in lysis 
buffer were sonicated on ice for 10 minutes using a sonication water bath. The lysed 
bacteria underwent centrifugation at 15 K rpm for 30 minutes at 4 °C to pellet the 
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bacterial cell debris (SLA-1500 rotor). The TEV protease was produced as a soluble 
protein; the supernatant was collected and taken for purification. 
2.4 Protein purifications  
 
2.4.1 Purification of α-helical recPrP  
 
2.4.1.1 Immobilised metal ion affinity chromatography (IMAC) for α-helical recPrP  
The inclusion body pellets (refer to section 2.3.1) were first purified by means of 
nickel immobilised metal ion affinity chromatography (IMAC), which purifies PrP 
by binding of the histidine residues found on the N- terminal of the protein to nickel 
ions on the column. Any other proteins present were washed through leaving the 
PrP to be eluted. Buffer A (0.1 M sodium phosphate, 0.01 M tris, 8 M urea pH 8 & 
210 μl β- mercaptoethanol) and buffer B (100 ml of buffer A pH 4.5 & 70 μl β-
mercaptoethanol) were made up, the inclusion body pellets were re-suspended in 
buffer A; 5 ml of buffer per gram of cell pellet. They were left to re-suspend for 1 
hour or more and then centrifuged at 15 K rpm for 20 minutes (SLA-1500 rotor). The 
supernatant was loaded onto a column made with nickel-NTA superflow resin 
(Qiagen), which had been equilibrated in buffer A. The column was washed with 
buffer A and the protein was eluted by a step gradient of 100 % buffer B, recPrP was 
detected as a single UV peak (absorbance 280 nm) which was collected. The eluted 
protein was analysed by SDS-PAGE to confirm the presence of recPrP. The recPrP 
containing fraction was diluted 1:1 with ion exchange buffer A (8 M urea, 0.05 M 
HEPES pH 8), this was left at 4 °C overnight. 
 
2.4.1.2 Ion exchange chromatography for α-helical recPrP 
The recPrP was purified further by means of ion exchange chromatography, which 
separated the recPrP from any other proteins by charge. PrP carries a positive 
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charge at neutral pH, therefore, a cation resin was used. Buffer A (8 M urea, 0.05 M 
HEPES pH 8) and buffer B (8 M urea, 0.05 M HEPES, 1.5 M NaCl, pH 8,) were made. 
The recPrP fraction from the IMAC step (section 2.4.1.1) was loaded onto a column 
made with SP sepharose fast flow cation resin (GE Healthcare), which had been 
equilibrated in buffer A. The column was washed with buffer A until the UV trace 
(absorbance 280 nm) reached baseline. The recPrP was eluted with a 0-50 % gradient 
of buffer B over 20 minutes. The eluting recPrP gave an absorbance peak at 280 nm, 
which was collected as one fraction. The eluted protein was analysed by SDS-PAGE 
to confirm the presence of recPrP and to assess the purity. The concentration of the 
recPrP was calculated using a spectrophotometer (see section 2.1.6). The recPrP was 
diluted to 0.1 mg/ml using buffers A + B. Following purification the protein was 
oxidised to form the disulphide bond at 4 °C for 16 hours with a five times molar 
excess of copper chloride. 
 
2.4.1.3 Dialysis of α-helical recPrP  
The oxidised and purified recPrP was dialysed to remove the 8 M urea present in 
the purification buffers. Approximately 5 litres of 50 mM sodium acetate and 10 mM 
EDTA (to chelate the copper ions) pH 5.5 was made, the recPrP was transferred to 
dialysis tubing with a molecular weight cut off of 12 kDa (Sigma). The PrP was 
dialysed for 4 hours at room temperature or overnight at 4 °C. Following this, the 
recPrP was dialysed for a further 4 hours at room temperature or overnight at 4 °C 
in 50 mM sodium acetate pH 5.5. Dialysis continued with buffer changes until the 
concentration of urea was calculated to be less than 100 nM, which was therefore 
dependent on the volume of recPrP (but usually would be 4-5 buffer changes). After 








2.4.1.4 Concentrating the purified protein 
The recPrP was concentrated using an Amicon concentration cell with an Amicon 
filter with a molecular weight cut off of 10 kDa. The Amicon concentration cell uses 
nitrogen gas to create a vacuum and force the solution through the filter, leaving the 
recPrP which is larger than 10 kDa. The concentration of the sample was tested 
periodically until the concentration reached approximately 1 mg/ml. The 
concentrated recPrP was divided into 500 μl aliquots and stored at -80 °C.  
 
2.4.2 Purification of recPrP for the production of oligomers and fibrils 
The following method described in section 2.4.2 was modified from Makarava and 
Baskakov 2008 (Makarava and Baskakov, 2008).  
 
2.4.2.1 IMAC for recPrP oligomers and fibrils 
The inclusion body pellets were solubilised in IMAC buffer A (8 M Urea, 0.1 M 
Na2HPO4, 10 mM tris-HCl, 10 mM reduced glutathione, pH 8) with stirring for 1 
hour at room temperature, the cell debris was pelleted by centrifugation at 15 K rpm 
for 30 minutes (SLA-1500 rotor). The supernatant was mixed with nickel-NTA 
agarose resin (Qiagen) and left to bind at room temperature on a rotator for 1 hour 
30 minutes. The resin was then transferred to a 5 ml polyethylene column (Qiagen); 
the resin was washed with 4 column volumes of IMAC buffer A. The protein was 
then eluted with IMAC buffer B (IMAC buffer A adjusted to pH 4.5); 5 ml fractions 
were collected to which 50 µl of 0.5 M EGTA were added. SDS-PAGE gel analysis 
showed which fractions contained the eluted recPrP.  
 
2.4.2.2 Desalting of recPrP for oligomers and fibrils  
The recPrP was separated from the reduced glutathione present in the IMAC buffers 
by desalting. The fractions with the highest concentration of recPrP were pooled, up 
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to a maximum volume of 13 ml, this was loaded onto a HiPrep 26/10 desalting 
column (GE healthcare) equilibrated in desalting buffer (6 M Urea, 0.1 M tris-HCl, 
pH 7.5). The eluting recPrP gave an absorbance peak at 280 nm, which was collected 
as one fraction. The concentration of the recPrP containing fraction was determined 
using a spectrophotometer (see section 2.1.6).  
 
2.4.2.3 Oxidation (disulphide-bond formation) of recPrP for oligomers and fibrils 
The recPrP was diluted to 0.3 mg/ml in desalting buffer, EGTA was added to a final 
concentration of 5 mM and oxidised glutathione to a final concentration of 0.075 
mM. The protein was left stirring overnight at 4 °C to oxidise (forming the 
disulphide bond) and refold. RecPrP with an intact disulphide bond will be referred 
to as oxidised PrP and recPrP without a disulphide bond will be referred to as 
disulphide-reduced PrP. 
 
2.4.2.4 Reverse phase chromatography of recPrP for oligomers and fibrils 
The recPrP was further purified by reverse phase (RP) chromatography, using a 
Dionex HPLC and Grace VYDAC® 214TP C4 reversed phase column. The oxidised 
recPrP sample was diluted 1:3 in RP buffer A (0.1 % trifluoroacetic acid (TFA) in 
H2O) and then filtered. It was loaded onto the C4 column, which had been 
equilibrated in RP buffer A, in batches of approximately 6 mg of protein. The recPrP 
was eluted from the column by a gradient of buffer B (0.1 % TFA in acetonitrile) 0-15 
% buffer B in 5 minutes, 15-35 % in 30 minutes, 35-50 % in 10 minutes and then up 
to 100 % B in 5 minutes, before returning to 0 % B. All fractions were analysed by 








2.4.2.5 Analysis of intact proteins by online LC-MS 
All mass spectrometry analyses were performed by dedicated staff in the Roslin 
Institute Proteomics and Metabolomics Facility. Samples for analysis were diluted 
to approximately 1 pmole/μl in HPLC A buffer (0.1 % (v/v) trifluoroacetic acid in 
water) except where their concentration could not be determined when they were 
used neat. 5 μl of the resulting sample was injected, by means of an Ultimate 3000 
autosampler (Dionex, Thermo) onto a Vydac MS C4 reversed phase HPLC column. 
Buffer was pumped through the column at 10 μl/min by means of an Ultimate 3000 
Pump (Dionex, Thermo) and retained components were eluted by means of a 
multistep gradient from 100% HPLC buffer A to 100% HPLC Buffer B (0.1 % (v/v) 
TFA in acetonitrile) as follows: 0 mins, 0% B; 3 mins, 20% B; 25 mins, 60% B; 26 mins, 
100% B. These conditions produced rapid separation of proteinaceous species from 
salts/buffers and from each other. 
The output from the HPLC column was routed to the electrospray source of an 
Amazon ETD ion trap mass spectrometer (Bruker) operated in positive ion mode. 
This instrument acquired full scan mass spectra from m/z 500-2000 (trap target 
200,000; maximum accumulation time 200 ms, 5 averages per spectrum) and was 
operated in ultrascan mode (32,500 m/z per sec). All total ion count (TIC) 
chromatograms in this thesis were prepared without smoothing. Mass spectra were 
smoothed and deconvoluted to give accurate measures of mass and to confirm the 
presence or absence of modifications such as glutathione adducts. 
 
2.4.2.6 RecPrP disulphide-bond reduction  
Oxidised lyophilised recPrP was solubilised in ion exchange buffer A (8 M urea, 
50.3 mM HEPES, pH 8, with DTT to a final concentration of 1 mM), this was left to 
reduce overnight on a roller at room temperature. The disulphide-reduced recPrP 
was then purified by RP; see purification of oxidised recPrP. The only modification 
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was that the eluting gradient was 0-20% buffer B in 5 minutes, 20-40% buffer B in 30 
minutes and 40-50% B in 5 minutes. The eluted protein was analysed by SDS-PAGE 
for purity and mass spectrometry to confirm the disulphide-reduced state. 
Disulphide-reduced recPrP fractions were lyophilised and stored at -20 °C.  
 
2.4.3 Purification of recAβ 1-40 and recAβ 1-42 fusion proteins 
The following protocol was adapted from Finder et al.(Finder et al., 2010). 
 
2.4.3.1 IMAC for recAβ 1-40 and recAβ 1-42 
For either recAβ 1-40 or recAβ 1-42, the supernatant which was collected following 
centrifugation (see section 2.2.2) was loaded onto a column containing nickel-NTA 
superflow resin (Qiagen). The column had been previously equilibrated with 6 M 
GdnHCl pH 8.0. Following loading of the sample the column was washed with 20 
ml of 6 M GdnHCl pH 8.0, followed by washing with 6 M GdnHCl pH 6.0 for 4 
column volumes (CV). The fusion proteins were eluted with 3 CVs of 6 M GdnHCl 
pH 2.0 and stored at 4 °C overnight prior to RP chromatography. Fractions were 
confirmed to contain recAβ 1-40 or recAβ 1-42 by SDS-PAGE.  
 
2.4.3.2 RP chromatography for recAβ 1-40 and recAβ 1-42 
RecAβ 1-40 and recAβ 1-42 were purified further by reverse phase chromatography, 
using a Dionex HPLC and Grace VYDAC® 214TP C4 reversed phase column. 
RecAβ 1-40 or recAβ 1-42 IMAC fractions were diluted 1:3 in RP buffer A (0.1 % 
TFA in H2O) and filtered using a 0.22 µM filter. The sample was loaded onto the C4 
column which had been equilibrated in RP buffer A, in batches of approximately 6 
mg of protein. RecAβ 1-40 or recAβ 1-42 was eluted from the column by a gradient 
of buffer B (0.1 % TFA in Acetonitrile) 0-10 % buffer B in 5 minutes, 10-50 % in 30 
minutes, 50-100 % in 5 minutes, before returning to 0 % B. All fractions were 
analysed by SDS-PAGE to check which fractions contained the correct protein and 
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to assess the purity of the sample. Fractions containing recAβ fusion protein were 
lyophilised and stored at -20 °C.  
 
2.4.4 Purification of recTEV protease 
 
2.4.4.1 IMAC for recTEV produced as a soluble protein 
The supernatant which was collected following centrifugation (see section 2.2.3) was 
loaded onto a column containing nickel-NTA superflow resin (Qiagen). The column 
had been previously equilibrated with load buffer (50 mM HEPES pH 7.5, 800 mM 
NaCl, 10 % (v/v) glycerol, 10 mM imidazole). Following loading of the sample the 
column was washed with 2 CVs of the load buffer and washed with 3 CVs of the 
wash buffer (load buffer with 50 mM NaCl). The recTEV protease was eluted with a 
step gradient to 100 % elution buffer (wash buffer with 400 mM imidazole pH 7.4). 
The peak at absorbance 280 nm was collected in one fraction and diluted 8 fold with 
the wash buffer. This was then stored at 4 °C overnight prior to cation exchange 
chromatography. Fractions were confirmed to contain recTEV by SDS-PAGE.  
 
2.4.4.2 Cation exchange for recTEV protease 
RecTEV containing fractions from IMAC were loaded onto an ion exchange column 
containing SP sepharose fast flow cation exchange resin (GE Healthcare). The 
column had first been equilibrated in the load buffer (50 mM HEPES pH 7.5, 50 mM 
NaCl, 10 % (v/v) glycerol, 10 mM imidazole). Following the sample being loaded, 
the column was washed with 3 CVs of the load buffer. The recTEV was eluted with 
a 0-100 % gradient over 25 minutes with the elution buffer (50 mM HEPES, pH 7.5, 
800 mM NaCl, 10 % (v/v) glycerol, 10 mM imidazole). The UV peak at 280 nm was 
collected and analysed by SDS-PAGE. The recTEV containing fraction was 





2.4.4.3 Desalting buffer exchange for recTEV protease 
Prior to buffer exchange using a desalting column (to exchange the imidazole 
containing purification buffer to a suitable storage buffer) the recTEV was first 
concentrated using a Vivaspin concentration column (GE healthcare). The protein 
was applied to the Vivaspin column which had a filter cut off of 10 kDa, and spun in 
a centrifuge until the volume was 1-2 ml. The concentrated protein was applied to a 
HiPrep 26/10 desalting column (GE healthcare), which was equilibrated in storage 
buffer (50 mM HEPES pH 7.5, 300 mM NaCl, 10% (v/v) glycerol). A peak at 280 nm 
showed the eluting recTEV protease, which was collected. The recTEV fraction was 
analysed by SDS-PAGE and the concentration was determined using a 
spectrophotometer (see section 2.1.6). The recTEV was split into aliquots which were 
snap frozen and stored at -20 °C until needed for cleavage reactions.  
 
2.4.5 Cleavage of recAβ 1-40 and recAβ 1-42 fusion proteins and subsequent 
purification 
 
2.4.5.1 Cleavage of fusion proteins 
Cleavage of the recAβ 1-40 and recAβ 1-42 fusion proteins was achieved by 
solubilising either the lyophilised recAβ 1-40 or recAβ 1-42 fusion protein with TEV 
cleavage buffer (10 mM tris-HCl, 0.5 mM EDTA, 1 mM DTT, pH 8) so that the 
concentration was approximately 1 mg/ml. RecTEV was added to the solution (with 
the ratio of 1:20 TEV: fusion protein), this was mixed before being incubated at 30 °C 
for recAβ 1-40 for 16 hours or 4 °C for recAβ 1-42 for 16 hours (recAβ 1-42 
aggregated at 30 °C). Cleavage was confirmed by SDS-PAGE as indicated by the 






2.4.5.2 Purification by RP chromatography of recAβ 1-40 and recAβ 1-42 following 
TEV cleavage 
Once cleaved, recAβ is prone to aggregation. To disaggregate the solution the 
cleaved recAβ was diluted 1:3 with 70 % formic acid. The sample was diluted 1:3 
with RP buffer A (0.1 % TFA in H2O) and filtered using a 0.22 µM filter. The recAβ 
sample was loaded onto a Zorbax SB300 C8 column (Agilent), which was heated at 
80 °C on a heat block with a 2.5 ml coil preceding it to increase heat exchange. To 
separate recAβ 1-40, the column was equilibrated in 30 % RP buffer B (0.1 % TFA in 
acetonitrile) and 70 % buffer A, the recAβ 1-40 sample was loaded and would elute 
straight away. To separate recAβ 1-42, the column was equilibrated in 32 % RP 
buffer B and 68 % buffer A, the recAβ 1-42 sample was loaded and would elute 
straight away. The absorbance for both recAβ 1-40 and recAβ 1-42 was set to 214 nm 
since both absorb poorly at 280 nm, all separate absorbance peaks were collected. 
The purity of the fractions was analysed by SDS-PAGE. The recAβ 1-40 and recAβ 
1-42 containing fractions were lyophilised and stored at -20 °C.  
 
2.4.5.3 RecAβ monomerisation 
Purified recAβ has a tendency to aggregate, therefore following purification it was 
important to monomerise the protein so that the starting material for 
oligomerisation and fibrillisation assays was defined. Pure lyophilised recAβ was 
solubilised in hexafluoroisopropanol (HFIP), 50 µl was added to each tube of 
cleaved Aβ and the tubes were pooled. Aβ was left in the HFIP for 30 minutes at 
room temperature. The HFIP was removed using a vacuum concentrator 




2.5 Protein characterisation  
 
2.5.1 Circular dichroism (CD) spectroscopy  
The secondary structure of recPrP was analysed by CD spectroscopy (Jasco J-710, 
spectropolarimeter). Generally the concentration of the sample was 1 mg/ml so a cell 
with a path length of 0.1 mm was appropriate. Scans between 260 and 190 nm were 
acquired, with 20 scans taken for each sample. The following parameters were used: 
step resolution: 0.1 nm, speed: 100 nm/min, bandwidth 2.0 nm and sensitivity: 20 
mdeg. A buffer control sample was also analysed and subtracted from the recPrP 
spectrum.  
 
2.5.2 Dynamic light scattering (DLS) 
DLS measures the hydrodynamic radii of proteins present in a sample. Larger 
proteins cause the light to scatter more than smaller proteins, and a protein 
assembly or oligomer would scatter the light more than a monomer. Samples were 
analysed by DLS to determine whether the proteins were in a monomeric form or 
assembled into oligomers or fibrils. Approximately 70 µl of sample was loaded onto 
a 384 well plate and applied to a Zetasizer auto plate sampler (Malvern Instruments 
ltd.) at 25 °C with a 830-nm laser. The hydrodynamic radii for proteins within each 
sample were determined by performing three independent runs of three 
measurements (13 × 10 second readings of each sample, with 120 second 
equilibration time). The mean diameter was then calculated within each run from 
the 3 replicates, and then an overall average was determined from 3 independent 
runs.  
 
2.5.3 Congo red staining 
To stain fibrils for amyloid, Congo red staining was used. Approximately 20 µL of 
fibrils (at approximately 1 mg/ml) underwent centrifugation at 16100 g at 4˚C for 2 
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hours to pellet all fibrillar protein. The supernatant was discarded and 50 µl of 
alkaline NaCl solution (0.02 mM NaCl made up in 80 % (v/v) ethanol with 100 µL 1 
% (w/v) NaOH) was added to the pellet, this was incubated at room temp for 20 
minutes. The fibrils were again pelleted by centrifugation at 16100 g at 4˚C for 15 
minutes. The supernatant was again discarded and 50 µl of alkaline Congo red 
solution (2.9 µM Congo red, made up in 0.2 mM NaCl in 80 % (v/v) ethanol + 100 µL 
1 % (w/v) sodium hydroxide) was added to the pellet. The pellet was mixed gently 
using a pipette and incubated for 20 minutes at room temperature. The fibrils were 
again pelleted by centrifugation at 16100 g at 4˚C for 15 minutes. The supernatant 
was discarded and 50 µl of 20 % (v/v) ethanol was added to the pellet and mixed 
gently with a pipette. The fibrils were once again pelleted by centrifugation at 16100 
g at 4˚C for 15 minutes and the supernatant was discarded, 50 μl of 20 % (v/v) 
ethanol was added to wash the pellet. The ethanol was removed by pipette and the 
pellet was allowed to air dry. The pellet was reconstituted in phosphate buffered 
saline (137 mM NaCl, 3 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.5) and 
applied to a coverslip where it was allowed to air dry. The slides were mounted and 
analysed using a Nikon E800 x/y stage with cross polarisers. Amyloid was 
visualised under polarised light as yellow/ green birefringence.  
 
2.5.4 Transmission electron microscopy (TEM) 
All TEM sample preparation and analyses were performed by dedicated staff at 
king’s buildings, University of Edinburgh. A droplet of the fibril suspension (fibrils 
were in 50 mM sodium acetate pH 5.5) was allowed to settle on a Formvar/Carbon 
200 mesh Copper grid for 10 minutes. Excess liquid was removed by touching the 
grid edge with filter paper. A drop of 1% uranyl acetate was applied for 30 seconds 
then removed by touching the grid edge with filter paper. The grids were air dried 
and were viewed in a Philips CM120 Transmission electron microscope. 
Representative images were taken on a Gatan Orius CCD camera. 
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2.6 Oligomerisation assays  
 
2.6.1 RecPrP oligomerisation 
The following method was adapted from Rezaei et al. (Rezaei et al., 2005) 
Lyophilised recPrP was solubilised in 20 mM sodium citrate pH 3.4 to 1 mg/ml, this 
was heated for 2.5 hours at 45 °C on a heat block. A TSKgelG4000SWxl gel filtration 
column (300 mm × 7.8 mm; TOSOH Bioscience) was equilibrated in 20 mM sodium 
citrate pH 3.4 and was used to analyse the oligomers. After 2.5 hours at 45 °C, 
approximately 15 µl of the oligomer sample was injected onto the column; 1 ml 
fractions were collected for SDS-PAGE gel analysis to confirm that the peaks at 
absorbance 280 nm were recPrP. When investigating the percentage of disulphide-
reduced recPrP needed to form the larger oligomer species, the oxidised and 
disulphide-reduced recPrP were both solubilised in 20 mM sodium citrate pH 3.4 to 
1 mg/ml, the disulphide-reduced recPrP was mixed with the oxidised recPrP to the 
desired percentage and then heated at 45 °C.  
 
2.6.2 Aβ oligomerisation 
The following method was adapted from Stine et al.(Stine et al., 2003)  
Monomerised recAβ was solubilised in dimethyl sulfoxide (DMSO) and the 
concentration was analysed using a spectrophotometer (see section 2.1.6). The 
desired concentration was above 3000 µM. The monomer in DMSO was diluted into 
ice cold DMEM/F-12 cell culture media with no phenol red (Invitrogen), to a final 
concentration of 100 µM. This was mixed gently with a pipette and incubated at 4 °C 
for 24 hours. The resulting oligomers were analysed by DLS (see section 2.5.2).  
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2.7 Fibrillisation assays  
 
2.7.1 RecPrP fibrillisation assay 
The following protocol was modified from Breydo et al. (Breydo et al., 2008). 
Lyophilised recPrP was solubilised in 6 M GdnHCl to a final concentration of 3-5 
mg/ml. Fibrillisation reactions were carried out in black bottom 96 well plates. The 
final reaction mixture for each well consisted of PrP (55.56 μl of 3-5 mg/ml stock), 
MES buffer (16.6 μl of 0.5 M pH 6), thiourea (3.3 μl of 0.5 M pH 6) and thioflavin T 
(1.67 μl of 1 mM). Each well also contained 3 Teflon spheres. A no PrP control was 
also set up, which contained all buffers but no PrP. This acted as a background 
control which was subtracted from the PrP fibrillisation reactions. The 96 well plate 
was shaken continuously for 24 hours at 37 °C using a microplate reader, 
fluorescence readings were taken at 5 minute intervals to follow fibril formation. 
The fibrils were removed from the plate and dialysed into 50 mM sodium acetate 
and were stored at 4 °C. A non-fibrillar control was not shaken and instead left at 
room temperature for 24 hours to be used in characterisation experiments.  
The fibrils were analysed by heating with a detergent to determine whether amyloid 
fibrils had formed or whether the protein had assembled into unstructured 
aggregates. Approximately 500-1500 ng of fibrils were mixed with triton X-100 and 
1 M tris in 3 tubes, tube 3 was heated to 80 °C for 15 minutes. Proteinase K (1: 100 
ratio of PK to PrP) was then added to tubes 2 and 3, they were both incubated at 37 
°C for 1 hour. The reaction was stopped with pefabloc and 8 μl of loading buffer 
(125 mM TRIZMA base, 4.5 M urea, 20 % glycerol, 1.25 M β-mercaptoethanol, 4 % 
SDS and 0.02 % (w/v) bromophenol blue) was added to each tube. The samples 
were analysed by SDS-PAGE and the gel was silver stained. The fibrils which had 
been heated to 80 °C and digested with PK showed a 16 kDa band, which is 
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characteristic of amyloid fibrils(Breydo et al., 2008). The non-fibrillar control 
underwent the same characterisation and was compared with the fibrils.  
 
2.7.2 Aβ fibrillisation assay 
Monomerised recAβ was solubilised in 10 mM sodium hydroxide and the 
concentration was analysed using a spectrophotometer (see section 2.1.6). The 
desired concentration was as close to 1000 μM as possible. The solubilised recAβ 
was diluted into 50 mM HEPES pH 7.4 to a final concentration of 100 µM and 
thioflavin T was added to a final concentration of 20 μM. Once the recAβ had been 
diluted with HEPES, it was loaded onto a 96 well, black bottom plate. A no Aβ 
control was also set up, which contained only buffer and thioflavin T. The 96 well 
plate was incubated at 37 °C using a microplate reader for 24 hours. Fluorescence 
readings were taken at 1 minute intervals to follow fibril formation. Before each 
reading the plate was gently agitated for 10 seconds to ensure the sample was 
homogenous. The fibrils were removed from the plate and stored at 4 °C.  
2.8 Primary cell culture experiments 
 
2.8.1 Culturing of primary cortical cells 
Cortical mouse neurons were cultured by members of the Hardingham lab and 
supplied to me after 9 days in vitro for toxicity experiments.  
Cortical neurons from E17 mice were cultured using the methods described in 
Papadia et al 2008 (Papadia et al., 2008). Briefly, 24 well tissue culture plates were 
incubated for at least two hours at 37 °C in poly-D-lysine and Laminin (Sigma). 
Embryos were anaesthetised with an intraperitoneal injection of sodium 
pentobarbital (Merial Animal Health) and decapitated. Brains were removed, 
cortices dissected and placed in dissociation medium (81.8 mM Na2SO4, 30 mM 
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K2SO4, 5.84 mM MgCl2, 252 µM CaCl2, 1 mM HEPES, 0. 1% Phenol Red, 20 mM 
glucose, and 1 mM Kyurenic acid). Once the required number of cortices had been 
isolated they were placed in a tube, excess liquid was removed and they were 
incubated for 20 minutes at 37 °C in dissociation medium containing 10 units/ml of 
papain (Worthington Biochemical Corporation). The media was then removed and 
this digestion step was repeated. The cortices were then washed twice in 
dissociation media and twice in growth medium (NeuroBasal-A Medium, 2 % B-27 
Supplement, 1 mM glutamine and anti-bacterial/anti-mycotic, (Invitrogen)). 
Following washing, the cortices were dissociated using a 2 ml disposable plastic 
pipette in 10 ml of warm growth medium. This cell suspension was then diluted 
using Opti-MEM (Invitrogen) containing 20 mM glucose, to a concentration of one 
cortical hemisphere per 14 ml of cell suspension. This solution was then plated into 
the pre-coated tissue culture plates, with 500 µl of cell suspension per well of the 24- 
well plate. The plates were then incubated at 37 °C with 5 % CO2 for 2.5 hours, the 
cell suspension was then removed and replaced with 1 ml of growth medium. After 
4 days in vitro, 1 ml of growth media supplemented with 9.6 μM cytosine β-D-
arabinofuranoside hydrochloride (AraC, Sigma) was added to the cells to prevent 
proliferation of glial cells. 
This cell model has been previously characterised and is shown in Gouix et al. 2009 
(Gouix et al., 2009). It was shown that when AraC is used to inhibit glial 
proliferation, the cultures are enriched for neurons and contain less than 5 % glia 
(Gouix et al., 2009, Deighton et al., 2014). This was shown clearly in both studies by 
immunocytochemistry using both glial and neuronal markers.  
 
2.8.2 Toxicity experiments 
At day 9 post culturing, the cells were incubated with basal medium for 2 hours 
before being dosed with the recPrP or recAβ samples, which had been diluted into 
basal medium. The cells were incubated with either the recPrP of recAβ samples in 
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a 37 °C incubator for 24 hours, before being fixed in 4 % paraformaldehyde for 20 
minutes. The cells were then washed with PBS and then incubated with PBS 
containing 0.05 % NP40 for 5 minutes to permeabilise the cells, this was then 
washed off with PBS. The cells were stained with DAPI mounting medium 
(VECTASHIELD®) and a coverslip was placed over the cells in each well. The cells 
were visualised using a Leica AF6000 LX imaging system with a DFC350 FX digital 
camera; 3-4 images were taken of each well using a 10 X 0.3 dry lens with a DAPI 
filter. For each image more than 500 cells were analysed. The images were analysed 
using IMAGE J, the pictures were converted into 8 bit files and the threshold of the 
fluorescence was adjusted until most nuclei could be seen without over exposing 
other nuclei, this was then converted into a black and white image (figure 2.1) A 
plug- in macro then numbered all nuclei and recorded the size of each (figure 2.1). 
They were then counted using the macro; cell viability was quantified by the 
number of non-apoptotic nuclei as a percentage of the total number of cells, which 
was determined by the size of the nuclei; with dead cells having small and shrunken 
nuclei compared to live cells. For each experiment the average size of a live cell 
nucleus was determined and the average size of a dead cell nucleus, this was then 
used to calculate the total number of live and dead cells. Cells were also dosed with 
the corresponding buffer controls: recPrP oligomers (20 mM sodium citrate pH 3.4), 
recPrP monomer or fibrils (50 mM sodium acetate pH 5.5), recAβ monomer 
(DMSO), recAβ oligomers (DMSO + DMEM/F12 media) or recAβ fibrils (sodium 
hydroxide and HEPES pH 7.4), to control for any background cell death caused by 





Figure 2.1 Cell viability image analysis 
Top left, DAPI image of untreated murine cortical cells. The DAPI image was 
converted into a black and white image in image J, (top right). A plug-in macro 
converted this into an image in which all nuclei were numbered and measured for 
their size (bottom right). A magnified section of the numbered image is shown in the 
bottom left. A list of the numbered nuclei with their size was produced, allowing cell 
viability to be calculated. The arrows in the top two images show shrunken nuclei 
indicative of dead cells.  
 
2.8.3 Caspase inhibitor experiments 
To investigate whether cells were dying by apoptosis, the caspase inhibitor Q-VD –
Oph was used (Merck). The cells at 9 days post culturing were first incubated with 
basal medium for 2 hours, this was removed and replaced with basal medium 
containing 50 µM Q-VD–Oph. The cells were incubated with the Q-VD–Oph for 1 
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hour, recPrP or recAβ was added and the cells were incubated in a 37 °C incubator 
for 24 hours, before being fixed and stained as shown for the toxicity experiments. 
Cells were also incubated with recPrP or recAβ alone so that the toxicity could be 
compared. Staurosporine (200 nM) was used as a positive control for apoptosis and 
was added to the cells in the same way as the recPrP or recAβ after the 1 hour 
incubation with Q-VD–Oph (50 µM). Cells were also treated with staurosporine 
alone so that toxicity could be compared between those treated with Q-VD–Oph 
and staurosporine or staurosporine alone.  
 
2.8.4 NMDA receptor antagonist experiments 
To investigate whether cells were dying by excitotoxicity, the NMDA receptor 
antagonist MK 801 (Tocris) was used. The cells at 9 days post culturing were first 
incubated with basal medium for 2 hours, this was removed and replaced with 
basal medium containing 10 µM MK 801. The cells were incubated with MK 801 for 
1 hour, before recPrP or recAβ was added and the cells were incubated in a 37 °C 
incubator for 24 hours. The cells were fixed and stained as shown for the toxicity 
experiments. Cells were also incubated with recPrP or recAβ alone so that the 
toxicity could be compared. NMDA (50 µM) was used as a positive control for 
excitotoxicity and was added to the cells in the same way as the recPrP or recAβ 
after the 1 hour incubation with MK 801. Cells were also treated with NMDA alone 
so that toxicity could be compared between those treated with NMDA and MK 801 
or NMDA alone.  
 
2.8.5 Cell viability data analysis 
For cell viability assays a minimum of 6 images were analysed for each condition (3- 
4 pictures per well with 2 wells for each), the treated cells were normalized to the 
buffer control and expressed as a percentage. A minimum of 3 repeats were carried 
out for each toxicity experiment. To test for significant differences in cell viability 
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between cells treated with different protein conformations, I first tested for 
normality using the Shapiro-Wilk test. This allowed me to ensure that the data was 
normally distributed within each group. I used the Shapiro-Wilk test because it is 
appropriate for small sample sizes. This analysis showed that the data was normally 
distributed which meant that a parametric statistical test such as an ANOVA was 
appropriate. I next used a one- way ANOVA with Bonferroni post hock correction, 
this corrected for the number of different pairwise comparisons making it less likely 
that there would be a significant difference found between two of the groups by 
chance. These analyses were done in SPSS version 21. To analyse whether there had 
been a significant recovery in cell viability in cells treated with the caspase inhibitor 
or NMDA receptor antagonist, a paired 2 tailed t-test was carried out to compare 
cells treated with protein alone (recPrP or recAβ, oligomers or fibrils) and cells 
treated with the protein and the inhibitor.  
 
2.8.6 Western blotting for caspases and ER stress markers 
Western blotting was used to probe for the presence or up-regulation of ER stress 
markers in cells treated with recPrP isoforms. Western blotting was also used to 
detect activated caspase 3 in recPrP treated cells, to test for cells undergoing 
apoptosis. The cells were lysed following incubation with the recPrP isoforms. The 
cell culture media was removed and replaced with 25 µl of RIPA lysis buffer (150 
mM sodium chloride, 50 mM tris, 1 % (v/v) triton X-100, 0.5 % (w/v) sodium 
deoxycholate, 0.1 % (w/v) sodium dodecyl sulphate (SDS), containing 1X complete 
protease inhibitor cocktail (roche)) per well. The cells were left to lyse on ice for 45 
minutes. The wells of the plate were scraped with a pipette tip and the lysates were 
transferred to 1.5 ml tubes. The lysates were sonicated in a sonicating water bath on 
ice for 10 minutes to ensure complete lysis. The cell debris was pelleted by 
centrifugation at 16100 g for 10 minutes at 4 °C. The lysate was removed being 
careful not to disturb the cell pellet. The lysate was either used straight away for 
western blotting, or frozen on dry ice and stored at -80 °C until use. The antibodies 
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used were: cleaved caspase-3 (Cell Signaling) used at 1:1000 dilution, BiP (Cell 
Signaling) used at 1:1000 dilution, caspase 12 (Cell Signaling) used at 1:1000 
dilution, β-actin (Cell Signaling) used at 1:3000 dilution, CHOP (Cell Signaling) used 
at 1:800 dilution, phospho-eIF2α (Cell Signaling) used at 1:1000 dilution, EIF2α (Cell 
Signaling) used at 1:1000 dilution and anti-rabbit IgG (AG154) secondary antibody 
was used for all western blots (sigma) at a dilution of 1: 2500. When western blotting 
for ER stress markers or caspases the western blotting protocol shown in section 
2.1.4 was followed except that for CHOP, phospho-eIF2α and EIF2α where the 
following modifications were made: 5% BSA was used for the primary antibody 
solution, 3 X 5 minute TBS-T washes were carried out first to wash off the blocking 





Chapter 3: Production and characterisation of disease associated isoforms of recPrP and recAβ  
Production and characterisation of 
disease associated isoforms of 





Protein misfolding diseases (PMDs) are a group of related conditions commonly 
associated with large insoluble aggregates or fibrils of disease associated proteins in 
the brain (Bucciantini et al., 2002, Caughey and Lansbury, 2003, Knowles et al., 2014, 
Braak et al., 2003). These insoluble protein deposits are seen as the hallmark features 
of many of these diseases, such as the amyloid beta (Aβ) plaque in Alzheimer’s 
(Alzheimer, 1907, Alzheimer, 1911, Braak and Braak, 1991) or Lewy bodies in 
Parkinson’s disease(Braak et al., 2003). Although large fibrillar aggregates are 
associated with these diseases, it is widely debated whether these fibrillar deposits 
are themselves toxic to surrounding cells, simply the end point of the aggregation 
process(Soto, 2003, Ross and Poirier, 2004, Dobson, 2003), or perhaps a protective 
mechanism by the cells (Haass and Selkoe, 2007, Treusch et al., 2009). By contrast, 
small soluble assemblies of disease associated proteins, which are often termed 
oligomers, are generally accepted to be important in the pathogenesis of PMDs (Kuo 
et al., 1996, Lue et al., 1999, Naslund et al., 2000, McLean et al., 1999, Mucke et al., 
2000a, Walsh et al., 2002, Quist et al., 2005, Kristiansen et al., 2007, Simoneau et al., 
2007, Volles et al., 2001). This has led to the hypothesis that there could be a shared 
mechanism leading to cell death instigated by oligomers (Glabe, 2006, Kayed et al., 
2003, Haass and Selkoe, 2007, Quist et al., 2005). 
As I stated in chapter 1, my main aims were to produce and characterise disease 
associated isoforms, namely oligomers and fibrils, of recPrP and recAβ, and to 
assess the toxicity and related mechanisms caused by these misfolded proteins. In 
order to investigate relationships between conformation and toxicity, it is crucially 
important to characterise the misfolded proteins prior to any toxicity experiments. 
In this chapter, I will discuss the production of recPrP and recAβ, the assays used to 
refold these proteins into both oligomers and fibrils and the subsequent 
characterisation of these misfolded proteins.  
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 Several studies have previously produced disease associated misfolded proteins in 
vitro, (Table 3.1). Clearly, the methods of producing oligomers and fibrils vary 
widely, as do the characterisation methods employed. This may explain why there 
is some variation seen in the literature regarding toxicity of oligomers and fibrils. 
This will be discussed further in chapter 4.  
The disease associated proteins I chose to work with were PrP, which is associated 
with prion diseases, and Aβ, which is thought to play a fundamental role in 
Alzheimer’s disease pathology. I chose PrP because it has been extensively used as a 
model for PMDs in vitro, and there are well developed methods for expressing and 
purifying PrP (Makarava and Baskakov, 2008), and producing oligomers and fibrils 
(Baskakov and Bocharova, 2005, Breydo et al., 2008, Rezaei et al., 2005). My project 
focused on PrP toxicity in the first instance, but in order to investigate whether 
misfolded proteins associated with different PMDs activate the same toxicity 
pathways, I needed to select another relevant protein to compare with PrP. I chose 
Aβ because there had been several papers published (Lee et al., 2005, Garai et al., 
2009, Finder et al., 2010, Macao et al., 2008), which had developed methods for 
producing recombinant Aβ. Additionally, the toxicity of misfolded isoforms of PrP 
and Aβ had not previously been compared. Therefore, by studying both PrP and Aβ 
I could elucidate any similarities or differences in toxicity and mechanisms leading 
to cell death. In addition to producing recPrP oligomers and fibrils, it was important 
to produce a protein to act as a negative control for the toxicity experiments. I 
produced recPrP with an α-helical structure similar to that of normal cellular prion 








Table 3.1 Published methods used for producing and characterising 
oligomers and fibrils 
Methods used for producing Aβ and PrP oligomers and fibrils. Abbreviations: 
Thioflavin T (ThT), Static light scattering (SLS), Quasi-elastic light scattering (QLS), 
Light scattering (LS), Size exclusion chromatography (SEC), Nuclear magnetic 
resonance (NMR), Circular dichroism (CD), Electron microscopy (EM), Atomic force 
microscopy (AFM), Fourier transform infrared spectroscopy (FTIR), Small-angle X-
ray scattering (SAXS), 8-anilino-1-naphthalenesulfonic acid (ANS).  
Many studies which have investigated Aβ in vitro used synthetic Aβ (Ferrão-
Gonzales et al., 2005, Paul and Axelsen, 2005, Stine et al., 2003, Lorenzo and 
Paper Protein Oligomer/ pre-fibrillar 
methods 





Aβ  0.01 M Tris-HCl, pH 7.2, 
at 37 °C  
0.1 M sodium citrate, 









Aβ 50 mM sodium 
phosphate, 100 mM 
sodium chloride, pH 7.4, 
37 °C + ANS derivatives 
50 mM sodium 
phosphate, 100 mM 
sodium chloride, pH 
7.4, 37 °C + ANS 
derivatives 
LS, SEC, NMR, 
CD 
Finder (Finder 
et al., 2010) 
Aβ N/A 10 mM H3PO4, pH 
7.4, 100 mM NaCl, 





Stine (Stine et 
al., 2003) 
Aβ Diluting into Ham’s F12 
media at 4 °C for 24 
hours 
Diluting into 10 mM 








PrP Partially denaturing 
conditions (1 M GdmCl, 3 
M urea) at 37 °C 
Partially denaturing 
conditions (1 M 
GdmCl, 3 M urea) 
with shaking at 37 
°C  







(Rezaei et al., 
2005) 
PrP 20 mM sodium citrate, pH 
3.4 at range of temps 






PrP Heating to 72 °C or 
tandem linked PrP 
Aging oligomers at 





(Torrent et al., 
2004) 
 
PrP 20 mM Tris-HCl buffer at 
pH 8.5, 40 °C, transient 
pressure at 600 MPa 
20 mM Tris-HCl 
buffer at pH 8.5, 40 
°C, overnight 
pressure of 600 MPa 
ANS + ThT 
fluorescence, LS, 
FTIR, congo red 
staining, PK 
resistance, EM.  
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Yankner, 1994, Texido et al., 2011). However, it has been shown that synthetic Aβ is 
generally less pure and behaves less like Aβ in vivo than recAβ (Finder et al., 2010), 
for example synthetic Aβ fibrillises more slowly (Finder et al., 2010). I therefore 
decided to use recAβ. In addition, by using recAβ I had greater control over the 
production and resulting purity of the protein. RecAβ is difficult to express and 
purify on its own, since it is small and aggregation prone, there are however several 
published methods for producing recAβ (Lee et al., 2005, Garai et al., 2009, Finder et 
al., 2010, Macao et al., 2008). Commonly a fusion protein system was used where the 
Aβ peptide is linked to a soluble polypeptide, usually with a modification such as a 
HIS-tag to assist in purification. The fusion proteins are then expressed in E.coli and 
purified. The pure fusion proteins are then cleaved at the cleavage site separating 
the Aβ peptide from the rest of the fusion protein, the protein is then further 
purified to obtain recAβ alone. I decided to use the fusion protein method published 
in Finder et al. (Finder et al., 2010), since they showed the highest yield of recAβ and 
the protease needed to cleave the fusion proteins was the tobacco etch virus (TEV) 
protease, which I could also produce recombinantly. I obtained plasmids from Prof. 
Glockshuber’s group for recAβ 1-40 and recAβ 1-42 fusion proteins. I followed the 
methods shown in their paper (Finder et al., 2010), but found that a lot of 
optimisation was needed to obtain pure recAβ at the end of the protocol as outlined 
in this chapter.  
I wanted to produce oligomers and fibrils for both the recAβ 1-40 peptide and the 
slightly longer and more aggregation prone recAβ 1-42, since it has been shown that 
both Aβ 1-40 and Aβ 1-42 are important in the disease pathogenesis of Alzheimer’s 
disease (van Oijen et al., 2006, Hartmann et al., 1997, Allan Butterfield, 2002, Dolev 
et al., 2013, Itkin et al., 2011).  
RecPrP is much less aggregation prone than recAβ and is, therefore, easier to purify 
and does not require the use of fusion proteins or specific ligands. Most published 
methods express recPrP in E.coli as insoluble inclusion bodies, which are solubilised 
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using a denaturing buffer such as 8 M urea (Rezaei et al., 2000, Hornemann et al., 
1997) or 8 M guanidine(Burns et al., 2003). Most methods then use purification 
techniques such as affinity chromatography and reverse phase chromatography. 
There are some variations between methods, which include different bacterial lysis 
techniques. Some employed the use of a French pressure cell (Hornemann et al., 
1997), while others use enzymatic cell disruption (Rezaei et al., 2000). In addition, 
there are some variations in refolding PrP following purification. Once PrP has been 
purified, the disulphide bond must be reformed to allow normal folding of the 
protein. Some methods involve refolding on the column (Rezaei et al., 2000), while 
others refold after elution (Hornemann et al., 1997, Kirby et al., 2010). To produce α-
helical PrP, which acted as a negative control in the toxicity experiments, I used the 
lysis and purification methods published in Kirby et al. (Kirby et al., 2010). This 
involved using lysozyme to lyse the bacterial cells, 8 M urea to solubilise the 
inclusion bodies, purification by means of affinity chromatography, and refolding of 
the protein after purification under oxidising conditions. However, to produce 
protein for production of oligomers and fibrils, I used the methods published in 
Makarava et al. (Makarava and Baskakov, 2008). The need for different purification 
procedures will be discussed in more detail later in this chapter.  
I used a range of methods to robustly and reliably characterise the oligomers and 
fibrils for both recAβ and recPrP. The size of the oligomers were analysed by size 
exclusion chromatography (SEC) and dynamic light scattering (DLS), in addition, 
their resistance to PK digestion was investigated. The fibrils were characterised by 
thioflavin T (ThT) fluorescence, Congo red staining for amyloid and resistance to PK 
digestion. The recPrP proteins also underwent some additional analysis, the 
secondary structure of the oligomers was investigated by circular dichroism (CD) 
and the recPrP fibrils were analysed by electron microscopy. 
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3.2 Production and characterisation of α-helical recPrP  
As previously outlined, I initially sought to produce recPrP with a structure similar 
to that of PrPC, which is not toxic in vivo, to act as a negative control in subsequent 
toxicity experiments. I expressed murine recPrP 23-230 in E.coli and purified using a 
multistep purification procedure (for full details, see materials and methods section 
2.4.1). Following purification, the recPrP was refolded under oxidising conditions. 
The purified protein was characterised using SDS-PAGE (figure 3.1A). The analysis 
revealed the protein to show a high level of purity and is the correct molecular 
weight. The secondary structure of the protein was investigated using CD. A typical 
CD spectrum for a protein with an α-helical secondary structure, such as PrPC, 
would show a double minima at 208 and 222 nm. Figure 3.1B shows the CD 
spectrum for the purified PrP protein, the spectrum is typical of an α-helical protein. 
The secondary structure of the purified protein is therefore similar to PrPC and so 




Figure 3.1 Characterisation of α-helical recPrP 
A) A typical SDS-PAGE gel with coomassie staining, showing serial dilution of 




3.3 Production and characterisation of recPrP disease associated 
isoforms 
In PMDs, oligomers and fibrils have both been highlighted as potential toxic species, 
causing the cell death seen in these disorders (Bucciantini et al., 2002, Caughey and 
Lansbury, 2003, Knowles et al., 2014, Braak et al., 2003, Kuo et al., 1996, Naslund et 
al., 2000, McLean et al., 1999, Mucke et al., 2000a, Walsh et al., 2002, Quist et al., 
2005, Kristiansen et al., 2007, Simoneau et al., 2007, Volles et al., 2001). Therefore, I 
wanted to produce both oligomers and fibrils and investigate their ability to cause 
toxicity.  
The recPrP oligomerisation and fibrillisation protocols required different buffers, 
since recPrP fibrils form under partially denaturing conditions, while oligomers 
form under mildly acidic conditions. The purified recPrP was therefore needed in a 
lyophilised form, to allow solubilisation under either fibrillising or oligomerising 
conditions at specific concentrations. Therefore, this required a different purification 
procedure to that used to produce α-helical recPrP, with the final stage being 
reverse phase high performance liquid chromatography (HPLC), in which the 
protein is eluted in acetonitrile. Acetonitrile is a volatile solvent, which readily 
evaporates, meaning that under centrifugal vacuum the recPrP could be lyophilised 
(for full details see materials and methods section 2.4.2.4). A representative reverse 
phase (RP) chromatogram and SDS-PAGE analysis of the purification fractions is 
shown in supplementary figure 1 A+B.  
RecPrP oligomers were formed at pH 3.4 with heating at 45 °C, as published in 
Rezaei et al. (Rezaei et al., 2005) (for full details see materials and methods section 
2.6.1). The oligomers were analysed using SEC, as shown in figure 3.2A. Two main 
oligomer populations were formed under these conditions: larger oligomers 
thought to consist of approximately 36 PrP molecules, and smaller oligomers 
thought to consist of approximately 12 PrP molecules. The approximate size of the 
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oligomers which form when using this method was shown in Rezaei et al. (Rezaei et 
al., 2005). The larger oligomers which elute between 6-8 ml are labelled P1 in figure 
3.2A, the smaller oligomers elute between 8.5 -10 ml are labelled P2. The recPrP 
which remained as a monomer elutes between 11-12 ml and is labelled as P3 in 
figure 3.2A. In order to confirm that the absorbance peaks shown in figure 3.2A 
were protein, fractions were collected at 1 ml intervals and analysed using SDS-
PAGE and silver staining (figure 3.2B). Protein bands, which are the correct 
molecular weight to be recPrP, are shown in lanes corresponding with elution 
fractions from 7-8 ml (P1), 9-10 ml (P2) and 11-12 ml (P3), showing that the peaks in 
figure 3.2A are recPrP. Figure 3.2C shows a SEC at the start of the oligomerisation 
assay. The P1 peak shown in figure 3.2A is absent, and P2 is much smaller, with the 
majority of the protein being monomeric at the start of the assay (P3). This P3 peak 
is of much lower intensity once the oligomers have formed, as shown in figure 3.2A, 
since the monomer is converted to oligomers.  
When the oligomers form, the ratio of the larger to smaller oligomer species can 
vary. One variable which impacts this ratio is the proportion of oxidised recPrP 
(with the disulphide bond) compared to recPrP lacking the disulphide bond. I have 
found that oligomerising oxidised recPrP with an intact disulphide bond leads to 
the production of the smaller oligomer (12 mer) species. By contrast, oligomerising 
recPrP lacking the disulphide bond leads to the production of the larger oligomer 
(36-mer) species. Interestingly, it was found that even small quantities of recPrP 
lacking the disulphide bond drives the formation of the larger oligomer species. 
This will be discussed in detail in chapter 5. 
To investigate the secondary structure of the oligomers, I used CD as shown in 
figure 3.3. The structure is very different to that of the α-helical recPrP shown in 
figure 3.1B. The oligomer spectrum shows a single minimum at 215 nm, indicative 





Figure 3.2 Characterisation of recPrP oligomers 
A) SEC showing recPrP oligomers. P1 corresponds to a larger oligomer species 
thought to comprise approximately 36 PrP molecules. P2 corresponds to a smaller 
oligomer species, thought to comprise approximately 12 PrP molecules and P3 
corresponds to monomeric PrP. B) SDS-PAGE gel stained with silver nitrate, 
showing 1 ml fractions collected from the chromatogram shown in A; the band at 7-8 
ml corresponds with P1, a band at 9-10 ml with P2 and a band at 11-12 ml with P3. 
All bands show the correct molecular weight for recPrP. C) SEC chromatogram at 
time point 0 minutes of the oligomerisation assay. P2 corresponds to the smaller 





Figure 3.3 The secondary structure of recPrP oligomers 
Circular dichroism spectrum of recPrP oligomers, showing a single minimum at 215 
nm which is suggestive of a β-sheet rich structure. 
As mentioned previously, I wanted to assess the toxicity of oligomeric species of PrP 
since they are thought to play an important role in disease pathogenesis in prion 
diseases. The oligomerisation assay used in the Gill lab had previously been 
optimised to investigate the rate and mechanisms of oligomerisation. The protein 
was therefore heated on a HPLC auto-sampler and at 15 minute intervals a sample 
was injected onto the SEC column. However, I needed to adapt the assay to produce 
larger volumes of oligomers in order to test these for toxicity. I did this by heating 
larger volumes of recPrP on a heat block at 45 °C, instead of the auto-sampler, and 
after 2.5 hours the oligomers were then analysed using SEC. Once the assay had 
been optimised, it was then important to investigate the stability of the oligomers 
under different storage conditions. The oligomers were kept at both 4 °C and -20 °C 
for increasing lengths of time. At regular intervals the oligomers were tested using 
SEC, to assess whether the sample contained the same proportion of oligomers as it 
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did when first made. Figure 3.4 shows the SEC results for oligomers stored at 4 °C 
for 24 hours (B) and 4 days (D), and oligomers stored at -20 °C for 24 hours (A), 4 
days (C) and 4 months (E). The SEC chromatograms for the oligomers when first 
formed are shown in black, those stored at -20 °C are shown in green and those 
stored at 4 °C are shown in blue. Oligomers stored at 4 °C or -20 °C for 24 hours 
were both shown to be stable (figure 3.4 A + B), with the green and blue 
chromatograms overlaying the black chromatogram. At 4 days post oligomerisation, 
the oligomers stored at 4 °C shown by the blue chromatogram in figure 3.4D, shows 
a drop in the oligomer peak in comparison to the original chromatogram shown in 
black (indicated by the arrow). The drop in the oligomer peak for the green 
chromatogram in figure 3.4C in comparison to the original black chromatogram is 
much less, suggesting that the oligomers are more stable at -20 °C. A new batch of 
oligomers was made and stored at -20 °C for 4 months (figure 3.4E), the oligomers 
were shown to be stable with the green chromatogram overlaying the black 
chromatogram, with no drop in the oligomer peak. Once the stability of the 
oligomers had been established, oligomers for all cell experiments were stored at -20 




Figure 3.4 Storage conditions for recPrP oligomers. 
SECs showing different storage conditions for recPrP oligomers. A + C) Show fresh 
oligomers (black) and those stored at -20 °C (green) for 24 hours or 4 days 
respectively. B + D) Show fresh oligomers (black) and those stored at 4 °C (blue) for 
24 hours or 4 days respectively. The black arrow in D indicates the drop in 
absorbance for the oligomers stored under these conditions. E) Shows a different 
batch of fresh oligomers compared to A-D (black) and those stored at -20 °C for 4 
months (green).  
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In addition to the oligomers, I also wanted to produce fibrils with an amyloid 
structure to mimic the fibrillar deposits found in individuals infected with prion 
disease. Fibrils were formed under partially denaturing conditions (2 M guanidine) 
with vigorous shaking at 37 °C in a 96 well plate in a fluorescence plate reader (full 
details can be found in materials and methods, section 2.7.1). The fibrillisation assay 
had to be optimised to produce fibrils for toxicity experiments. Similar to the 
oligomerisation assay, the fibrillisation assay had been used previously to 
investigate fibril formation and fibrillisation kinetics (Breydo et al., 2008) not form 
fibrils for subsequent experiments. The concentration of the fibrils at the end of the 
assay was usually ~0.1 mg/ml, which was too low to dose the cells at the required 
concentration range while still keeping the volume of fibrils added to the cells low. 
This was important since if large volumes were added, the fibril buffer began to 
show toxicity. I therefore adjusted the reaction so that the recPrP starting 
concentration prior to addition of the fibrillisation buffer was ~4 mg/ml instead of 3 
mg/ml. Additionally, I omitted the 6 M guanidine from the fibrillisation buffer and 
instead increased the volume of recPrP (solubilised in 6 M guanidine) in each 
fibrillisation reaction to 53.6 µl from 26.8 µl. The result of this optimisation was 
fibrils which were ~1 mg/ml, which was concentrated enough for the cell 
experiments.  
Fibril formation was monitored over 24 hours using the dye ThT, which fluoresces 
when bound to amyloid. Fluorescence readings were taken at 5 minute intervals. A 
representative fibrillisation assay is shown in figure 3.5A. ThT data were averaged 
for 4 fibrillisation reactions and any background fluorescence, shown by a no PrP 
control, was subtracted. The data was then expressed as a percentage, and standard 
deviation error bars are shown indicating the variation between the fibrillisation 
reactions. The first 75 minutes of the assay shows low fluorescence: this is known as 
“the lag time”, which is generally thought to be the time it takes for monomeric 
recPrP to begin to nucleate and then aggregate into fibrils (Breydo et al., 2008, 
Bocharova et al., 2005). The increase in fluorescence seen between approximately 
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100 and 200 minutes indicates the fibrils forming, and the plateau seen after this is 
thought to indicate that all the monomeric recPrP has been incorporated into the 
fibrils. Once formed, the fibrils were dialysed into sodium acetate pH 5.5 and stored 
at 4 °C. For fibril toxicity experiments, I decided to make fibrils without ThT in case 
the ThT bound to the fibrils affected their toxicity. I therefore set up fibrillisation 
reactions without ThT, but under the same conditions and on the same plate as 
fibrils being monitored for ThT fluorescence. It was these ThT-free fibrils that were 
used in the cellular toxicity experiments. 
 Next, I investigated whether the fibrils had an amyloid structure or were just 
comprised of aggregated protein. PrPSc found in diseased tissues is known to be PK 
resistant (Parchi et al., 2000, Collinge et al., 1996); PK resistance is therefore a 
relevant characterisation method to investigate whether fibrils formed in vitro share 
properties with PrPSc. Additionally, it has been shown that fibrils have an insoluble 
PK resistant core of between 10-12 kDa (Breydo et al., 2008). When fibrils are heated 
to 80 °C with a mild detergent (known as maturation), this core expands to 16 kDa, 
which can be seen as a 16 kDa band after PK treatment by means of SDS-PAGE. This 
16 kDa band is therefore thought to be indicative of amyloid fibrils (Breydo et al., 
2008), and so I used this method to analyse the fibrils I had formed. The fibrils were 
digested with PK alone or following maturation, this was compared to the non-
fibrillar (NF) control (recPrP which had been under the same buffer conditions as 
the fibrils, but not shaken for 24 hours). All samples were analysed using SDS-
PAGE with silver staining as shown in figure 3.5B. The NF control was completely 
digested by PK in lanes 2 and 3. By contrast, the fibrils treated with PK in lane 5 
show 10 and 12 kDa bands, indicative of PK resistance. In lane 6, where the fibrils 
have undergone maturation and PK treatment, there is also a 16 kDa band 
(highlighted by the arrow). As mentioned previously, this band is thought to be 
characteristic of amyloid fibrils (Breydo et al., 2008). It is thought that during 
maturation, the insoluble core of a fibril expands from 10-12 kDa to 16 kDa resulting 
in this distinctive banding pattern (Breydo et al., 2008). Furthermore, the fibrils were 
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analysed using Congo red staining (figure 3.6A and 3.6B), which when observed 
under polarised light, shows a yellow- green birefringence indicating amyloid 
structures (Wolman and Bubis, 1965). The arrows in figure 3.6A and 3.6B indicate 
the birefringence caused by amyloid. Additionally, the fibrils were analysed using 
transmission electron microscopy (TEM), at two magnifications, as shown in figure 
3.6C and 3.6D. The SEM images show the fibrils are long and highly structured. 
Taken together, these results indicate that the recPrP has adopted a fibrillar amyloid 
structure with a PK resistant core. The fibrils used in the cellular toxicity 
experiments were stored at 4 °C for up to 6 months.  
Since PrPSc isolated from infected tissue is PK resistant, and the fibrils I have formed 
also show resistance to PK digestion, I wanted to investigate the PK resistance of the 
oligomers and α-helical recPrP and compare this with the fibrils. All three 
conformations were digested with PK for 30 minutes at 37 °C at 2 and 4 µg/ml, and 
analysed using SDS-PAGE and silver staining. Figure 3.7 shows the differences in 
PK resistance between all three conformations. The differences are particularly clear 
at 4 µg/ml; with the fibrils being the most PK resistant, oligomers showing some PK 
resistance, and the α-helical recPrP showing the least resistance. This again 
highlights that all three conformations have distinct structures, which confer 
differences in sensitivity to PK digestion. The PK sensitivity shown by the 
monomers and oligomers may be similar to the PK sensitivity of soluble PK 
sensitive PrP in vivo, which has also been shown to be infectious and toxic (Sajnani 




Figure 3.5 Production and characterisation of recPrP fibrils.  
A) ThT average fluorescence curve, showing readings over time as the recPrP fibrils 
form and ThT binds (average of 4 fibrillisation reactions) ± standard deviation error 
bars are shown. B) Characterisation of recPrP fibrils by maturation at 80 °C and PK 
digestion. Lanes 1-3 show the non-fibrillar (NF) control which underwent the same 
conditions as the fibrils, except they were not shaken for 24 hours. Lanes 4-6 show 
recPrP fibrils; either with no PK, with PK but not heated to 80 °C or with PK and 
heated to 80 °C (maturation). The 16 kDa band present in lane 6 (highlighted by the 
arrow) is characteristic of amyloid fibrils. The band at approximately 40 kDa in lanes 




Figure 3.6 Characterisation of recPrP fibrils.  
A and B show PrP fibrils with Congo red staining under polarised light, the yellow 
and green birefringence shows amyloid structures. C and D show scanning electron 
microscope pictures of recPrP fibrils, the black scale bar in the bottom left hand 
corner of C represents 1 µM. The scale bar in the bottom left hand corner of D 






Figure 3.7 PK resistance of different recPrP conformations  
SDS-PAGE gel which has been silver stained, showing differences in PK resistance 
between α-helical recPrP, oligomers and fibrils. Lanes 1-4 show α-helical recPrP 
(M), oligomers (O), oligomers which had been frozen and thawed (FT) and fibrils (F), 
with no PK treatment. Lanes 5-8 show the α-helical recPrP, oligomers and fibrils 
having been treated with PK at 2 µg/ml for 30 minutes, and lanes 9-12 shows the 




3.4 Production of recombinant Aβ fusion proteins 
The recAβ 1-40 and recAβ 1-42 peptides were produced using the fusion protein 
system developed by Prof. Glockshuber’s group(Finder et al., 2010), who provided 
plasmids containing the fusion proteins for recAβ 1-40 and recAβ 1-42. A schematic 
diagram of the fusion protein is shown in figure 3.8. The Aβ peptide is attached to a 
soluble polypeptide, linked to a histidine tag, which allows purification by 
immobilised metal ion affinity chromatography (IMAC). The Aβ peptide and the 
fusion protein are separated by a cleavage site recognised by the tobacco etch virus 
(TEV) protease, which was used to cleave the fusion protein from the Aβ peptide.  
 
Figure 3.8 Schematic diagram of Aβ fusion protein 
This schematic diagram from Finder et al. (Finder et al., 2010) shows the Aβ fusion 
protein. The Aβ peptide on the right hand side is shown to be linked to the soluble 
polypeptide, with a histidine tag on the left hand side. The scissors indicate the 
cleavage site which is recognised by TEV protease. The amino acid sequences for 
Aβ 1-40 and Aβ 1-42 are also shown.  
E. coli transformed with the Aβ 1-40 and Aβ 1-42 fusion protein plasmids were 
grown in 400 ml cultures, and fusion protein expression was induced by IPTG (for 
more detail see materials and methods section 2.2.2). Samples were taken prior to 
induction and at regular intervals after induction, to assess the production of recAβ 
1-40 and recAβ 1-42 fusion proteins. Theses samples were analysed by SDS-PAGE, 
as shown in figure 3.9A and 3.9B. The arrows show bands at the correct molecular 
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weight for the recAβ 1-40 and recAβ 1-42 fusion proteins, which increase in 
intensity over time. Following expression, the bacteria were lysed and the inclusion 
bodies containing the fusion proteins were solubilised using 6 M guanidine 
hydrochloride. The fusion proteins were purified first by immobilised metal ion 
affinity chromatography and then by reverse phase chromatography. Figure 3.10A 
shows the reverse phase chromatogram for the recAβ 1-40 fusion protein. The 
fractions collected from the purification were analysed using SDS-PAGE in figure 
3.10B. The bands shown in lanes 11 + 12 were confirmed to be the recAβ 1-40 fusion 
protein by western blotting with a HIS-TAG antibody (figure 3.10C). The same 
procedure was carried out for the recAβ 1-42 fusion protein. The reverse phase 
chromatogram and corresponding fractions shown by SDS-PAGE and western blot 
are shown in figure 3.11A-C. The reverse phase chromatograms and SDS-PAGE gels 





Figure 3.9 Expression of recAβ 1-40 and 1-42 fusion proteins 
RecAβ 1-40 and recAβ 1-42 fusion proteins were expressed in BL21 E.coli and 
induced using IPTG. A) SDS-PAGE gel with coomassie staining, showing 
expression of recAβ 1-40: lane 1: un-induced bacteria, lane 2: 1 hour after induction, 
lane 3: 2 hours after induction and lane 4: 16 hours after induction (arrows indicate 
the recAβ 1-40 fusion protein bands). B) Composite SDS-PAGE gel with coomassie 
staining, showing expression of recAβ 1-42: lane 1: un-induced bacteria, lane 2: 1 
hour after induction, lane 3: 2 hours after induction and lane 4: 16 hours after 





Figure 3.10 Purification of recAβ 1-40 fusion protein 
A) Reverse phase chromatogram for recAβ 1-40 fusion protein purification, the large 
peak is the eluting fusion protein. B) SDS-PAGE gel with coomassie staining, 
showing fractions collected from the reverse phase chromatogram (A), lanes 11 + 
12 show the recAβ 1- 40 fusion protein which corresponds to the large peak in A. C) 
Western blot of fractions from the recAβ 1-40 fusion protein purification. Lanes 1-3 




Figure 3.11 Purification of recAβ 1-42 fusion protein 
A) Reverse phase chromatogram for recAβ 1-42 fusion protein purification, the large 
peaks correspond to the eluting fusion protein. B) SDS-PAGE gel with coomassie 
staining, showing fractions collected from the reverse phase chromatogram (A), 
lanes 4-7 show the recAβ 1-42 fusion protein which corresponds to the peaks in A. 
C) Western blot of fractions from the recAβ 1-42 fusion protein purification. Lanes 1-
4 correspond to lanes 4-7 in B; a HIS-tag antibody was used.  
3.5 Production of recombinant TEV protease  
Once I had purified both fusion proteins, I needed to obtain TEV protease in order 
to cleave them. At the time, TEV protease was not available commercially so I 
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produced it as a recombinant protein. A glycerol stock of E.coli containing a TEV 
protease plasmid was available in the Gill group; this allowed me to express 
recTEV. TEV protease expression was induced using IPTG and samples were taken 
before and after induction and analysed using SDS-PAGE (figure 3.12A). The 
recTEV protease accumulated in inclusion bodies, which were solubilised with 8 M 
urea. The recTEV protease was then purified using IMAC and the resulting fractions 
were analysed using SDS-PAGE (figure 3.12B). The fraction shown in lane 5 was 
dialysed into a tris/EDTA buffer with a pH of 7.5. However, this resulted in a high 
degree of precipitation. This precipitation occurred despite substantial 
modifications to the protocol, including using purification buffers with or without 
reducing agent, allowing the protein to refold on the column, or changing the 
temperature the protein was dialysed at (4 °C or room temperature).  
The recTEV protease which was still in solution after the precipitate had been 
pelleted was not concentrated enough, or was already beginning to precipitate 
further, which meant that it could not successfully cleave the fusion proteins. Figure 
3.12C, shows samples taken from a cleavage reaction and analysed by SDS-PAGE, 
the blue arrow indicates recTEV protease, and the red arrow indicates the fusion 
protein. RecAβ 1-42 is approximately 4.5 kDa, and, therefore, if cleavage had been 
successful there would have been a protein band at this size, which is indicated by 
the black arrow. No low molecular weight bands were seen, showing that the 
recTEV protease had failed to cleave the fusion protein. Therefore, I decided that 
this was not a viable method for producing recTEV protease to cleave the recAβ 
fusion proteins. The main problem with producing recTEV protease using this 
method was the precipitation that occurred in the dialysis step. The dialysis step 
was, however, needed to dilute the urea in the purification buffers. Therefore, I 
wanted to use a method which did not need denaturants such as urea, which would 
eliminate the need for a dialysis step. Since urea was needed to solubilise the 
inclusion bodies that formed during expression of the protein, an alternative 
84 
 
method was to express TEV as a soluble protein, eliminating any need for 
denaturing buffers.  
 
Figure 3.12 Production of recTEV protease as insoluble inclusion bodies 
A) SDS-PAGE gel which has been coomassie stained, showing expression of TEV 
protease in E.coli. Lane 1: before induction, lane 2: 1 hour after induction, lane 3: 2 
hours after induction and lane 4: 16 hours after induction. B) SDS-PAGE gel which 
has been coomassie stained, showing TEV protease fractions from IMAC 
purification. Lane 1: initial sample, lane 2: flow through, lane 3: wash fraction, lanes 
4- 7: elution fractions. C) SDS-PAGE gel which has been coomassie stained, 
showing Aβ 1-42 fusion protein and TEV protease in increasing amounts, after 
incubation overnight. The blue arrow indicates TEV protease, the red arrow 
indicates un-cleaved Aβ 1-42 fusion protein, and the black arrow indicates where 
the Aβ 1-42 band would be if the cleavage had been successful.  
When recombinant proteins are expressed at 30- 37 °C, such as in the expression 
system previously tested, they are produced in such abundant quantities that the 
protein aggregates into insoluble inclusion bodies, where the protein is not correctly 
folded. When producing proteins which need to be enzymatically active and, 
therefore, correctly folded (such as in the case of TEV protease), it is preferable to 
produce a soluble protein that is correctly folded in the bacteria. One way to 
increase the amount of soluble protein produced by expression bacteria is to 
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decrease the temperature, however, most E.coli chaperonins are very inefficient at 
low temperatures(Ferrer et al., 2003). The ArcticExpress competent cells from 
Agilent technologies contain chaperonins found in Oleispira Antarctica, which is a 
psychrophilic bacterium; these chaperonins are able to refold proteins efficiently at 
low temperatures, allowing soluble recombinant proteins to be produced efficiently. 
Therefore, I chose to use the ArcticExpress bacteria to express TEV protease as a 
soluble protein. The TEV protease containing plasmids were transformed into 
ArcticExpress bacteria and grown in 200 ml cultures, expression was then induced 
with IPTG. Cultures were grown for 24 hours at 12 °C, (for more detail see materials 
and methods section 2.2.3). Samples were taken before and after induction and 
analysed using SDS-PAGE, (figure 3.13A).  
The protease was purified by non-denaturing IMAC and cation exchange 
chromatography, followed by a desalting step to exchange the imidazole containing 
purification buffer to an imidazole free- storage buffer. Fractions from each 
purification step were collected and analysed using SDS-PAGE, shown in figure 
3.13B-D. The resulting protein, shown in lane 5 of figure 3.13D, was soluble and 
showed no precipitation. RecTEV always appeared as a doublet when analysed by 
SDS-PAGE, it is not clear why, however, it did not seem to affect its enzymatic 
capability. Following the successful purification of recTEV using this method, I 
tested the ability of the protease to cleave the recAβ fusion proteins. The recAβ 
fusion proteins were incubated with recTEV protease, which resulted in efficient 
cleavage of both fusion proteins. Figure 3.14A+B shows cleaved and un-cleaved 
fusion proteins analysed by SDS-PAGE. Figure 3.14A shows the successful cleavage 
of recAβ 1-40 as shown by the low molecular weight band, figure 3.14B shows the 




Figure 3.13 Production of recTEV as a soluble protein 
A-D: SDS-PAGE gels which have been coomassie stained, showing TEV 
expression and purifications. A) Induction of TEV as a soluble protein, expressed at 
12 °C. Lanes 1-3 show un-induced bacteria from 3 flasks, lanes 4- 6 show 3 flasks 
of bacteria 2 hours after induction, lanes 7- 9 show 3 flasks of bacteria 16 hours 
after induction. B) RecTEV protease fractions from IMAC purification, with non-
denaturing buffers. Lane 1: initial sample, lane 2: flow through, lane 3: wash fraction, 
lanes 4- 6: elution fractions. C) Cation purification fractions, lane 1: initial sample, 
lane 2: flow through, lane 3: wash fraction, lanes 4- 8: elution fractions. D) Desalting 





Figure 3.14 Cleavage of recAβ 1-40 and recAβ 1-42 fusion proteins  
A) Coomassie stained SDS-PAGE gel showing cleavage of recAβ 1-40 with recTEV 
protease. B) Coomassie stained SDS-PAGE gel showing cleavage of recAβ 1-42 
with recTEV protease. 
3.6 Production of recAβ  
Once successful cleavage of both fusion proteins had been achieved, the cleaved 
recAβ peptides needed to be separated from the un-cleaved fusion protein, the other 
half of the cleaved fusion protein, and recTEV, leaving recAβ 1-40 or 1-42 alone. 
This was first attempted for recAβ 1-40 using RP chromatography with a Grace 
VYDAC® 214TP C4 reversed phase column. However, this did not result in 
separation of the different components of the sample. The RP chromatogram for this 
purification is shown in figure 3.15A. The fractions from this purification were 
analysed by SDS-PAGE and are shown in figure 3.15B; lane 6 shows the fraction 
which corresponds to the peak highlighted by the arrow in A. It is clear that all 
components are in the same fraction. Following the failure of the C4 column to 
separate the components of the sample, I used a C8 column as shown in Finder et al. 
(Finder et al., 2010). However, as shown in figure 3.15C+D this also did not result in 
successful separation. The C8 column was not exactly the same as the one used in 
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Finder et al. (Finder et al., 2010), which may have affected the separation. 
Subsequently, separation was attempted using nickel IMAC, since both the fusion 
protein and TEV have a HIS-tag, while the cleaved recAβ peptides do not. However, 
whilst this did result in successful separation as shown in figure 3.15E (lane 6 shows 
pure recAβ 1-40 highlighted by *), the yield was low and when repeated the 
separation was variable. I therefore decided to obtain a semi-preparative Zorbax 
SB300 C8 column, which is the exact column used in Finder et al. (Finder et al., 





Figure 3.15 Optimisation of recAβ separation following recTEV cleavage.  
A-B) Purification of recAβ 1-40 following TEV cleavage using a Grace VYDAC® 
214TP C4 reversed phase column. A) RP chromatogram; the arrow indicates the 
elution fraction show in lane 6 (B). B) SDS-PAGE with coomassie staining of the 
fractions collected from A. C-D) Purification of recAβ 1-40 following TEV cleavage 
using a Vydac C8 228TP1010 reversed phase column. C) Reverse phase 
chromatogram; the arrow indicates the elution fraction shown in lanes 6 +7 of D. D) 
SDS-PAGE with coomassie staining of the fractions collected from C. E) SDS-PAGE 
with silver staining, showing separation of recAβ 1-40 following recTEV cleavage 
using nickel IMAC to separate recAβ 1-40 from the other cleavage products, * 
indicates a fraction of pure recAβ 1-40.  
Separation using the SB300 C8 column was first attempted for recAβ 1-40 using a 
gradient of acetonitrile. Although this was not successful in fully separating recAβ 
1-40 from the recTEV protease, it did show separation from the un-cleaved fusion 
protein. The RP chromatogram for this is shown in figure 3.16A, fractions from this 
purification were then analysed by SDS-PAGE and are shown in figure 3.16B: the 
blue arrow highlights the recTEV protease which was not separated from the recAβ 
1-40. Next, I tried using a 28 % isocratic elution of acetonitrile as shown in Finder et 
al. (Finder et al., 2010). This was successful in separating recAβ 1-40 from the 
recTEV protease, but not the un-cleaved fusion protein. This is shown in figure 
3.16C+D, the black arrow highlighting the absorbance peak in C corresponds with 
the fraction shown in lane 11 of D, the un-cleaved fusion protein is highlighted by 
the blue arrow, which is in the same fraction as Aβ 1-40. Finally, successful 
separation of the recAβ 1-40 peptide was achieved using a 30 % isocratic elution of 
acetonitrile. This is shown in figure 3.16E+F, the arrow in E points to the absorbance 
peak showing the eluting Aβ 1-40 peptide and the corresponding fractions are 







Figure 3.16 Optimisation of recAβ 1-40 separation following recTEV cleavage, 
with SB300 C8 reversed phase column. 
A) Separation of recAβ 1-40 after cleavage with recTEV using a gradient of 0- 20 % 
acetonitrile in 5 minutes, 20- 40 % in 15 minutes and 40- 80 % in 10 minutes, the 
black arrow shows the eluting protein. B) SDS-PAGE gel which has been silver 
stained, showing the fractions collected from the purification shown in A (lanes 3-
10), lanes 1 + 2 show un-cleaved and cleaved recAβ 1-40 respectively, and lane 11 
shows recTEV protease alone. The recAβ 1-40 peptide was separated from the un-
cleaved fusion protein, but not recTEV protease as shown in lane 7, highlighted by 
the blue arrow. C) Separation of recAβ 1-40 after cleavage with recTEV using a 28 
% isocratic gradient, as shown in Finder et al.(Finder et al., 2010), the black arrow 
shows the eluting protein. D) SDS-PAGE gel which has been silver stained, showing 
the fractions collected from the purification shown in C (lanes 3-12), lanes 1 + 2 
show un-cleaved and cleaved recAβ 1-40 respectively, and lane 13 shows recTEV 
protease alone. The recAβ 1-40 peptide was separated from recTEV protease as 
shown in lane 11, but not from the un-cleaved fusion protein, highlighted by the blue 
arrow. E) Separation of recAβ 1-40 after cleavage with recTEV using a 30 % 
isocratic gradient, the black arrow shows the eluting protein (UV absorbance was 
set to 214 nm). F) SDS-PAGE gel which has been silver stained, showing the 
fractions collected from the purification shown in E (lanes 3-13), lanes 1 + 2 show 
un-cleaved and cleaved recAβ 1-40 respectively, and lane 14 shows recTEV 
protease alone. The recAβ 1-40 peptide was separated from both recTEV protease 
and the un-cleaved fusion protein as shown in lanes 8 + 9.  
 
Separating the cleaved recAβ 1-42 peptide was found to be more problematic than 
separating recAβ 1-40. I initially used an isocratic elution of 30.5 % acetonitrile as 
shown in Finder et al. (Finder et al., 2010). However, separation using this gradient 
was poor, with no separation of recAβ 1-42 from the un-cleaved fusion protein. This 
is shown in figure 3.17A, where it is clear from the eluting protein highlighted by 
the black arrow that there was little separation. The fractions from this are shown by 
SDS-PAGE in figure 3.17B, where lanes 7-11 all contain recAβ 1-42 and the other 
cleavage components. Given the failure of the isocratic elution to separate the 
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sample, next, I heated the column to 80 °C by resting it on a heat block, since Finder 
et al. (Finder et al., 2010) used a column heater at 80 °C to separate the recAβ 
peptides. However, no separation was seen (data not shown). I subsequently heated 
a 2.5 ml metal coil preceding the column, to heat the buffer entering the column, 
since I speculated that the diameter of the column was too large to successfully 
conduct heat from the heat block. Using the heated coil and column and the 30.5 % 
isocratic elution of acetonitrile resulted in better separation than previous attempts, 
as shown in figure 3.17C+D. The chromatogram in C shows peaks which have 
separated to a greater extent than in the preceding chromatogram, but the recAβ 1-
42 highlighted by the black arrow is still not completely separated from the larger 
peak preceding it. Figure 3.17D shows the fractions from the chromatogram in C; 
Aβ 1-42 in lanes 10 + 11 show a much higher level of purity than seen before, but 
there is still a small amount of un-cleaved fusion protein present in the recAβ 1-42 
fractions, which is indicated by the blue arrow. Lastly, I tried an isocratic elution of 
32 % acetonitrile with heating of the column and coil at 80 °C. This method gave 
substantially better separation, and can be seen in figure 3.17E+F. The black arrow in 
E highlights the eluting peak of recAβ 1-42, which shows good separation from all 
other peaks. The fractions from this purification are shown in F; lane 8, which 






Figure 3.17 Optimisation of recAβ 1-42 separation following recTEV cleavage, 
with SB300 C8 reversed phase column. 
A) Separation of recAβ 1-42 after cleavage with recTEV, using a 30.5 % isocratic 
gradient as shown in Finder et al. (Finder et al., 2010), the black arrow shows the 
eluting protein B) SDS-PAGE gel which has been silver stained, showing the 
fractions collected from the purification shown in A (lanes 2-12), lane 1 shows 
cleaved recAβ 1-42 . The recAβ 1-42 peptide was not separated from the fusion 
protein shown in lanes 5-11 or TEV protease shown in lanes 10 + 11. C) Separation 
of recAβ 1-42 after cleavage with recTEV using a 30.5% isocratic gradient as shown 
in Finder et al. (Finder et al., 2010), with the column and a 2.5 ml coil preceding it 
heated to 80 °C on a heat-block, the black arrow shows the eluting protein. D) SDS-
PAGE gel which has been silver stained, showing the fractions collected from the 
purification shown in C (lanes 3-14), lanes 1 + 2 show un-cleaved and cleaved 
recAβ 1-42 respectively. The purification shows incomplete separation of recAβ 1-42 
from the fusion protein, shown in lanes 10 + 11, highlighted by the blue arrow. E) 
Separation of recAβ 1-42 after cleavage with TEV using a 32 % isocratic gradient 
and heating the column and 2.5 ml coil to 80 °C on a heat-block, the black arrow 
shows the eluting protein. F) SDS-PAGE gel which has been silver stained, showing 
the fractions collected from the purification shown in E (lanes 3-14), lanes 1 + 2 
show un-cleaved and cleaved recAβ 1-42 respectively. The recAβ 1-42 peptide was 
separated from both recTEV protease and the fusion protein, shown in lane 8.  
 
3.7 Production and characterisation of recAβ disease associated 
isoforms 
As previously stated, I wanted to investigate the toxicity of both oligomers and 
fibrils for recPrP and recAβ. This would allow comparisons to be made between 
potential important toxic species and the mechanisms leading to cell death. 
Therefore, once I had optimised the purification of the recAβ peptides, I wanted to 
develop assays to produce recAβ oligomers and fibrils. Controlling the starting 
conformation of recAβ 1-40 and recAβ 1-42 is crucially important in order to 
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compare the fibrillisation rates of the recAβ species, and to eliminate any initial 
aggregates from the oligomerisation preparations. I therefore needed to 
monomerise the recAβ peptides, since recAβ aggregates very readily and, therefore, 
is unlikely to be monomeric following purification. The recAβ peptides were 
monomerised by treating the pure lyophilised recAβ with hexafluoroisopropanol 
(HFIP), for 30 minutes at room temperature, and then removing the HFIP using a 
centrifugal vacuum. This method is widely accepted to eliminate any aggregates, 
leaving monomeric protein (Stine et al., 2003, Ferrão-Gonzales et al., 2005, Dahlgren 
et al., 2002, Young et al., 2009, Sondag et al., 2009).  
Due to the propensity of Aβ to aggregate, in order to form oligomers it is necessary 
to stabilise the protein and slow down the fibrillisation process. I first trialled a 
method using a sulfonated hydrophobic molecule, 4,4’-dianilino- 1,1’-binaphthyl-
5,5’-disulfonate (bis-ANS), which has been shown to bind to Aβ and stabilise it, thus 
slowing down fibrillisation and leading to the production of low molecular weight 
species (LMW) of Aβ. These LMW species were shown to be toxic to a murine 
monocyte-macrophage cell line (RAW) (Ferrão-Gonzales et al., 2005). I used bis-
ANS at 150 μM, since at this concentration it had been shown to stabilise Aβ for 
more than 30 minutes (Ferrão-Gonzales et al., 2005), which I rationalised would be 
long enough to dose the cells before the Aβ began to aggregate. I incubated recAβ 1-
42 with bis-ANS at 37 °C for 2-3 hours, and over the time course, I took samples and 
analysed them using SEC (a TSK3000 SWXL column). However, the chromatogram 
didn’t change over time, and the eluting peak occurred after the bed volume of the 
column. In addition, the leading edge of the peak was very straight, which 
suggested the protein was interacting with the column. I tried to optimise this by 
using higher concentrations of sodium chloride in the running buffer, to reduce 
ionic interactions, but this did little to change the chromatograms. An example of 
recAβ 1-42 oligomers analysed by SEC, is shown in figure 3.18A, the bed volume of 
the column is 13 ml. I decided that SEC was not a reliable way to characterise the 
size of the oligomers formed using bis-ANS. Therefore, I used DLS instead, which is 
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a non-column based approach for investigating the hydrodynamic radius of a 
protein (for full details see methods and materials, section 2.5.2). I solubilised the 
monomeric Aβ in oligomerisation buffer (50 mM sodium phosphate, 100 mM 
sodium chloride, pH 7.4) with bis-ANS at 150 µM, and incubated the protein at 
room temperature for 30 minutes. I then analysed the size of the assemblies which 
had formed using DLS. The data showed that the recAβ species were large and of 
variable size, as shown in figure 3.18B (blue). Additionally, I produced oligomers 
and incubated these at -20 °C for 16 hours to see if the oligomers were stable when 
stored at -20 °C (as I did for recPrP oligomers).  
The DLS data for the oligomers stored at -20 °C, showed them to be smaller and 
more stable than those made fresh, this is shown figure 3.18B (red). Surprisingly, the 
data suggested that freezing the oligomers helped stabilise the assemblies. Multiple 
repeats showed that a stable recAβ 1-42 oligomer population reproducibly formed 
under these conditions (figure 3.18C). Additionally, I found that after storage at -20 
°C, the mean hydrodynamic radius for both recAβ 1-40 and recAβ 1-42 was smaller 
than that of fresh oligomers, which is shown in figure 3.17D. Therefore, I stored the 
oligomers at -20 °C prior to cellular toxicity assays. As mentioned previously, Aβ 
oligomers formed using bis-ANS had been found to be toxic to cells from a murine 
macrophage cell line, and the bis-ANS itself was found to not cause toxicity(Ferrão-
Gonzales et al., 2005). Unfortunately, in initial trials bis-ANS did cause toxicity to 
murine primary cortical cells. The toxicity of bis-ANS, therefore, confounded the 
oligomer toxicity results, since it was not clear whether cellular toxicity was caused 
by the oligomers or the bis-ANS.  
Therefore, I used an alternative method to make recAβ oligomers. This alternative 
method, published by Stine et al. (Stine et al., 2003) used ice-cold Ham’s F12 cell 
culture medium to stabilise Aβ oligomers (Lambert et al., 1998, Stine et al., 2003). 
They showed the resulting Aβ species were small and globular, reminiscent of 
oligomers rather than resembling fibrils (Stine et al., 2003). I therefore followed this 
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method and analysed the resulting oligomers using DLS. The hydrodynamic radius 
and stability of the recAβ 1-42 oligomers were reproducible, and similar to those 
formed with the bis-ANS protocol (figure 3.19A). The recAβ 1-40 oligomers, 
however, were shown to be more heterogeneous than the recAβ 1-42 oligomers, 
with some much larger species suggestive of aggregation. The recAβ 1-42 and recAβ 
1-40 oligomers formed using this method were used in the cellular toxicity and 





Figure 3.18 Characterisation of recAβ oligomers, using BIS-ANS. 
A) SEC for recAβ 1-42 oligomers after 30 minute incubation with BIS-ANS. Protein 
is eluting later than bed volume of the column (absorbance 214 nm). B) DLS data; 
size distribution by volume of recAβ 1-42 oligomers after 30 minute incubation with 
bis-ANS (blue) and after 30 minute incubation with bis-ANS + storage at – 20 °C 
(red). C) DLS data, showing size distribution by volume of recAβ 1-42 oligomers 
after 30 minute incubation with bis-ANS + storage at – 20 °C, (red, blue and green 
show 3 repeats). D) Mean hydrodynamic radius data from DLS is shown for recAβ 
1-40 and recAβ 1-42 oligomers, made after 30 minute incubation with bis-ANS + 
those stored at – 20 °C. 
 
 
Figure 3.19 Characterisation of recAβ oligomers made in F12 media at 4 °C. 
A+ B) DLS data, showing size distribution by volume of recAβ oligomers formed 
using Ham’s F12 cell culture medium at 4 °C. A) RecAβ 1-42 oligomers with 3 
repeats (green, red and black). B) RecAβ 1-40 oligomers with 4 repeats (black, blue, 
green and red). recAβ 1-42 oligomers showed greater stability and more 
reproducible data when compared to recAβ 1-40 oligomers, which showed greater 




In addition to oligomers, it was also important to produce an Aβ species which 
resembled the Aβ plaque that could be tested for toxicity on the cells. The protocol I 
employed was adapted from published methods(Paul and Axelsen, 2005, Finder et 
al., 2010) and involved fibrils being formed by solubilising recAβ in sodium 
hydroxide and then diluting with HEPES pH 7.4 (for full details see methods and 
materials, section 2.7.2). I monitored fibril formation using ThT, as I had done for 
recPrP fibrillisation. However, since I found recAβ to fibrillise much faster than 
recPrP, fluorescence readings were taken at 1 minute intervals instead of 5 minute 
intervals as was done for recPrP. Additionally, in the recPrP fibrillisation assay the 
fibrils were shaken constantly. However, the recAβ fibrillisation assay was 
conducted without shaking, since agitation resulted in the fibrils forming too 
rapidly to monitor the fibrillisation reaction.  
A representative fibrillisation assay for recAβ 1-40 and recAβ 1-42 is shown in figure 
3.20A. ThT data was averaged for 5 fibrillisation reactions and background 
fluorescence, shown by a no recAβ control reaction, was subtracted. The data was 
then expressed as a percentage and standard deviation error bars are shown which 
indicate variation between the fibrillisation reactions. The lag time (the time taken 
for fibrils to begin to form) is represented as a period of low fluorescence at the 
beginning of the assay, and is considerably longer for recAβ 1-40 (figure 3.20A: 
blue) when compared with recAβ 1-42 (figure 3.20A: red). These data indicate that 
recAβ 1-42 fibrillises more readily than recAβ 1-40. Interestingly, the increased 
fibrillisation rate of Aβ 1-42 may also occur in vivo since during disease, Aβ 1-42 
forms fibrillar plaques more readily than Aβ 1-40(Lansbury and Lashuel, 2006, 
Suzuki et al., 1994).  
The recAβ fibrils have an amyloid structure as shown by Congo red staining, where 
under polarised light the characteristic yellow and green birefringence can be seen 
(figure 3.20B). The sensitivity of the recAβ fibrils to PK digestion was also tested as 
it was for the recPrP fibrils. Interestingly, the recAβ fibrils were found to be PK 
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resistant, but no difference was seen with maturation and PK treatment. When 
recPrP fibrils are digested with or without maturation, a different banding pattern is 
seen compared to recPrP fibrils that have not been digested (figure 3.21A + B, lanes 
8 + 9 compared to lane 7). The recAβ fibrils, however, looked no different when 
treated with or without PK, as shown in figure 3.21A for recAβ 1-40 and 3.21B for 
recAβ 1-42. The monomer is shown for comparison. Interestingly, the maturation 
step seems to increase the PK resistance of the monomer for both recAβ 1-40 and 
recAβ 1-42, shown in lane 3 of A and B (monomer after maturation), in comparison 
to lane 2 of A and B.  
 
 
Figure 3.20 Characterisation of recAβ fibrils. 
A) ThT average fluorescence curves, showing readings over time as the recAβ 
fibrils form and ThT binds (average of 5 fibrillisation reactions) ± standard deviation 
error (recAβ 1-42 is shown in red and recAβ 1-40 is shown in blue). B) RecAβ fibrils 
with Congo red staining under polarised light, the yellow and green birefringence 






Figure 3.21 Characterisation of recAβ fibrils. 
A) Characterisation of recAβ 1-40 fibrils by maturation at 80 °C and PK digestion, in 
A+B recPrP fibrils (PrP F) are shown as a control for PK resistance in lanes 7-9. A) 
Lanes 1-3 show recAβ 1-40 monomer (M) and lanes 4-6 show recAβ 1-40 fibrils (F). 
All were either treated with no PK, with PK but not heated to 80 °C or with PK and 
were heated to 80 °C (maturation). B) Characterisation of recAβ 1- 42 fibrils by 
maturation at 80 °C and PK digestion. Lanes 1-3 show recAβ 1-42 monomer (M) 
and lanes 4-6 show recAβ 1-42 fibrils (F). All were either treated with no PK, with PK 





Most studies which have investigated protein toxicity have not compared different 
isoforms of multiple disease associated proteins. However, studies which have 
analysed the toxicity of more than one disease associated protein (Ferreiro et al., 
2006, Silei et al., 1999, Brown et al., 1997, Sáez-Valero et al., 2000) rarely characterise 
the misfolded proteins before investigating toxicity and associated mechanisms. 
This makes it difficult to link protein conformation with toxicity and to compare the 
mechanisms leading to cell death between different proteins. In this chapter, I have 
optimised the production and characterisation of different isoforms of both recPrP 
and recAβ so that the toxicity and mechanisms leading to cell death can be 
investigated. These toxicity and mechanistic experiments are described in detail in 
chapters 4 and 6. In this chapter however, I have focused on how I produced these 
isoforms and how they have been characterised, since it is important to first define 
the structure of the misfolded proteins before testing toxicity, so that clear links 
between certain misfolded species and toxicity can be established. 
Importantly, I have produced a protein which can be used as a negative control in 
toxicity experiments, since a criticism of assessing toxicity by dosing cells with 
misfolded proteins in vitro, is that exposing cells to exogenous protein will cause 
toxicity. The protein I produced to act as a negative control was α-helical recPrP, 
with a structure mimicking that of PrPC. Since PrPC does not cause toxicity in vivo, I 
reasoned that if I dosed the cells with an equivalent concentration of α-helical 
recPrP compared to oligomers or fibrils, then the lack of toxicity induced by α-
helical recPrP would rule out the possibility that the toxicity was due to exogenous 
protein concentration. Instead, it would show that toxicity caused by oligomers or 
fibrils must be conformation dependent. For this reason, it was important to 
establish that the α-helical recPrP showed a high level of purity and was correctly 
folded to give an α-helical structure, which is shown in figure 3.1A+B.  
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Oligomers and small assemblies of misfolded proteins are thought to be 
fundamental in causing pathology in PMDs (Kuo et al., 1996, Naslund et al., 2000, 
McLean et al., 1999, Mucke et al., 2000a, Walsh et al., 2002, Quist et al., 2005, 
Kristiansen et al., 2007, Simoneau et al., 2007, Volles et al., 2001). Therefore, it was 
crucial to produce recPrP oligomers which were of a size and structure relevant to 
those seen in disease. It has been postulated that, in vivo, β-sheet rich (Glabe and 
Kayed, 2006, Cobb and Surewicz, 2009, Prusiner, 1998a) oligomer structures 
between 14 to 28 PrP monomers in size are infectious and are critical to the 
pathology of the disease (Silveira et al., 2005). The method which I used was 
adapted from Rezaei et al. (Rezaei et al., 2005), who demonstrated that this method 
produced two main populations of oligomers: a smaller population which consisted 
of approximately 12 PrP molecules, and a larger oligomer population which 
consisted of approximately 36 PrP molecules. The size of these oligomers is 
therefore similar to what would be relevant in vivo, and CD analysis showed the 
oligomers I had produced had a β-sheet rich structure, which is characteristic of 
oligomers in disease. 
In addition to oligomers, I formed recPrP fibrils to mimic the large insoluble 
amyloid structures which are found in the brains of individuals infected with prion 
disease. As mentioned previously, it is widely debated whether fibrils are toxic to 
neurons, or if they are a protective mechanism to sequester small soluble forms of 
the misfolded protein (Haass and Selkoe, 2007, Treusch et al., 2009). It was therefore 
important to investigate the toxicity of recPrP fibrils in relation to oligomers. PrP 
fibrils isolated from infected tissue appear fibrillar and “rod-like” when analysed by 
electron microscopy (Prusiner et al., 1983), they show resistance to PK digestion 
(Parchi et al., 2000, Collinge et al., 1996), and, exhibit green birefringence under 
polarised light when stained with Congo red (Prusiner et al., 1983). The fibrils I 
formed in vitro, shared similar characteristics to fibrils found in vivo, with an 
amyloid, PK resistant structure.  
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In order to compare the toxicity and associated mechanisms for two important 
disease associated proteins, I also produced the Aβ protein, which is involved in 
Alzheimer’s disease. With much optimisation, I produced a reproducible protocol to 
generate recAβ with a high degree of purity.  
Before making oligomers or fibrils, I monomerised the recAβ by established 
methods (Stine et al., 2003, Barghorn et al., 2005, Dahlgren et al., 2002) to eliminate 
any aggregates so that the starting conformation of recAβ for making both 
oligomers and fibrils was the same. This was important to ensure reproducibility, 
particularly for the oligomers, since aggregates or fibrillar structures within the 
oligomer preparations could confound the toxicity data. It was also important that 
the recAβ was monomeric for the fibrillisation assays, in order to accurately 
compare rates of fibrillisation between recAβ 1-40 and recAβ 1-42.  
Substantial optimisation of published methods (Ferrão-Gonzales et al., 2005, Stine et 
al., 2003) was required to produce recAβ oligomers, which could be tested for 
toxicity. First, I used a sulfonated hydrophobic molecule, bis-ANS, which has been 
shown to stabilise Aβ and slow down fibrillisation (Ferrão-Gonzales et al., 2005). 
However, during initial toxicity assays I found that bis-ANS was toxic to the 
primary cells, which meant that I could not distinguish between toxicity caused by 
the oligomers or by bis-ANS. I therefore had to optimise another method to make 
oligomers.  
Next, I trialled a method using Ham’s F12 cell culture media to make oligomers, 
which was derived from Stine et al. (Stine et al., 2003). This method has the 
advantage that the oligomerisation buffer is cell culture media and, therefore, not 
toxic to cells. The method had also been extensively characterised (Stine et al., 2003, 
Dahlgren et al., 2002, Sondag et al., 2009, Young et al., 2009), with Aβ being 
incubated with the Ham’s F12 cell culture media and then analysed by atomic force 
microscopy (AFM) under various conditions, such as temperature, length of 
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incubation, addition of salts, and pH (Stine et al., 2003). It was shown that when Aβ 
was incubated at 4 °C for 24 hours in F12 media, small globular oligomers formed 
and larger aggregates were absent (Stine et al., 2003). Therefore, I decided that this 
may be a more reliable method for producing recAβ oligomers and in the absence of 
a toxic buffer. In the bis-ANS method, the binding of the bis-ANS molecule to recAβ 
results in stabilisation of the protein and slows down the formation of fibrils 
(Ferrão-Gonzales et al., 2005). It is likely that the F12 cell culture media method 
works on a similar principle, with the amino acids present in the media acting to 
stabilise the oligomers, since it has been shown previously that several amino acids 
present in F12 media, including arginine, glycine, glutamate, histidine, lysine, 
proline, and serine have been shown to have stabilising properties (Falconer et al., 
2011, Arakawa et al., 2007) when purifying, or trying to prevent aggregation of 
proteins (Falconer et al., 2011, Arakawa et al., 2007).  
The disease associated conformations I have formed are comparable to what has 
been published previously. The recPrP fibrils I have produced show comparable 
Congo red staining and EM analysis (Alvarez-Martinez et al., 2011, Bocharova et al., 
2005, Baskakov et al., 2002, Panza et al., 2008), and the oligomers show a β-sheet rich 
structure consistent with several publications (Rezaei et al., 2005, Hosszu et al., 2009, 
Tahiri-Alaoui et al., 2006), and possess similar characteristics to those produced by 
Rezaei et al. (Rezaei et al., 2005). 
There have been less papers published analysing Aβ oligomers formed in vitro, in 
comparison to PrP, likely because Aβ tends to be relatively unstable in this 
conformation, and, as I have found, the reproducible production of these structures 
is technically challenging. Most studies which have estimated the size of Aβ 
oligomers have done so using techniques such as AFM (Stine et al., 2003), which is a 
crude measure of size and gives more of a general impression as to whether small 
globular structures or larger aggregates are present. Studies which have used SEC 
seem to have chromatograms which are comparable to mine, with the protein 
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eluting after the bed volume (Ferrão-Gonzales et al., 2005). This observation 
suggests the protein was interacting with the column, which may therefore give an 
unreliable estimate of size. In contrast, a few papers have used light scattering 
techniques such as dynamic light scattering or static light scattering to investigate 
the size of Aβ oligomers (Bitan et al., 2003, Carrotta et al., 2006, Walsh et al., 1999). 
These results, however, are quite variable likely because of the different methods 
used to form or isolate oligomers and whether synthetic or recAβ was used. In this 
chapter, I have presented DLS data that reproducibly shows that there are 
differences between the size and stability of oligomers formed by recAβ 1-40 or 
recAβ 1-42. 
The recAβ and recPrP fibrils both showed similar characteristics, with amyloid 
structures, ThT fluorescence, and resistance to PK digestion. The recAβ fibrils 
however, formed much more readily than recPrP fibrils. The recPrP fibrils were 
formed under semi-denaturing conditions with shaking. By contrast, recAβ fibrils 
were formed under non-denaturing conditions without shaking showing the 
different propensities of the proteins to form amyloid. This may have implications 
for the pathologies and disease processes for prion or Alzheimer’s disease, and 
whether the fibrils are protective or harmful to the cells. 
I have produced and characterised oligomers and fibrils of both recAβ and recPrP. 
The toxicity of these isoforms will be discussed in chapter 4. The robust 
characterisation of the misfolded proteins, which was carried out in this chapter, 





Chapter 4: Toxicity of disease associated isoforms of recPrP and recAβ 
Toxicity of disease associated 





The main objective of this project was to investigate the toxicity and associated 
mechanisms caused by specific conformations of misfolded proteins. In chapter 3, I 
outlined the production and characterisation of disease associated isoforms of 
recPrP and recAβ. These misfolded isoforms included oligomers and fibrils. In this 
chapter, I will describe investigations of toxicity of these misfolded proteins. I 
wanted to investigate the toxicity of oligomers since they are thought to play a 
crucial role in the pathogenesis of many PMDs (Kuo et al., 1996, Naslund et al., 
2000, McLean et al., 1999, Mucke et al., 2000a, Walsh et al., 2002, Quist et al., 2005, 
Kristiansen et al., 2007, Simoneau et al., 2007, Volles et al., 2001, Lue et al., 1999). 
Furthermore, I wanted to investigate the toxicity of fibrils, since there is much 
debate and controversy concerning the potential toxicity of fibrillar deposits in 
many PMDs (Soto, 2003, Ross and Poirier, 2004, Dobson, 2003, Haass and Selkoe, 
2007, Treusch et al., 2009).  
Studies investigating PMDs generally use in vitro or in vivo models, which each have 
advantages and disadvantages. In vivo experiments often use either transgenic 
animals overexpressing the disease associated protein, or animals with genetic 
mutations to mimic genetic forms of these diseases. Transgenic animals replicate 
some of the characteristic features and symptoms associated with naturally 
occurring PMDs. However, it is not known how overexpressing proteins may affect 
the conformation and resulting toxic species in these transgenic animals. The 
mechanisms and rates of protein misfolding in naturally occurring PMDs, which 
may take decades, may be different when compared to disease in a transgenic 
animal. When investigating a PMD in vivo, the misfolded protein deposits and 
associated cellular toxicity are generally analysed at specific time points within the 
disease process, or at the disease end point. This can make it very difficult to link 
specific protein conformations with toxicity and to understand which misfolded 
species are important. Therefore, it can be helpful to study PMDs in vitro. In such 
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experiments, proteins can be misfolded under controlled conditions into particular 
conformations, characterised, and subsequently tested for toxicity (Baskakov and 
Bocharova, 2005, Bocharova et al., 2005, Breydo et al., 2008, Ferrão-Gonzales et al., 
2005, Finder et al., 2010, Simoneau et al., 2007). By studying the toxicity of well 
characterised isoforms we can investigate relationships between protein 
conformation and disease (Simoneau et al., 2007, Lambert et al., 1998, Stine et al., 
2003). It is also possible to investigate mechanisms and rates of misfolding in vitro, 
which can shed light on how proteins fold or misfold under certain conditions. By 
studying the potential toxicity of misfolded proteins in vitro, it can help us to 
elucidate which misfolded species may be important in vivo. Additionally, in vitro 
studies can allow us to compare the toxicity and related mechanisms induced by 
misfolded proteins associated with different PMDs.  
In this study, I wanted to determine what conformation of recPrP and recAβ was 
most toxic, and, therefore, the most likely to be important in disease pathogenesis. 
In order to make specific links between protein conformation and resulting toxicity, 
an in vitro approach was needed. In vitro experiments allow characterisation of the 
misfolded proteins and controlled toxicity assays, which cannot be achieved in vivo. 
For these reasons, I used in vitro experimentation to investigate the toxicity of 
disease associated isoforms of recPrP and recAβ. I used primary cells as opposed to 
a cell line, since although cell lines are useful for high throughput assays they are 
often isolated from cancer cells or are cells which have been immortalised. This can 
mean that they have lost certain characteristics which would be associated with the 
equivalent cell in vivo, therefore, any toxicity data may not be representative of a 
normal cell (Pan et al., 2009, Burdall et al., 2003, Stansley et al., 2012). Primary cells 
resemble cells in vivo more closely since they are grown straight from the organism 
and not passaged or immortalised (Pan et al., 2009). Primary cells have the 
limitations of being grown as a monolayer, so that the architecture of the organ is 
lost, but they are thought to better represent cells in vivo than cell lines (Pan et al., 
2009). Another option would have been to use organotypic slice cultures (OSCs). 
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OSCs have many of the advantages of primary cells (imaging and control over 
growth in vitro) but they keep much of the architecture of the organ from which they 
were isolated (Cho et al., 2007, Elias and Kriegstein, 2007). However, OSCs are less 
high throughput than primary cells for toxicity experiments. Therefore, I chose to 
use primary cells since they are more physiologically relevant than cell lines and 
they allow a more high throughput approach than OSCs. The primary cells I used 
were murine cortical cells. These were chosen because the cortex is a relevant brain 
area for both AD and prion diseases such as CJD.  
Previously, studies which have looked at the toxicity of PrP or Aβ in vitro have 
generated conflicting data about whether oligomers or fibrils are more toxic 
(Simoneau et al., 2007, Novitskaya et al., 2006, Lorenzo and Yankner, 1994). This is 
likely due to different methods for producing oligomers and fibrils, which leads to 
discrete conformations with different toxic properties. So far there have not been 
any studies which have investigated the toxicity of well characterised misfolded 
forms of both PrP and Aβ using the same toxicity model, which allows the data to 
be directly compared. Previous studies have compared the toxicity of PrP fragments 
with Aβ fragments (Brown et al., 1997, Silei et al., 1999, Sáez-Valero et al., 2000), or 
with full length Aβ 1-40 (Ferreiro et al., 2006). These studies dosed either primary 
neurons or microglia with synthetic peptides (Ferreiro et al., 2006, Silei et al., 1999, 
Brown et al., 1997, Sáez-Valero et al., 2000). The results from these studies showed 
that fragments of PrP or Aβ can cause neuronal toxicity, which may be mediated 
through different pathways (Brown et al., 1997). However, since these peptide 
fragments had not been misfolded or characterised first, no conclusions can be 
drawn about the conformation of these protein fragments in relation to toxicity. In 
the absence of characterisation we cannot know whether the fragments were 
monomeric, or whether they had assembled into oligomers or fibrils prior to 
incubation with the cells. These considerations confound the ability to use these 
studies to link protein conformation and toxicity, which may be crucial to 
understanding these diseases.  
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In chapter 3 I produced full length recPrP and recAβ 1-40 and recAβ 1-42, misfolded 
these into oligomers and fibrils and performed extensive characterisation before 
undertaking any toxicity experiments. This should directly address the limitations 
of these previous studies. In this chapter, I will detail investigations of toxicity for 
these misfolded proteins using murine primary cortical cells. This will hopefully 
give a more complete picture of what the important toxic species are, and addresses 
whether they are the same for different PMDs. Additionally, it will highlight 
whether recPrP and recAβ elicit similar levels of toxicity.  
4.2 Toxicity of disease associated isoforms of recPrP 
The toxicity of recPrP was investigated using primary cortical cells, which were 
incubated with the recPrP isoforms for 24 hours before being fixed and stained with 
DAPI. Cell viability was then established by a live/dead cell count (see section 2.8.1). 
The recPrP cell viability data was normalised to buffer controls for each isoform, 
which accounted for any background toxicity caused by the buffers. If the buffer 
controls caused toxicity (if cell viability was less than 85 %), then the experiment 
was excluded since the background level of cell death was deemed unacceptably 
high. Firstly I tested the toxicity of all isoforms at the concentration range: 3-10 µM 
as shown in Simoneau et al. (Simoneau et al., 2007), but the volume of protein added 
to the cells which was needed to achieve these concentrations meant that all cells 
including the buffer controls showed high toxicity (data not shown). Therefore, I 
reduced the concentration range to: 1.3–5.2 µM (figure 4.1A), which allowed me to 
add lower volumes of protein or buffer to the cells. Once I had lowered the volume 
of buffer being added to the cells, the cell viability in the controls was above the 
acceptable threshold (85 %). As mentioned in chapter 3 α-helical recPrP was 
produced to mimic PrPC, which is not toxic in vivo. The data shows that at the lowest 
concentration the α-helical recPrP caused low levels of toxicity. By contrast, the 
oligomers and fibrils caused a reduction in cell viability of 50 % or more. At the two 
higher concentrations of 2.6 µM and 5.2 µM all three conformations were toxic. In 
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order to demonstrate that recPrP is not in itself toxic and, therefore, any toxicity 
shown by the oligomers or fibrils must be conformation dependent, I wanted to 
select a concentration range at which α-helical recPrP causes low levels of toxicity, 
as PrPC would in vivo. With this in mind, I next trialled a broader, lower 
concentration range (figure 4.1B). The data in figure 4.1B shows that all recPrP 
isoforms caused low levels of toxicity between 0.01- 0.29 µM. However, above 0.29 
µM differences in toxicity between the isoforms are evident. Therefore, I decided to 
use the concentration range 0.43–1.73 µM to investigate the toxicity of the different 
isoforms in greater depth. At this range the α-helical recPrP shows low toxicity, and 
the oligomers and fibrils both elicit a toxic response from the cells.  
To obtain average toxicity data, which was important to reliably determine the 
differences in toxicity between the isoforms, I carried out multiple experiments 
(minimum of n=4) at the concentration range from 0.43–1.73 µM (figure 4.2). The 
results show that the α-helical recPrP caused low toxicity at all concentrations, with 
no significant difference in toxicity when compared to the buffer control. The fibrils 
were shown to be significantly more toxic than α-helical recPrP at all concentrations 
(p value <0.05, figure 4.2) and the oligomers were shown to be significantly more 
toxic than α-helical recPrP at 0.87 µM and 1.73 µM. At 1.73 µM there was no 
significant difference in toxicity between oligomers and fibrils, however, at 0.87 µM 
the fibrils were significantly more toxic than the oligomers (p value <0.05). This was 
an unexpected finding, since oligomers are often thought to be more toxic than 
fibrils in PMDs (Chabry et al., 2003, Ma et al., 2002, Simoneau et al., 2007). The 
concentrations for the cell experiments were based on the monomer concentration. 
Therefore, for 12 monomers in the α-helical recPrP condition this would be 
equivalent to one 12 mer oligomer. If each monomer, oligomer or fibril is referred to 
as a unit then 1 oligomer unit would be equivalent to 12 monomer units. Fibrils are 
likely comprised of hundreds or thousands of monomers, therefore, one fibril unit 
may be equivalent to 1000 monomers and approximately 80 oligomers. This would 
mean that the fibrils and oligomers are even more toxic than indicated, since the 
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number of oligomer and fibril units are less compared to the monomer. 
Additionally, the number of fibril units compared to oligomer units is also 




Figure 4.1 Toxicity of misfolded conformations of recPrP across a broad 
concentration range. 
A+B) Bar charts to show the toxicity of different recPrP preparations: α-helical 
recPrP (dark grey), oligomers (light grey) and fibrils (white). A) Shows a 
concentration range from 1.3- 5.2 µM (equivalent to 30-120 µg/ml of recPrP). The 
cell viability is shown as a percentage of the buffer control ± standard error (SE). B) 
Shows a concentration range from 0.01- 2.6 µM (equivalent to 0.25- 60 µg/ml of 






Figure 4.2 Average toxicity data for misfolded conformations of recPrP. 
Bar chart to show the toxicity of different recPrP preparations: α-helical recPrP (dark 
grey), oligomers (light grey) and fibrils (white) at a concentration range from 0.43- 
1.73 µM (equivalent to 10-40 µg/ml of recPrP). Cell viability is shown as a 
percentage of the buffer control ± standard error (SE), a minimum of 6 readings (3- 
4 pictures per well with 2 wells for each) were taken for each recPrP preparation in 
each experiment (minimum n = 4). * indicates the oligomers or ** indicates the fibrils 
are significantly more toxic than the α-helical recPrP *** indicates the fibrils are 
significantly more toxic than the oligomers (one-way ANOVA; p value <0.05).  
 
4.3 Toxicity of disease associated isoforms of recAβ 
Once I had established the relative toxicities of the different recPrP isoforms, I 
wanted to compare the toxicity of recPrP oligomers and fibrils to another disease 
associated protein. By comparing multiple disease associated proteins, it would 
enable me to determine the importance of specific misfolded protein conformations 
in different PMDs. Therefore I investigated the toxicity of monomers, oligomers and 
fibrils formed from recAβ 1-40 and recAβ 1-42, which have both been shown to be 
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involved in AD. In chapter 3, I showed that recAβ 1-40 and recAβ 1-42 behave 
differently in terms of their fibrillisation kinetics and the size of oligomers which 
they form. It was therefore important to investigate both forms of recAβ, to see if 
these differences affect their relative toxicities. As with recPrP, it was important to 
establish a concentration range of monomeric recAβ which was not toxic to the cells. 
To do this, I exposed the primary cells to monomeric recAβ 1-40 and recAβ 1-42 at 
the range 0.11-1.73 µM (figure 4.3). They revealed that unlike recPrP which showed 
a dose dependent toxic effect, the cells treated with the recAβ monomers did not. 
Instead, the cells treated with recAβ 1-40 and recAβ 1-42 monomers showed 
relatively low levels of toxicity at all concentrations. However, when the results 
were analysed more closely, it became apparent that recAβ at 0.43 µM was more 
toxic than recAβ at the two higher concentrations (0.87 and 1.73 µM), suggesting an 
inverse dose response. However, this observation was not statistically significant. 
The inverse trend which was observed was investigated further, and is discussed in 
section 4.5. 
Having established that the recAβ monomer caused low levels of toxicity, I chose to 
investigate the toxicity of the recAβ oligomers and fibrils at the concentration range 
0.43-1.73 µM, which I used for the recPrP experiments. This allowed a direct 
comparison between recPrP and recAβ. I carried out multiple experiments at this 
concentration range to obtain reliable average toxicity data for each isoform of 
recAβ 1-40 and recAβ 1-42 (figure 4.4). The data revealed that cells treated with any 
of the recAβ 1-40 conformations showed no significant difference in viability when 
compared to each other at any of the concentrations tested. All cells which were 
treated with recAβ 1-40 showed a 20- 25 % drop in cell viability (figure 4.4A), 
suggesting that all conformations of recAβ 1-40 cause relatively low toxicity. By 
contrast, the recAβ 1-42 oligomers were shown to be significantly more toxic than 
the recAβ 1-42 fibrils at 0.87 µM (p value < 0.05). This shows that recAβ 1-42 
oligomers are toxic to the cells, and cause a drop in cell viability of approximately 35 
% at 0.87 µM. While the toxicity caused by the recAβ 1-42 monomers was not 
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statistically significant, the monomers do appear to cause some toxicity at the lower 
concentrations. However, given the propensity of recAβ 1- 42 to fibrillise, it is 
difficult to determine whether the toxicity was caused by recAβ 1- 42 in a 
monomeric state, or if toxicity could have been caused by recAβ 1- 42 assembling 
into oligomeric species on the pathway to forming fibrils. It is likely that if recAβ 1- 
42 monomers had fibrillised during incubation with the cells, then it would be 
intermediates in the fibrillisation process which caused the toxicity since recAβ 
fibrils are not toxic. This will be investigated and discussed further in section 4.5. I 
presented data in chapter 3 that showed differences in the size of recAβ 1- 40 and 
recAβ 1- 42 oligomers. I analysed the toxicity of the different oligomers and found 
that there was no significant difference between the recAβ 1- 40 oligomers and the 
recAβ 1- 42 oligomers at any of the concentrations. The differences in the size of the 





Figure 4.3 Toxicity of recAβ monomer across a broad concentration range. 
Bar chart to show the toxicity of recAβ 1- 40 monomer (light blue) and recAβ 1- 42 
monomer (pink), at a concentration range from 0.11-1.73 µM. Cell viability is shown 
as a percentage of the buffer control ± standard error (SE), a minimum of 6 readings 
(3- 4 pictures per well with 2 wells for each) were taken for both recAβ 1- 40 and 





Figure 4.4 Toxicity of misfolded conformations of recAβ. 
Bar chart to show the toxicity of different recAβ preparations at a concentration 
range from 0.43-1.73 µM. Cell viability is shown as a percentage of the buffer 
control ± standard error (SE), a minimum of 6 readings (3- 4 pictures per well with 2 
wells for each) were taken for each recAβ preparation in each experiment (minimum 
of n=3 for all preparations at all concentrations). A) Shows the toxicity of different 
conformations of recAβ 1-40: monomers (light blue), oligomers (mid-blue) and fibrils 
(dark blue). B) Shows the toxicity of different conformations of recAβ 1-42: 
monomers (light pink), oligomers (dark pink) and fibrils (red). ** indicates the 




4.4 Further characterisation of recPrP fibrils 
There is controversy surrounding the role of fibrils in disease, and it is unclear 
whether fibrillar plaques found in diseases such as AD are a protective end point in 
the protein misfolding pathway, or whether they are involved in causing cellular 
toxicity (Soto, 2003, Ross and Poirier, 2004, Dobson, 2003, Haass and Selkoe, 2007, 
Treusch et al., 2009, Novitskaya et al., 2006). Generally, it is thought that oligomers 
play a more fundamental role in causing cell death than fibrils in PMDs (Kuo et al., 
1996, Naslund et al., 2000, McLean et al., 1999, Mucke et al., 2000a, Walsh et al., 2002, 
Quist et al., 2005, Kristiansen et al., 2007, Simoneau et al., 2007, Volles et al., 2001, 
Lue et al., 1999).  
The cellular toxicity data for recPrP fibrils shown in section 4.2 revealed that recPrP 
fibrils cause high levels of toxicity to primary cortical neurons, and were found to be 
significantly more toxic than oligomers. This was unexpected, since as mentioned 
previously, fibrils are often thought to be less toxic than oligomers. The toxicity data 
for the recAβ fibrils shown in section 4.3 highlighted that recAβ fibrils cause very 
low toxicity, which coincides with this hypothesis. Therefore, I decided to further 
characterise the recPrP fibrils.  
Oligomers are generally thought to be important in causing cell death in PMDs. In 
light of this, I wanted to investigate whether there were any smaller oligomer-like 
misfolded forms of recPrP present in the fibril preparations, which could potentially 
be contributing to their toxicity. I considered that since oligomers are small and 
soluble and fibrils are much larger and insoluble, I would be able to test for the 
presence of oligomer-like assemblies in the fibril preparations by centrifugation and 
analysis of the resulting supernatant. To do this, I pelleted the fibrils at 16100 g for 
differing lengths of time (between 10-60 minutes) and analysed the resulting 
supernatant by SDS-PAGE. Silver staining of the gel was carried out to identify low 
concentrations of recPrP present in the supernatant. To ensure that smaller species 
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of recPrP would remain in the supernatant under these centrifugation conditions, I 
used an oligomer sample alongside the fibrils as a control. The results (figure 4.5) 
show that, as expected, the oligomers are soluble and remain in the supernatant 
following centrifugation. This is shown by the intensity of the recPrP band in lanes 
2, 4, 6 and 8, which does not decrease following centrifugation. If there was no 
soluble protein present in the fibril preparations then there would be an absence of a 
recPrP band following centrifugation. Interestingly, this was not found to be the 
case, the results show that soluble protein does exists in the fibril preparations. This 
is shown by the recPrP band in lanes 3, 5 and 7 after centrifugation, indicating that 
soluble recPrP is present in the supernatant of the fibril preparations.  
 
 
Figure 4.5 Analysis of fibril supernatant 
SDS-PAGE gel which has been silver stained showing recPrP oligomers (O) and 
fibrils (F) before and after centrifugation for 10, 30 or 60 minutes. Only the 




Considering that the fibril preparations were shown to contain small, soluble 
isoforms of recPrP I next wanted to determine the size of these soluble protein 
species. I first tried to do this using SEC. The storage buffer for the fibrils was 50 
mM sodium acetate pH 5.5, so I used this as the running buffer for the size exclusion 
column. However, the fibrils seemed to interact with the column under these 
conditions. Even with the addition of 150 mM sodium chloride to reduce ionic 
interactions, the results were the same. The SEC results with 50 mM sodium acetate 
pH 5.5 and 150 mM sodium chloride running buffer are shown in figure 4.6A. The 
fibril supernatant is shown in red, and for reference oligomers are shown in blue 
and monomeric recPrP is shown in black. The chromatograms show the proteins are 
all eluting at the same time, suggesting that they are all the same size. However, I 
know this is not accurate since the oligomers (blue) when analysed by SEC under 
different buffer conditions (sodium citrate pH 3.4) elute between 6-9 ml. This 
indicates that with the sodium acetate buffer conditions the protein is interacting 
with the size exclusion column. Therefore, it is not possible to obtain a reliable 
estimate of size using SEC for the protein species present in the fibril supernatant.  
I instead decided to use DLS to analyse the fibril supernatant, which I reasoned 
should provide more robust data, since DLS is a non-column based technique. 
Figure 4.6B shows the fibril supernatant DLS data, which clearly suggests that the 
protein species present in the fibril supernatant (shown in red) are much larger than 
monomeric recPrP (black) and the 12 mer oligomer species (blue), but smaller than 
the fibrils (shown in green). Some overlap in size can be seen between the fibril 
supernatant protein species and the fibrils, but the majority of the fibril supernatant 
protein does appear to be smaller. The protein present in the fibril supernatant is 
perhaps a pre-fibrillar species, or what is often referred to as a “protofibril”, which 
is thought to be between an oligomer and a fibril in size(Caughey and Lansbury, 
2003, Kayed et al., 2009, Ross and Poirier, 2004, Ross and Poirier, 2005, Williams et 
al., 2005). I decided to test the protein present in the fibril supernatant for other 




Figure 4.6 Characterisation of the size of protein species present in the fibril 
supernatant.  
A) Size exclusion chromatogram showing recPrP monomer (black), oligomers (blue) 
and the supernatant from recPrP fibrils after a 45 minute spin (red). The running 
buffer was 50 mM sodium acetate and 150 mM sodium chloride pH 5.5. B) DLS data 
showing size distribution by volume of monomeric recPrP (black), recPrP oligomers 
(blue), recPrP fibrils (green) and the recPrP fibril supernatant (red).  
In chapter 3, I showed that recPrP fibrils are resistant to PK treatment and have an 
insoluble core which expands under heating (maturation). In light of this, I next 
investigated whether the protein present in the fibril supernatant shared these 
characteristics. I reasoned that these characteristics would help distinguish whether 
the protein species present in the fibril supernatant was a smaller fibrillar species 
and, therefore, PK resistant, or whether it was sensitive to PK and therefore had 
characteristics more similar to the oligomers. To do this, I digested the fibrils, the 
fibril supernatant and the fibril pellet that was re-suspended after centrifugation 
with PK, with and without maturation. All the samples were then analysed by SDS-
PAGE with silver staining, the results are shown in figure 4.7. These results show 
that the protein from the fibril supernatant also has an insoluble core, which 
expands under maturation conditions (shown in lane 9 of figure 4.7, highlighted by 
the arrow). The other PK resistant bands shown in lanes 8 + 9 for the fibril 
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supernatant, which are between 10-12 kDa, are the same as the bands seen for the 
fibrils or fibril pellet (lanes 2 + 3 and 5 + 6 respectively). This suggests that the 
protein species present in the fibril supernatant does share PK resistant properties 
similar to a fibril.  
 
 
Figure 4.7 Further characterisation of fibril preparations. 
SDS-PAGE gel with silver staining, lanes 1-3 show recPrP fibrils (F). Lanes 4-6 
show the recPrP fibril pellet (P) following 45 minute centrifugation and re-
suspension. Lanes 7-9 show the supernatant taken from the fibrils following 45 
minute centrifugation. The fibrils, fibril pellet and fibril supernatant were all treated 
with no PK, with PK but not heated to 80 °C or with PK and heated to 80 °C 
(maturation). The 16 kDa band present in lanes 3, 6 and 9 shows that all fibril 
components have an insoluble PK resistant core, suggestive of amyloid.  
Since pre-fibrillar forms of recPrP (I will refer to these as protofibrils) were found in 
the fibril supernatant, it was important to investigate the potential toxicity of these 
species to understand whether they could be contributing to the toxicity of the fibril 
preparations. I removed the supernatant after centrifugation of the fibrils, and tested 
the concentration by spectrophotometer. I then dosed the primary cortical neurons 
with the supernatant, the fibrils, or the re-suspended fibril pellet, at a range of 
124 
 
concentrations (0.22 – 0.87 µM). Multiple repeats were carried out, which allowed 
average toxicity data to be calculated for each of the fibril components. The average 
toxicity data is shown in figure 4.8. The data shows that the fibril supernatant is as 
toxic as the fibrils. Taking these results into consideration, it is likely that the 
protofibrils found in the fibril supernatant contribute to the toxicity of the fibrils. 
Conversely, the fibril pellet was also found to be toxic. I found no significant 
difference in toxicity between the fibril supernatant and the any of the fibril 
components. This may suggest that both the fibrils and the protofibrils are toxic to 
the cells.  
However, it is also possible that the protofibrils may exist in equilibrium with the 
fibrils, and that new protofibrils may form from fibrils once they are removed. This 
possibility may be unlikely though, since the concentration of proteins in the 
supernatant of the re-suspended pellet after 24 hours was below the threshold for 
the spectrophotometer to analyse. This would suggest that protofibrils do not 
readily form from fibrils over a 24 hour period. Overall, the data suggests that 
protofibrils present in the fibril preparations are toxic and may, therefore, be 
contributing to the toxicity of the fibrils preparations. But, the fibrils alone were also 





Figure 4.8 Toxicity of separated recPrP fibril components. 
Bar chart to show the toxicity of separate components of recPrP fibril preparations at 
a concentration range from 0.22- 0.87 µM. Graph shows average data for 3 
experiments, fibrils (white), the re-suspended fibril pellet following 45 minute 
centrifugation (green), and the supernatant taken from the fibrils following 45 minute 
centrifugation (red). All show high levels of toxicity when compared to the α-helical 
recPrP control (black) dosed at the highest concentration. There was no significant 
difference in toxicity between any of the fibril components.  
4.5 RecAβ monomer fibrillises in cell culture media 
As shown in figure 4.9A, the toxicity of the recAβ 1-40 monomer is suggestive of an 
inverse dose response. Although the differences are not statistically significant, 
there is a definite trend, and it is possible that with more replications the differences 
would reach statistical significance. In light of this I next investigated the factors 
which underpinned this inverse dose response, which I hypothesised may be due to 
the monomer fibrillising in the cell culture media in a concentration dependent 
manner. It is likely that lower concentrations of monomer would take longer to 
interact in the solution and begin to assemble and fibrillise, since there are fewer 
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molecules to interact. This would imply that the higher concentrations of monomer 
would fibrillise more quickly. The fibrillisation of monomers into fibrils would be 
expected to reduce toxicity, since as shown in figure 4.4, recAβ fibrils cause low 
toxicity. The slower rate of recAβ fibrillisation at lower concentrations may mean 
that the cells are exposed to smaller pre-fibrillar assemblies for longer, such as 
oligomers, which may be more toxic than the fibrils. To investigate this, I incubated 
the recAβ 1-40 monomers in cell culture media (with no supplements or serum) at 
37 °C for 24 hours, to mimic the conditions the proteins are exposed to when 
incubated with the cells. I did this at a range of concentrations and monitored any 
fibril formation using ThT, as I did for the fibrillisation assays (see section 3.3). The 
lower concentrations of 0.43 and 0.87 µM were too dilute to detect any ThT 
fluorescence. However, a concentration range from 1.73 – 7 µM did show an 
increase in ThT fluorescence (suggestive of fibrils forming) in a concentration and 
time- dependent manner (figure 4.9B).  
The ThT data would suggest that recAβ monomers fibrillise in a dose-dependent 
fashion, however, since the lower concentrations were too dilute to be investigated 
by ThT fluorescence, I investigated the possibility that fibrils had formed using 
native PAGE. To do this, I analysed fibrils concurrently on native and denaturing 
gels. I discovered that whilst fibrils could be seen in denaturing gels, they were not 
soluble enough to resolve on a native gel. Therefore, the presence of protein on a 
denaturing gel with a corresponding absence of protein resolved on a native gel was 
indicative of fibrils. Figure 4.9D shows a denaturing gel with the recAβ 1-40 
monomer in lane 1 and recAβ 1-40 fibrils in lane 2. In figure 4.9C, the same samples 
were run on a native gel: recAβ 1-40 monomer in lane 1 and recAβ 1-40 fibrils in 
lane 2. In lane 2 there is a clear lack of protein, since there is protein in the sample 
(shown by lane 2, figure 4.9D), the absence of protein in the native gel suggests the 
size or insoluble nature of the fibrils prevents it from being resolved by the gel. The 
native gel shown in figure 4.9E, shows recAβ 1-40 monomer in lane 1, oligomers in 
lane 2 and recAβ 1-40 fibrils in lane 3. Lanes 4–8 are samples from recAβ 1-40 
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monomer kept in cell culture media at 37 °C for 24 hours at 0.43 µM, 0.87 µM, 1.73 
µM, 3.5 µM and 7 µM respectively. The absence of any protein bands in lanes 4-8 
suggests that the recAβ 1-40 monomer had fibrillised at all concentrations. Taken 
together, this data suggests that the recAβ 1-40 monomer does fibrillise even at low 
concentrations. But the more concentrated the solution is the more quickly this will 
occur, thus making the higher concentrations less toxic. The fibrillisation of recAβ 1-
42 monomer was also investigated. However, the ThT experiments showed that the 
recAβ 1-42 monomer fibrillised very quickly at all concentrations. This meant that it 
was not possible to identify a dose and time dependent pattern of fibrillisation, as I 
have done for recAβ 1-40. But it is likely that the fibrillisation process of the recAβ 1-





Figure 4.9 Analysis of recAβ 1-40 monomer fibrillisation in cell culture media. 
A) Bar chart to show the toxicity of recAβ 1-40 monomer at a concentration range 
from 0.43-1.73 µM. Cell viability is shown as a percentage of the buffer control ± 
standard error (SE), a minimum of 6 readings (3- 4 pictures per well with 2 wells for 
each) were taken for each concentration in each experiment (minimum of n=3 for all 
concentrations). B) RecAβ 1-40 monomer at 1.73 µM (green), 3.5 µM (blue) and 7 
µM (red) in cell culture media, with ThT to monitor fibrillisation over 24 hours with 
fluorescence readings taken at 5 minute intervals. Dashed lines show the point at 
which ThT fluorescence starts to rise for each concentration, showing the formation 
of fibrils. C) Silver stained native gel, lane 1: recAβ 1-40 monomer, lane 2: recAβ 1-
40 fibrils. No band can be seen for the recAβ 1-40 fibrils. D) Silver stained 
denaturing SDS-PAGE gel, with the same samples loaded as shown in C. In lane 2 
there is recAβ 1-40 fibril band, showing the absence of a band on the native gel is 
not from a lack of protein in the sample. E) Silver stained native gel; lane 1: recAβ 1-
40 monomer, lane 2: recAβ 1-40 oligomers made with bis-ANS, lane 3: recAβ 1-40 
fibrils, lanes 4-8: recAβ 1-40 monomer after overnight incubation in cell culture 
media, at the following concentrations: lane 4: 0.43 µM, lane 5: 0.87 µM, lane 6: 
1.73 µM, lane 7: 3.5 µM and lane 8: 7 µM. No bands can be seen for the recAβ 1-40 
fibrils in lanes 3-8.  
4.6 Comparison of toxicity caused by misfolded isoforms of recPrP and 
recAβ 
I further analysed the differences in toxicity caused by recPrP and recAβ isoforms. 
Figure 4.10 shows the comparative toxicity data for recPrP and recAβ monomers, 
oligomers and fibrils. There was no significant difference in toxicity found between 
monomeric recAβ and recPrP (figure 4.10A), additionally, there was no significant 
difference in toxicity between recAβ oligomers and recPrP oligomers at 0.43 µM or 
0.87 µM. Interesting, at 1.73 µM recPrP oligomers were significantly more toxic than 
both recAβ oligomers (p value <0.05). This is perhaps not surprising since recPrP 
oligomers cause a distinct dose-response and the recPrP oligomers show 
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considerable toxicity at 1.73 µM. This means that recPrP oligomers are significantly 
more toxic than recAβ oligomers at increasing concentration.  
The difference in toxicity between the recPrP and recAβ fibrils was striking. The 
recAβ fibrils cause low toxicity, while the recPrP fibrils cause extensive toxicity to 
the cells. The recPrP fibrils were shown to be significantly more toxic than the recAβ 
1-40 and recAβ 1-42 fibrils at all concentrations tested (p value <0.05, figure 4.1C). 
This may be a result of the structure of the fibrils formed in vitro, which causes the 
recPrP fibrils to be significantly more toxic than the recAβ fibrils. However, it could 
be suggestive of the type of fibrillar plaques which form during disease and their 
involvement in causing cellular toxicity. Aβ may form fibrillar plaques, which cause 
little toxicity. By contrast, PrP may form fibrils which can cause considerable 
toxicity and cell damage. These findings may be important when understanding 






Figure 4.10 Comparison of toxicity caused by misfolded isoforms of recPrP 
and recAβ  
Bar charts to compare the toxicity of recPrP with recAβ 1-40 and recAβ 1-42 
monomers, oligomers and fibrils. A-C show cell viability as a percentage of the 
buffer control ± standard error (SE), a minimum of 6 readings (3- 4 pictures per well 
with 2 wells for each) were taken for each concentration in each experiment 
(minimum of n=3 for all concentrations). * indicates a significant difference in cell 
viability between cells treated with recPrP and recAβ 1-42, ** indicates a significant 
difference in cell viability between cells treated with recPrP or recAβ 1-40 (one-way 
ANOVA; p value <0.05). A) Bar chart to compare the toxicity of recPrP monomers 
with recAβ 1-40 and recAβ 1-42 monomers B) Bar chart to compare the toxicity of 
recPrP oligomers with recAβ 1-40 and recAβ 1-42 oligomers C) Bar chart to 
compare the toxicity of recPrP fibrils with recAβ 1-40 and recAβ 1-42 fibrils. 
4.6 Discussion 
In this chapter, I have investigated the toxicity of well characterised disease 
associated conformations of recPrP and recAβ. These included fibrils, to mimic the 
fibrillar plaques found in both prion disease and AD. In addition, I produced 
oligomers to assess the toxicity of smaller, soluble assemblies of the misfolded 
proteins. I found that recPrP oligomers and fibrils both caused significant toxicity to 
primary cortical cells, while α-helical recPrP at the same concentration range (0.43–
1.73 µM) caused no significant toxicity. This demonstrates that recPrP is not in itself 
toxic, but suggests that toxicity is conformation dependent. Furthermore, at 0.87 µM 
the recPrP fibrils were found to be significantly more toxic than the oligomers. This 
finding was unexpected, since fibrils are often thought to be less toxic than 
oligomers and, therefore, less important in the pathogenesis of PMDs (Simoneau et 
al., 2007, Kuo et al., 1996, Naslund et al., 2000, McLean et al., 1999, Mucke et al., 
2000a, Walsh et al., 2002, Quist et al., 2005, Kristiansen et al., 2007, Volles et al., 2001, 
Lue et al., 1999). With this in mind, I decided to further characterise the recPrP 
fibrils to identify any characteristics which could be contributing to their toxicity. 
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Additional characterisation of the recPrP fibrils showed that the fibril preparations 
contained smaller isoforms of recPrP that remained in solution following 
centrifugation. DLS analysis revealed that these isoforms are larger than a monomer 
or an oligomer, but smaller than the true fibril population. Intriguingly these 
smaller isoforms have some “fibril-like” characteristics; they are PK resistant and 
have an insoluble core. Therefore, this smaller protein species present in the fibril 
preparations may represent a “pre-fibril” or “protofibril”. Investigating the toxicity 
of the protofibrils revealed that these assemblies caused cell death at a level 
comparable with the fibrils, with no significant difference between the fibrils and 
protofibrils. This may suggest that the smaller protofibrils present in the fibril 
preparations contribute to the toxicity caused by the recPrP fibrils. However, my 
data also suggest that the fibrils are themselves toxic, since the fibril pellet which 
was re-suspended following centrifugation and removal of the supernatant was as 
toxic as the protofibrils. Overall these data show that the recPrP fibrils contain 
smaller protofibrils, which have fibril-like characteristics and are highly toxic to the 
cells. It is possible that these protofibrils may form during the fibrillisation assay on 
the pathway to becoming a fibril, or they may form through a separate distinct 
pathway. Alternatively, these protofibrils may have broken off from the main fibrils. 
It is possible that these protofibrils may contribute to the toxicity of the fibril 
preparations, which could help explain why the recPrP fibrils are so toxic.  
Previously, there has been much controversy surrounding whether oligomers or 
fibrils are more toxic and, therefore, more important in the pathogenesis of prion 
disease. It seems likely that both may play a part, oligomers are soluble and much 
smaller than fibrils and are able to diffuse throughout the extracellular space 
allowing more widespread toxicity (Aguzzi and Falsig, 2012). In addition, it has 
been shown that PrP can cause toxicity in vivo in the absence of fibrillar deposits or 
fibrils. Oligomeric PrP present in the cytosol of a cell has been shown to be highly 
toxic (Ma et al., 2002), and non-fibrillar fragments of PrP (118-135) also elicit a very 
strong toxic response in vivo and in vitro (Chabry et al., 2003). However, it has also 
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been shown that the process of fibrillisation and sites surrounding fibrils in the 
brain show tissue damage (Jeffrey et al., 1997), which suggests that fibrils can cause 
toxicity in vivo. Interestingly, this observation seems to be dependent on brain area 
with some areas showing more vulnerability to fibril deposition compared with 
other regions (Jeffrey et al., 1997). In Novitskaya et al. fibrils were shown to cause 
toxicity in vitro, in this study the same method which I used for producing fibrils 
was employed (Novitskaya et al., 2006). This may suggest that the type of fibrils 
produced from this method have a particularly toxic structure, or are perhaps prone 
to shearing; producing small protofibrils which contribute to toxicity. Fibrils are 
perhaps more variable than oligomers in their toxicity due to their more 
heterogeneous size and structure, ranging from small fibrils made up of ~100 
molecules up to large plaques made up of 1000s of molecules (Silveira et al., 2005, 
Prusiner et al., 1983). Their insoluble nature may also mean that access to cells 
during disease is more limited, without the ability to diffuse between cells. 
Therefore, although I have shown that recPrP fibrils are more toxic than recPrP 
oligomers, during disease the fibrils may play less of a fundamental role in causing 
toxicity due to their insolubility. Furthermore, it may be possible that the structure 
of some PrP fibrils gives rise to smaller isoforms of misfolded PrP. These smaller 
pre-fibrillar structures may then contribute to the oligomer burden and toxicity.  
In stark contrast to the recPrP fibril toxicity data, the recAβ fibrils were shown to 
cause low toxicity at all concentrations tested. They were found to be significantly 
less toxic than the recPrP fibrils at all concentrations. This could indicate structural 
differences between the fibrils formed in vitro for recPrP and recAβ, or it may 
suggest that the function of fibrillar plaque deposition in disease differs between 
PMDs. For example, in AD if fibrillar plaques are non-toxic then they may be a 
protective mechanism to sequester more harmful oligomeric species. However, in 
prion diseases it is possible that fibrillar plaques may be the end point in a toxic 
fibrillisation process. Together, the toxicity data in this chapter suggest that fibrils 
may play different roles in the pathogenesis of different PMDs.  
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In addition to the fibrillisation toxicity data, I have shown that recAβ monomers 
fibrillise in cell culture media which reduces toxicity; suggesting that the propensity 
of Aβ to fibrillise may be protective. The illustration in figure 4.11 demonstrates 
how recAβ monomers may fibrillise in the cell culture media. I have shown that 
recAβ monomers fibrillise in a concentration and time dependent manner, and that 
the faster the recAβ fibrillised the less toxic it was to the cells. It is possible that the 
monomers will first form oligomers and protofibrils before becoming non-toxic 
fibrils (figure 4.11). The greater the concentration of monomers the faster this 
process will happen, therefore, the less toxic the recAβ sample would be. This 
would also mean that the lower the concentration of monomers, the slower the 
process meaning that the recAβ could spend more time in a pre-fibrillar state which 
would likely be more toxic. This would explain the inverse dose response that was 
seen for the recAβ monomers and support the hypothesis that the fibrillisation 
process in AD is protective.  
 
 
Figure 4.11 Illustration showing the potential fibrillisation process of recAβ 
Illustration demonstrating how recAβ monomers may fibrillise in cell culture media 
Previously Aβ oligomers have been shown to be more toxic than fibrils (Kuo et al., 
1996, Naslund et al., 2000, McLean et al., 1999, Mucke et al., 2000a, Manzoni et al., 
2011, Haass and Selkoe, 2007, El-Agnaf et al., 2000, Cleary et al., 2005, Texido et al., 
2011) and, therefore, are thought to be more important in disease pathogenesis. This 
would coincide with my data, which shows that recAβ 1-42 oligomers are 
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significantly more toxic than recAβ 1-42 fibrils at 0.87 µM. Previously, Aβ 1-42 has 
been shown to be more toxic than Aβ 1-40 (El-Agnaf et al., 2000), however, my data 
demonstrated that there was no significant difference in toxicity between the recAβ 
1-40 oligomers and the recAβ 1-42 oligomers. Studies which have used the same 
methods I have to produce Aβ 1-42 oligomers also found them to be toxic (Sondag 
et al., 2009, Young et al., 2009, Lambert et al., 1998). The toxicity data published 
previously has shown these oligomers to cause toxicity to neuronal cell lines, 
primary cells and microglia (Sondag et al., 2009, Young et al., 2009, Lambert et al., 
1998). Therefore, it is likely that Aβ oligomers produced using this method have a 
structure which is toxic and, therefore, is perhaps similar in conformation to Aβ 
oligomers seen in disease.  
The clinical phase in AD compared to most human prion diseases is much longer. 
On average, the clinical phase of AD is between 3 and 10 years (Zanetti et al., 2009). 
If the patient is diagnosed in their 60s or 70s then it is more likely to be 7-10 years 
(Zanetti et al., 2009). By contrast, the clinical phase of CJD, the most common human 
prion disease, is only 3 months (personal communication Dr M.W. Head). It is 
possible that this may be due to the comparative toxicities of the causative 
misfolded proteins. I have shown that at higher concentrations (1.73 µM), recPrP 
oligomers are significantly more toxic than recAβ 1-40 and recAβ 1-42 oligomers. At 
the clinical stage of disease the concentration of misfolded protein would likely be at 
its highest, since levels build up during the pre-clinical phase (Selkoe, 2003). This 
may mean that high levels of PrP oligomers would cause widespread cell death and 
mortality earlier than in AD, where the oligomers are less toxic and so the process 
may be slower.  
The toxicity data from this chapter provides insights into how the structure of 
misfolded proteins can cause toxicity. However, the misfolded protein conformers 
were formed in vitro meaning that they may not replicate the conformation of 
misfolded proteins in disease. I have tried to account for these limitations by 
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characterising the proteins to try and produce conformations with similar properties 
to those found in disease, however, there may be differences. Furthermore, the in 
vitro system I have used for testing toxicity is also artificial and does not replicate 
the same chronic process that occurs during disease. Therefore, while I cannot draw 
conclusions about how misfolded proteins lead to neurodegeneration in PMDs, I 
can suggest that certain conformations of proteins have the ability to cause toxicity 
and may therefore be important in causing neuronal cell death in these diseases.  
In this chapter, I have shown that both recPrP oligomers and fibrils cause significant 
toxicity to primary cortical cells in a dose dependent fashion. Interestingly, recPrP 
fibrils were found to be significantly more toxic than recPrP oligomers. Further 
analysis revealed that the recPrP fibril preparations contained small soluble 
protofibril-like isoforms, which were smaller than the main fibril population but 
had fibril-like characteristics. These protofibrils were found to be as toxic as the 
fibrils and may contribute to the toxicity of the fibril preparations. In addition, 
recAβ 1-42 oligomers were found to be significantly more toxic than recAβ 1-42 
fibrils. However, recAβ 1-40 oligomers were not found to be significantly more toxic 
than Aβ 1-40 monomers or fibrils. The mechanisms leading to recPrP and recAβ 
induced cell death will be investigated in chapter 6. In the next chapter, I will 
explore the importance of the disulphide bond in recPrP in relation to 





Chapter 5: The presence of the disulphide bond in recPrP determines oligomer size and toxicity 
The presence of the disulphide 
bond in recPrP determines 





In prion diseases, the disease process appears to be driven by the conformational 
conversion of PrPC into an abnormal isoform, designated PrPSc. While the presence 
of PrPSc is diagnostic of prion disease, there is considerable doubt as to whether 
PrPSc is itself toxic to cells (Aguzzi and Falsig, 2012, Radford and Mallucci, 2010, 
Sandberg et al., 2014, Krasemann et al., 2013, Collinge and Clarke, 2007). PrPSc can 
be detected in infected brains prior to overt neuronal loss (Sandberg et al., 2014, 
Aguzzi and Falsig, 2012, Collinge and Clarke, 2007), however, there can be a lack of 
correlation between the temporal and spatial distribution of protein deposition and 
neuronal cell death (Sandberg et al., 2014, Aguzzi and Falsig, 2012, Collinge and 
Clarke, 2007). Instead, small soluble oligomeric assemblies of prion protein 
represent a plausible alternative species that causes neuronal toxicity (Harris and 
True, 2006, Simoneau et al., 2007). Whilst there has been some evidence to suggest 
that the size of oligomers is important in toxicity (Silveira et al., 2005), very little is 
known about what causes different sized oligomers to form.  
Post-translational modifications of proteins occur in the endoplasmic reticulum 
(ER), where there is a high concentration of chaperones to assist in folding proteins 
into their correct tertiary structure (Kleizen and Braakman, 2004). These include 
oxidising components to support disulphide bond formation (Kleizen and 
Braakman, 2004), which is an important component of PrPC. In addition, other post-
translational modifications are made such as cleavage of the N-terminal signal 
peptide (Harris, 2003), attachment of the GPI-anchor and addition of N-linked 
glycans to residues 180 and 196 (Wiseman et al., 2005). In vivo, the glycosylation of 
PrP is variable; the protein can be un-, mono- or di- glycosylated (Tuzi et al., 2008, 
Wiseman et al., 2005).  
All post-translational modifications are thought to be important for the normal 
folding and functioning of PrPC (Wiseman et al., 2005, Tuzi et al., 2008, Jackson et al., 
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1999, Sang et al., 2012) and, therefore, changes to these could be important in the 
conversion of PrPC to PrPSc. Glycosylation is thought to be important for stability of 
the protein, but as yet it has not been proven to play a major determining role in 
conversion of PrPC to PrPSc or in propagation of PrPSc (Wiseman et al., 2005, Tuzi et 
al., 2008). The GPI anchor is thought to play a part in increasing susceptibility to 
prion infection, since the cell surface is thought to be a possible site of conversion for 
PrPC to PrPSc. However, animals expressing anchorless protein are still susceptible to 
prion infection, although these show altered pathology and are less likely to exhibit 
clinical signs (Chesebro et al., 2005, Klingeborn et al., 2011). It is thought that the 
GPI anchor may be important for neuroinvasion and spread of PrPSc (Klingeborn et 
al., 2011), which may go some way to explain why clinical signs are less frequently 
seen in infected GPI-anchorless mice. However, studies using the N-terminal and 
middle domain of the yeast prion protein Sup35 (Sup35NM) have shown that 
aggregates of cytosolic Sup35NM can spread to other cells (Hofmann et al., 2013). 
This shows that membrane anchoring is not required for cell to cell infection of 
prions (Hofmann et al., 2013). Thus it is likely that the GPI anchor is important, but 
not essential for infection.  
The disulphide bond is important for the normal folding of the protein, although it 
is unclear how the absence of the disulphide bond in PrP may impact on misfolding 
during disease. Studies to date have shown that reduction of the disulphide bond 
results in a switch from the mainly α-helical structure of PrP with an intact 
disulphide bond, to one composed primarily of β-sheets (Jackson et al., 1999, Sang et 
al., 2012). It has also been demonstrated that a free thiol group may be needed for 
conversion of PrPC to PrPSc (Lucassen et al., 2003), which would suggest that the 
oxidation state of PrP is important in disease. Transgenic mice with C-terminal 
deletions of PrP, meaning that they lack the disulphide bond, develop a 
neurodegenerative disease with symptoms similar to a neuronal storage disorder 
(Muramoto et al., 1997). Whilst this finding may not be entirely attributable to the 
loss of the disulphide bond, since the disulphide bond was not all that was deleted, 
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it does suggest that PrP without a disulphide bond can be neurotoxic and capable of 
causing disease.  
In this chapter, I will explore how the oxidative state of recPrP is important in 
oligomerisation and is deterministic of the size of oligomers which subsequently 
form. I will investigate how the presence or absence of the disulphide bond in 
recPrP can alter its biophysical properties when prepared under the same 
conditions. Furthermore, I will analyse the differences in toxicity caused by 
oligomers formed from recPrP with or without the disulphide bond. This will help 
elucidate how changes to post-translational modifications such as the disulphide 
bond can affect how a protein misfolds and causes toxicity. Henceforth, I will refer 
to recPrP with an intact disulphide bond as oxidised recPrP and recPrP without a 
disulphide bond as disulphide-reduced recPrP.  
5.2 Reverse phase chromatography produces purification fractions with 
different oligomerisation properties 
In this study, recPrP was purified from bacteria before being refolded into disease 
associated conformations. The final stage when purifying recPrP is RP 
chromatography. RP chromatography is a purification method which separates 
proteins in a sample by their hydrophobicity. A concentration gradient of 
acetonitrile is used to elute proteins from the column. The more hydrophobic a 
protein is, the higher the percentage of acetonitrile needed to elute it. When 
purifying recPrP by preparative RP chromatography, a broad UV peak seen at an 
absorbance of 280 nm represents the protein eluting and is collected as one fraction 
or as multiple fractions. To obtain recPrP with a very high purity, I decided to 
collect multiple fractions across the eluting peak. This gave a better chance of 
separating recPrP from any impurities, which may elute around the same time as 




When I performed oligomerisation reactions on separate recPrP fractions, I 
observed that oligomers which formed from fractions collected across the RP peak 
were different. The oligomerisation assay (heating at 45 °C for 2.5 hours at pH 3.4), 
which I have used is adapted from Rezaei et al. (Rezaei et al., 2005) and produces 
two main populations of oligomers. The proportions of these two populations, 
which Rezaei et al. showed to consist of 12 recPrP molecules (12 mer) and 36 recPrP 
molecules (36 mer), seemed to be affected by where in the RP peak they had been 
collected. Figure 5.1A shows a RP chromatogram with the different fractions which 
were collected separately highlighted as F1 and F2. These fractions were 
oligomerised and analysed by SEC (figure 5.1C+D). Fraction 1, which was collected 
from the left hand side of the RP peak, produced oligomers which were almost all 
P2 (smaller 12 mer population). Fraction 2, which was collected from the right hand 
side of the RP peak, produced oligomers which had a high proportion of P1 (larger 
36 mer population). The differences between the two chromatograms are distinct. 
The fractions were analysed by SDS-PAGE to examine purity (figure 5.1B), fraction 
1 is shown in lane 7 and fraction 2 is shown in lane 9. The purity of the two fractions 
is similar and not likely to account for such stark differences in oligomerisation 
profiles. Therefore, the differences in oligomerisation profiles for the different RP 
fractions must be caused by another variable. 
To investigate what this unknown variable could be, I had the samples analysed by 
mass spectrometry. Mass spectrometry can identify very small changes in mass, 
including the loss or addition of side chains and the loss or addition of specific 
bonds. The purification protocol I used to purify recPrP involves an oxidation step, 
in which oxidised glutathione is added to the recPrP sample and left overnight. This 
step is crucial for normal folding of the protein, since it allows the disulphide bond 
found in the C-terminal to form. Oxidised glutathione is used to slow down 
disulphide-bond formation, which encourages intramolecular disulphide bonds 
instead of intermolecular bonds. This procedure results in five possible oxidation 
states. The most abundant is oxidised recPrP with an intact disulphide bond. RecPrP 
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can also occur with a glutathione attached to each cysteine, so it is reduced but has 
no free thiol groups. RecPrP can occur with no disulphide bond and with one 
glutathione attached to either of the cysteines. Lastly, recPrP can exist with no 
disulphide bond and no glutathione attached (disulphide-reduced recPrP). Figure 
5.2 shows the total ion count (TIC) chromatogram from liquid chromatography 
mass spectrometry (LC-MS) analysis. The TIC chromatogram shows a recPrP 
fraction containing all of the possible oxidation states. The chromatogram shows 
that the oxidised recPrP elutes first, followed by those with glutathione attached 
and the disulphide-reduced recPrP elutes last.  
The mass spectrometry data showed that the RP fraction collected from the leading 
edge of the eluting peak was comprised of oxidised recPrP (figure 5.3A). By 
contrast, the RP fraction collected from the right hand side of the eluting peak had a 
large proportion of disulphide-reduced recPrP (figure 5.3C). The RP fraction 
collected from the top of the RP peak was also analysed, it showed a combination of 
all oxidation states of recPrP. These results suggest that the presence or absence of 
the disulphide bond in recPrP may be responsible for causing such different 
oligomerisation profiles. This led to the hypothesis that the oxidation state of recPrP, 
whether it has an intact disulphide bond or not, can determine the size of the 






Figure 5.1 Sequential purification fractions show different oligomerisation 
profiles. 
A) RP chromatogram for recPrP: fractions were collected from the left-hand side, top 
and right-hand side of the eluting peak. The left and right-hand fractions are labelled 
as F1 and F2, missing out the fraction collected from the top of the peak. B) SDS-
PAGE gel with coomassie staining, showing the fractions collected from the RP 
chromatogram in A. F1 and F2 are shown in lanes 7 and 9 respectively, both show 
equal levels of purity. The higher molecular weight band at approximately 46 kDa 
shows recPrP dimer. C) Oligomerisation chromatogram of fraction 1 (F1) collected 
from the left-hand side of the RP peak shown in A. D) Oligomerisation 
chromatogram of fraction 2 (F2) collected from the right-hand side of the RP peak 
shown in A. C+D) P1 shows the larger 36 mer oligomer population, P2 highlights the 




Figure 5.2 Mass spectrometry data showing the different oxidation states of 
recPrP. 
TIC chromatogram from LC-MS analysis showing the different oxidation states of 
recPrP which can form from the protocol used. Arrows highlight which peaks 




Figure 5.3 TIC chromatograms of different RP chromatography fractions.  
A) TIC chromatogram from LC-MS analysis of RP purification fraction collected from 
the left- hand side of the eluting peak, all recPrP is shown to have the disulphide 
bond. B) TIC chromatogram from LC-MS analysis of RP purification fraction 
collected from the top of the eluting peak, arrows indicate the different oxidised 
states of recPrP present in the fraction. C) TIC chromatogram from LC-MS analysis 
of RP purification fraction collected from the right-hand side of the eluting peak, 
arrows indicate the different oxidised states of recPrP present in the fraction, the 
largest proportion of recPrP has no disulphide bond.  
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5.3 Disulphide-reduced recPrP drives the formation of larger oligomers  
The results in section 5.2, demonstrate that oligomers formed from recPrP collected 
from the left hand side of the RP elution peak consist almost entirely of the smaller 
12 mer oligomer species. Alternatively, recPrP collected from the right hand side of 
the RP peak formed oligomers with a high proportion of the large 36 mer 
population. Mass spectrometry data shows that the recPrP from the left hand side of 
the RP peak had an intact disulphide bond, and recPrP from the right hand side of 
the elution peak had a high proportion of disulphide-reduced recPrP.  
In light of this, I wanted to investigate whether the presence or absence of the 
disulphide bond was causing the differences in oligomerisation profiles. To do this, 
I first purified recPrP and analysed it using mass spectrometry to determine the 
oxidation state of the protein (figure 5.4A+B). RecPrP shown to be completely 
oxidised was oligomerised. The oxidised recPrP oligomers were shown to be 
comprised of almost entirely the 12 mer species (P2), with less than 3 % 36 mer 
oligomers (P1), (figure 5.4C). To ensure that the oligomer peaks shown by SEC were 
recPrP, I collected fractions to analyse by SDS-PAGE. The fractions which 
corresponded to the SEC peaks were shown to contain protein at the correct 
molecular weight for recPrP (figure 5.4D), demonstrating that the SEC peaks are 
recPrP oligomers. Next, I wanted to investigate the size of the oligomers which 





Figure 5.4 Oligomer profile for oxidised recPrP. 
A) TIC chromatogram from LC-MS analysis showing only oxidised recPrP which 
was used for oligomerisation in C. B) Mass spectrum of the protein shown in A. The 
various peaks all correspond to full length recPrP but with different charges (as 
labelled). Multiplying each peak’s m/z value with the charge and then subtracting the 
charge, gives a measure of mass. The average of all the peaks was calculated, 
which generated the mass of the protein. The mass was shown to be 23,061.8 Da, 
which corresponds to oxidised recPrP. C) Oligomerisation chromatogram of 100 % 
oxidised recPrP. P1 shows the larger 36 mer oligomer population, P2 highlights the 
smaller 12 mer oligomer population and P3 shows the monomer. D) SDS-PAGE gel 
with silver staining, showing fractions collected from the chromatogram in C. The 
bands correspond to the peaks in C and are the correct molecular weight for recPrP.   
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To analyse how disulphide-reduced recPrP would behave in the oligomerisation 
assay, I took recPrP which was shown by mass spectrometry to be completely 
oxidised (did not contain recPrP with other oxidation states) and treated this with 
the reducing agent DTT. Following reduction, recPrP was re-purified by RP 
chromatography to remove the DTT. The recPrP was analysed by mass 
spectrometry to ensure that the reduction reaction had been successful. The data 
show that the reduced recPrP samples contained only disulphide-reduced recPrP 
(figure 5.5A+B).  
The disulphide-reduced recPrP was oligomerised and analysed by SEC (figure 
5.5C). The disulphide-reduced recPrP oligomers had a very high proportion of the 
large 36 mer species (P1) and much less of the smaller 12 mer species (P2). In 
addition, the monomer peak (shown as P3) was less intense in the reduced state 
than in the oxidised oligomer chromatogram (figure 5.4C), suggesting that 
oligomerisation was more complete. To confirm that the SEC oligomer peaks were 
recPrP, fractions were collected and analysed by SDS-PAGE (figure 5.5D). The 
fractions which corresponded to the oligomer peaks were shown to contain protein 
with the correct molecular weight to be recPrP.  
The data shows that the presence or absence of the disulphide bond in recPrP 
impacts the size of the oligomers which subsequently form. RecPrP with no 
disulphide bond will result in oligomers with a high proportion of the large 36 mer 
species. By contrast, oxidised recPrP forms oligomers which consist almost entirely 
of the smaller 12 mer oligomer population. Next, I wanted to investigate how much 




Figure 5.5 Oligomer profile for disulphide-reduced recPrP. 
A) TIC chromatogram from LC-MS analysis showing disulphide-reduced recPrP 
which was used for oligomerisation in C. B) Mass spectrum of the protein shown in 
A. The peaks all correspond to full length recPrP but with different charges (as 
labelled). The average mass was calculated, which was shown to be 23,063,5 Da, 
which corresponds with disulphide-reduced recPrP. It is approximately 2 Da more 
than oxidised recPrP, because there are 2 extra hydrogen atoms attached to the 
cysteine residues. C) Oligomerisation chromatogram of disulphide-reduced recPrP. 
P1 shows the larger 36 mer oligomer population, P2 highlights the smaller 12 mer 
oligomer population and P3 shows the monomer. D) SDS-PAGE gel with silver 
staining, showing fractions collected from the chromatogram in C. The bands 
correspond to the peaks in A and are the correct molecular weight for recPrP.   
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5.4 Investigating the proportion of disulphide-reduced recPrP needed to 
drive the formation of the larger oligomer species 
I have demonstrated that the presence or absence of the disulphide bond in recPrP 
affects the size of the oligomers which form, with disulphide-reduced recPrP 
driving the formation of the larger 36 mer species. With this in mind, I wanted to 
investigate what percentage of disulphide-reduced recPrP was needed to instigate a 
significant increase in 36 mer production. To do this, I solubilised both oxidised 
recPrP and disulphide-reduced recPrP in the acidic oligomerisation buffer and 
mixed a controlled percentage of the disulphide-reduced recPrP with the oxidised 
recPrP. This was then oligomerised by heating at 45 °C for 2.5 hours. Following 
oligomerisation, all samples were analysed by SEC. Figure 5.6 shows oligomers 
formed with 0-100 % disulphide-reduced recPrP. The results clearly show that the 
36 mer (P1) peak increases with the increasing percentage of disulphide-reduced 
recPrP. The area under each peak was calculated and expressed as a percentage of 
total protein; multiple repeats were carried out to obtain average data as shown in 
figure 5.7.  
The integration data shows that when 1 % disulphide-reduced recPrP was 
oligomerised, there was no significant increase in 36 mer production when 
compared to 0 % disulphide-reduced recPrP oligomers (t-test p value > 0.05). 
However, there was a significant increase in 36 mer production with 5 % 
disulphide-reduced recPrP when compared to 0 % disulphide-reduced oligomers (t-
test p value < 0.01). This suggests that a 5 % or greater proportion of disulphide-
reduced recPrP is needed in order to produce a significant amount of the 36 mer 
species. At this concentration (1 mg/ml) the proportion of the P1 oligomer species 
does not reach 100 % even with 100 % disulphide-reduced recPrP, this may be 
because the 12 mer and 36 mer oligomers exist in equilibrium. Therefore, it may not 
be possible to produce 100 % P1 oligomers if 12 mer oligomers assemble to become 





Figure 5.6 Size exclusion chromatograms for oligomers formed with 0-100 % 
disulphide-reduced recPrP. 
Size exclusion chromatograms for oligomers formed with 0 % disulphide-reduced 
recPrP (100 % oxidised, lightest green) up to 100 % disulphide-reduced recPrP 
(dark blue). P1 shows the larger 36 mer oligomer population, P2 highlights the 





Figure 5.7 Integration data for oligomers formed with 0-100 % disulphide-
reduced recPrP. 
Bar chart to show the average integration data from oligomers formed from 0-100 % 
disulphide-reduced recPrP. The area under each peak from the size exclusion 
chromatograms was calculated as a percentage of the total area under all peaks, for 
oligomers formed from 0, 1, 5, 10, 25, 50 and 100 % disulphide-reduced recPrP, 
with a minimum of n=3 for each, ± standard error (SE) bars are shown. P1 shows 
the larger 36 mer oligomer population, P2 shows the smaller 12 mer oligomer 
population and P3 shows the monomer. 
The concept that disulphide-reduced recPrP was driving the formation of the larger 
P1 oligomer species, was strengthened by data collected in the Gill group for the 
mutant S169N recPrP. The S169N mutant is murine recPrP with a point mutation at 
residue 169. Oxidised and disulphide-reduced S169N recPrP were mixed so that the 
final sample contained 25 % disulphide-reduced recPrP, this was oligomerised and 
fractions were collected for each peak (figure 5.8A). The fractions were then 
analysed by mass spectrometry to investigate the proportion of oxidised and 
disulphide-reduced recPrP present in each of the oligomer species. The data show 
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that the P1 oligomers contain the most disulphide-reduced recPrP, with much less 
in the P2 oligomers and very little in the monomer. Interestingly, the P1 peak 
contained both disulphide-reduced recPrP and oxidised recPrP. This would suggest 
that the disulphide-reduced recPrP is recruiting the oxidised recPrP into the larger 
oligomer species and, therefore, is driving 36 mer production. Although this 
analysis was carried out using S169N recPrP, there are no indicators that would 
suggest this mutant would behave differently to wild type recPrP.  
 
Figure 5.8 Mass spectrometry data for oligomer fractions  
A) Oligomerisation chromatogram of S169N mutant recPrP. P1 shows the larger 36 
mer oligomer population, P2 highlights the smaller 12 mer oligomer population and 
P3 shows the monomer. Fractions were collected and analysed by mass 
spectrometry. B) TIC chromatogram from LC-MS analysis from the P1 peak in A. C) 
TIC chromatogram from LC-MS analysis from the P2 peak in A. D) TIC 





5.5 Oligomers formed from disulphide-reduced recPrP are significantly 
more toxic than oxidised oligomers 
Once I had established that the absence of the disulphide bond in recPrP affected 
the size of the oligomers which formed, I wanted to explore whether this would also 
affect the toxicity of the oligomers. With this in mind, I produced oligomers with 
100 % oxidised recPrP and 100 % disulphide-reduced recPrP. The oligomers formed 
with oxidised recPrP were made up almost solely of the 12 mer species, while the 
oligomers formed with the disulphide-reduced recPrP had a high proportion of the 
36 mer species (figures 5.4 and 5.5 respectively). The toxicity of both oligomer 
preparations was investigated using murine primary cortical cells. The oligomers 
were diluted into cell culture media to give a final concentration of 0.65 or 1.3 µM. 
These concentrations were used since they fall within the range I showed causes 
toxicity (chapter 4). The cells were incubated with the oligomers for 24 hours before 
being fixed and stained with DAPI. Once the cells were stained they were imaged 
and a live/dead cell count was carried out, allowing toxicity to be assessed.  
The viability data for the cells following treatment with the oligomers is shown in 
figure 5.9. Interestingly, the data shows that at 0.65 µM the oxidised recPrP 
oligomers, which consisted of the 12 mer species, were significantly less toxic than 
the oligomers formed with the disulphide reduced recPrP, which contained a high 
proportion of the 36 mer species (p value <0.05). This would suggest that at this 
concentration the larger 36 mer oligomers are more toxic than the smaller 12 mer 
species. At the higher concentration of 1.3 µM there was not a significant difference 
in toxicity between the two oligomer preparations, however, a suggestive p value of 
0.071 was observed, which may indicate that with further repeats a significant 
difference would have been seen. The cells were also treated with α-helical recPrP at 
the higher concentration of 1.3 µM. There was no significant difference in toxicity 
between the α-helical recPrP and the buffer control, which demonstrates that recPrP 
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is not in itself toxic and that any toxicity seen in the oligomer treated cells must be 
conformation dependent.  
 
Figure 5.9 Toxicity of oligomers formed from oxidised or disulphide-reduced 
recPrP. 
Bar chart to show the toxicity of oligomers formed with 100 % oxidised recPrP (blue) 
or 100 % disulphide-reduced recPrP (black) at 0.65 and 1.3 µM, α-helical 
monomeric recPrP (green) is shown at the higher concentration for comparison. Cell 
viability is shown as a percentage of the buffer control, a minimum of 6 readings (3- 
4 pictures per well with 2 wells for each) were taken for each recPrP preparation in 
each experiment (n=4) ± standard error (SE) bars are shown. * indicates a 
significant difference (ANOVA: p value <0.05). 
I have shown that the larger 36 mer oligomer species formed from disulphide-
reduced recPrP are significantly more toxic than the oxidised oligomers at least at 
0.65 µM. With this in mind, I decided next to investigate whether it was the size of 
the oligomers formed from disulphide-reduced recPrP which was making them 
more toxic or whether the absence of the disulphide bond was increasing toxicity. I 
wanted to determine whether disulphide-reduced recPrP was itself intrinsically 
156 
 
toxic, or if the ability for disulphide-reduced recPrP to drive the formation of larger 
oligomers increased its toxicity. To do this, I solubilised both oxidised and 
disulphide-reduced recPrP in buffer typically used to produce monomeric recPrP 
(sodium acetate pH 5.5). Under these conditions oxidised recPrP is monomeric and 
α-helical. Therefore I assumed that disulphide-reduced recPrP would also be 
monomeric. If both oxidised and disulphide-reduced recPrP were monomeric, then 
any differences in toxicity would be due to the different oxidation states rather than 
differences in size. Therefore, I tested the toxicity of oxidised and disulphide-
reduced recPrP under neutral “monomeric” buffer conditions. Intriguingly, the 
disulphide-reduced recPrP was found to be significantly more toxic than the 
oxidised recPrP under neutral buffer conditions (p-value < 0.05, figure 5.10), at both 
0.65 and 1.3 µM. However, before drawing the conclusion that disulphide-reduced 
recPrP is intrinsically more toxic than oxidised recPrP, I wanted to ensure that the 
disulphide-reduced recPrP was monomeric under these buffer conditions. Since if 
disulphide-reduced recPrP is not monomeric at pH 5.5, then the differences in 
toxicity between disulphide-reduced recPrP and oxidised recPrP are not necessarily 






Figure 5.10 Toxicity of oxidised or disulphide-reduced recPrP prepared under 
“monomeric” conditions. 
Bar chart to show the toxicity caused by oxidised (blue) or disulphide-reduced (red) 
recPrP conformations formed in sodium acetate buffer at pH 5.5 at 0.65 and 1.3 µM. 
α-helical monomeric recPrP (green) is shown at the higher concentration for 
comparison. Cell viability is shown as a percentage of the buffer control, a minimum 
of 6 readings (3- 4 pictures per well with 2 wells for each) were taken for each 
recPrP preparation in each experiment (n=4) ± standard error (SE) bars are shown. 
* indicates a significant difference (ANOVA: p value <0.05). 
5.6 Structural comparison of oxidised and disulphide-reduced recPrP 
under neutral and acidic conditions  
I have shown that disulphide-reduced recPrP is more toxic than oxidised recPrP, 
both under neutral monomeric conditions and under acidic oligomeric conditions. 
Under oligomeric conditions, I have shown that disulphide-reduced recPrP forms 
oligomers which are larger than those formed from oxidised recPrP and 
significantly more toxic. Under neutral “monomeric” buffer conditions (pH 5.5), 
disulphide-reduced recPrP was also found to be more toxic than oxidised recPrP. I 
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wanted to investigate the size of disulphide-reduced recPrP at pH 5.5 to determine 
whether it was monomeric, like oxidised recPrP, or if it forms oligomers.  
In chapter 4, I explored the size of soluble misfolded species of recPrP in the fibril 
preparations and found that SEC was not reliable when using sodium acetate pH 5.5 
as the running buffer. The monomeric buffer conditions are the same as the fibril 
storage buffer, therefore, I knew that SEC would not be a robust method to 
investigate the size of disulphide-reduced recPrP under these conditions. In light of 
this, I decided to use DLS to analyse the size of disulphide-reduced recPrP in 
sodium acetate pH 5.5. For comparison, I also analysed the size of oxidised recPrP 
under the same buffer conditions and oxidised and disulphide-reduced oligomers 
(formed at pH 3.4).  
The DLS data shows that disulphide reduced recPrP under “monomeric” buffer 
conditions (pH 5.5) is not a monomer. The hydrodynamic radius of disulphide-
reduced recPrP at pH 5.5 was significantly greater than oxidised recPrP under the 
same conditions (figure 5.11B). Additionally, the hydrodynamic radius of 
disulphide-reduced recPrP at pH 5.5 was significantly greater than oxidised recPrP 
under oligomeric conditions (pH 3.4). The SEC data I have for the oxidised 
oligomers (figure 5.4A) shows them to be almost entirely the P2 species, which as 
Rezaei et al. showed, relates to approximately 12 PrP molecules(Rezaei et al., 2005). 
Therefore, this would suggest that disulphide-reduced recPrP at pH 5.5 exists as an 
oligomer which is larger than a 12 mer (figure 5.11). Furthermore, the DLS data 
shows that there was no significant difference in hydrodynamic radius between 
disulphide-reduced recPrP at pH 5.5 and disulphide-reduced recPrP that had been 
oligomerised at pH 3.4 (figure 5.11B). This would suggest that disulphide-reduced 
recPrP forms oligomers even at pH 5.5, and that the size of the oligomers are not 
significantly different to those formed at pH 3.4. The DLS percentage volume data 
(figure 5.11A) suggests that disulphide-reduced recPrP at pH 5.5 forms oligomers 
which are less heterogeneous than those formed at pH 3.4. This is shown by the 
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narrow peak for disulphide-reduced recPrP at pH 5.5 in figure 5.11A (red), showing 
spread of oligomer size, in comparison to disulphide-reduced recPrP at pH 3.4 
(black) which is much broader. Therefore, while the oligomers formed from 
disulphide-reduced recPrP at pH 3.4 are a mixture of both 36 mer and 12 mer 
species, those formed from disulphide-reduced recPrP at pH 5.5 may exist as a more 
homogenous population.  
In light of this, the toxicity data presented in figure 5.10 did not compare the toxicity 
of oxidised and disulphide-reduced monomers. Instead, the toxicity of oxidised 
monomers was compared to oligomers produced from disulphide-reduced recPrP 
under neutral conditions. Without toxicity data for the disulphide-reduced 
monomer, it is very difficult to determine whether disulphide-reduced recPrP is in 
itself toxic or if it is its ability to form large oligomers which makes it highly toxic. 
Therefore, it is impossible to say whether oligomers formed from disulphide-
reduced recPrP are more toxic because they are larger, or because disulphide-
reduced recPrP is in itself toxic. However, if disulphide-reduced recPrP does not 
exist as a monomer even under relatively neutral buffer conditions, then perhaps 




Figure 5.11 Dynamic light scattering data for oxidised and disulphide-reduced 
recPrP conformations formed under “monomeric” or “oligomeric” conditions. 
A) DLS data showing size distribution by volume of both oxidised and disulphide-
reduced recPrP under either “monomeric” conditions (sodium acetate pH 5.5, green 
for oxidised and red for reduced) or “oligomeric” conditions (sodium citrate pH 3.4, 
blue for oxidised and black for reduced). B) Average mean hydrodynamic radius 
DLS data, for both oxidised and disulphide-reduced recPrP under either 
“monomeric” conditions (sodium acetate pH 5.5, green for oxidised and red for 
reduced) or “oligomeric” conditions (sodium citrate pH 3.4, blue for oxidised and 
black for reduced). N=3 for each recPrP conformation, ± standard error (SE) bars 




The toxicity of oligomers in vivo and in vitro is often ascribed to their β-sheet rich 
structures (Glabe and Kayed, 2006, Cobb and Surewicz, 2009, Prusiner, 1998a). 
Therefore, I wanted to investigate whether oligomers formed from disulphide-
reduced recPrP under neutral buffer conditions had a β-sheet rich structure, which 
may contribute to their toxicity. I investigated the secondary structure of 
disulphide-reduced recPrP at pH 5.5 using CD. The secondary structure of 
disulphide-reduced recPrP at pH 5.5 was found to have a high β-sheet content 
(figure 5.12, red). The CD spectrum for disulphide-reduced recPrP oligomers 
formed at pH 5.5 was similar to that of disulphide-reduced oligomers formed at pH 
3.4 (figure 5.12, black). This suggests that oligomers formed from disulphide-
reduced recPrP whether they form at a more neutral or an acidic pH, have a β-sheet 
rich structure. By contrast, oxidised recPrP at pH 5.5 has an α-helical structure 
(figure 5.12, green) showing a conformation similar to that of PrPC. Lastly, oligomers 
formed from oxidised recPrP at pH 3.4 have a secondary structure in between that 
of the oxidised α-helical monomer and the disulphide-reduced oligomers. This 
would suggest that the oxidised oligomers have a higher β-sheet content than the 
oxidised monomer at pH 5.5, but a lower β-sheet content than the disulphide-





Figure 5.12 Secondary structure of oxidised and disulphide-reduced recPrP 
shown by circular dichroism.  
CD spectra for both oxidised and disulphide-reduced recPrP, under monomeric 
conditions (sodium acetate pH 5.5, green for oxidised and red for reduced) and 
under oligomeric conditions (sodium citrate pH 3.4, blue for oxidised and black for 
reduced).  
I wanted to investigate whether there were any differences in toxicity between 
oligomers formed at pH 3.4 or pH 5.5. Interestingly, disulphide-reduced oligomers 
formed at pH 3.4 were found to be significantly more toxic than disulphide-reduced 
oligomers formed at pH 5.5 at 0.65 µM (p value <0.05, figure 5.13). This would 
suggest that the oligomers formed under different pH buffer conditions must have 
some structural differences, which confer different toxicities. Additionally, oxidised 
oligomers made at pH 3.4 were found to be significantly more toxic than oxidised 
monomers made at pH 5.5 (p value <0.05, figure 5.13). This was not surprising since 
oxidised recPrP under these conditions is monomeric and α-helical and I have 
previously shown it to be non-toxic.  
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Overall, the data show that disulphide-reduced recPrP can form oligomers with β-
sheet rich structures at both pH 5.5 and 3.4. The DLS data suggests that there is no 
significant difference in hydrodynamic radius between the oligomers which form at 
pH 5.5 and pH 3.4 (figure 5.11B). However, the volume percentage data (figure 
5.11A) suggests that the oligomers formed at pH 5.5 are more homogenous than 
those formed at pH 3.4. It is possible that the more heterogeneous nature of the 
oligomers formed at pH 3.4 contribute to their toxicity, or there may be other 
structural differences between the oligomers. Further investigation would be 






Figure 5.13 Toxicity of oxidised and disulphide reduced recPrP conformations 
formed under “monomeric” or “oligomeric” conditions. 
Bar chart to show the toxicity of oxidised or disulphide-reduced recPrP 
conformations formed under either “monomeric” conditions (sodium acetate pH 5.5, 
red) or “oligomeric” conditions (sodium citrate pH 3.4, yellow) at 0.65 and 1.3 µM. 
The α-helical monomeric control (green) is shown at the higher concentration for 
comparison. Cell viability is shown as a percentage of the buffer control, a minimum 
of 6 readings (3- 4 pictures per well with 2 wells for each) were taken for each 
recPrP preparation in each experiment (n=4) ± standard error (SE) bars are shown. 





The importance and involvement of small, soluble oligomeric forms of misfolded 
proteins in PMDs is widely accepted (Kuo et al., 1996, Naslund et al., 2000, McLean 
et al., 1999, Mucke et al., 2000a, Walsh et al., 2002, Quist et al., 2005, Kristiansen et 
al., 2007, Simoneau et al., 2007, Volles et al., 2001, Lue et al., 1999). However, the 
pathways leading to the production of oligomers and the factors which affect their 
size and toxicity are not well defined. In this chapter, I have demonstrated that the 
presence or absence of the disulphide bond in recPrP is crucial in determining the 
size of the oligomers which will form and, importantly, their toxicity. I found that 
recPrP lacking the disulphide bond (disulphide-reduced) formed oligomers with a 
high proportion of the large 36 mer species. This was in stark contrast to oligomers 
formed from oxidised recPrP, which consisted almost entirely of the smaller 12 mer 
oligomers. The differences in the size of the oligomers also affected their toxicity, 
with the larger disulphide-reduced oligomers causing significantly more toxicity 
than the smaller oxidised oligomers. In addition, the disulphide-reduced oligomers 
were shown to have a more β-sheet rich structure when compared to the oxidised 
oligomers. Under relatively neutral buffer conditions with a pH of 5.5, oxidised 
recPrP is monomeric, α-helical, and non-toxic to the cells. Under the same buffer 
conditions I discovered that disulphide-reduced recPrP forms highly toxic 
oligomers. This highlights how the absence of the disulphide bond can dramatically 
affect the ability of recPrP to form oligomers and cause toxicity.  
Previous studies show conflicting evidence relating to how disulphide-reduced 
recPrP behaves under different buffer conditions, and whether it exists as a 
monomer or an oligomer (Jackson et al., 1999, Hosszu et al., 2009, Maiti and 
Surewicz, 2001, Sasaki et al., 2008). It has been postulated that disulphide-reduced 
recPrP can exist as a β-sheet rich monomer (Jackson et al., 1999), however, various 
studies dispute this finding and instead show disulphide-reduced recPrP to be 
oligomeric (Maiti and Surewicz, 2001, Hosszu et al., 2009, Sasaki et al., 2008). Some 
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studies have shown that lowering the pH or increasing the concentration of salts is 
needed to instigate oligomerisation (Trevitt et al., 2014, Maiti and Surewicz, 2001), 
while others have shown an oligomeric structure is possible even under neutral 
conditions (Hosszu et al., 2009, Sang et al., 2012). The differences in techniques used 
to analyse the structure of the protein and differences in the recPrP species used 
may all contribute to these inconsistencies. Additionally, some papers analysed the 
structure of truncated disulphide-reduced PrP (amino acids 91-231) instead of full 
length PrP (Jackson et al., 1999, Hosszu et al., 2009), which behaves differently as 
shown by Trevitt et al. (Trevitt et al., 2014). This is also likely to account for some of 
the disparity seen between studies.  
There has been some speculation about whether oligomers during disease are 
formed through intermolecular disulphide bonds (Knaus et al., 2001, Lee and 
Eisenberg, 2003). If this was the case, then disulphide-reduced PrP could recruit 
oxidised PrP and reform disulphide bonds between molecules. This may be possible 
in some cases, however, my data would suggest that the oligomers formed by 
disulphide-reduced recPrP do not contain intermolecular disulphide bonds, since 
when they are analysed by mass spectrometry they appear as monomers. If they 
were assembled and linked by disulphide bonds, then they would remain 
oligomeric during mass spectrometry. Additionally, Sang et al. (Sang et al., 2012) 
showed that oligomers formed by mutant PrP containing no disulphide bonds were 
not assembled by intermolecular disulphide bonds, since oligomerisation was the 
same even under DTT reducing conditions.  
When studying the importance of the disulphide bond in PrP and how it might 
relate to disease, it is important to establish whether disulphide-reduced PrP can 
occur naturally in vivo. It has been shown that PrP has a “weak” signal peptide, 
which can cause it to not be transported into the ER. Instead it can be translocated to 
the cytosol (Orsi et al., 2006), since it has not been through the ER this form of PrP 
has no disulphide bond and an intact signal peptide (Orsi et al., 2006). Under ER 
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stress conditions, it has been shown that levels of this cytosolic PrP increases (Orsi et 
al., 2006) and that it is likely toxic (Ma et al., 2002). Another potential source of 
disulphide-reduced PrP in the cell is termed PrPCTM, which spans the ER membrane 
and is not processed and refolded properly. PrPCTM has been shown to be 
translocated away from the ER to either the Golgi or the cytosol, where it is thought 
to cause toxicity (Orsi et al., 2006, Lisa et al., 2012). Both these sources of cytosolic 
PrP lack a disulphide bond and would normally be degraded by the proteasome. 
However, in some cases where the proteasome is inhibited or working less 
efficiently, such as in aged individuals or during an infection, there could be a 
build- up in the cytosol. It has also been shown that ER stress or inhibition of the 
proteasome can lead to PrP aggregation in the cell (Nunziante et al., 2011), and that 
these aggregates can be transported to the cell membrane (Nunziante et al., 2011). 
This could lead to a seeding event and spontaneous disease (Ma and Lindquist, 
1999).  
In mice, it has been shown that various mutations in the Prnp gene can cause an up 
regulation of PrPCTM, which causes neurodegeneration (Hegde et al., 1998, Stewart 
and Harris, 2005). Mutations which caused the highest levels of PrPCTM had the 
shortest life span, and those with lower levels took significantly longer to develop 
disease (Hegde et al., 1999). It was shown that if PrPCTM was down regulated then 
disease no longer occurred, indicating that PrPCTM was directly involved in toxicity 
(Hegde et al., 1998). During a prion infection it has been shown that levels of PrPCTM 
increase as the disease progresses (Hegde et al., 1999), so it is possible that PrPCTM 
could be responsible for the cellular toxicity seen in these diseases. Once formed, 
PrPCTM has been shown to exit the ER (Yedidia et al., 2001, Hegde et al., 1998) and by 
an unknown mechanism cause toxicity (Hegde et al., 1998). Additionally, mice with 
mutations which cause increased levels of PrPCTM were shown to have an absence of 
PK resistant fibrillar deposits (Hegde et al., 1998) suggesting that the toxic species 
was perhaps soluble and oligomeric. It has been found that there is an increase in 
PrPCTM found in the brains of those affected with GSS disease caused by the A117V 
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mutation(Hegde et al., 1998). Similar to the mice with increased levels of PrPCTM, 
patients with this mutation have little or no PK resistant PrPSc (Hegde et al., 1998). 
This would indicate that PrPCTM is playing a role in causing disease. 
It has been suggested that PrPCTM may play a role in causing neurodegeneration in 
prion diseases. If this hypothesis is correct and disulphide-reduced PrPCTM is 
upregulated under prion infection or because of a mutation, then there is the 
question of how PrPCTM causes toxicity once it has exited the ER. One possibility is 
that the disulphide-reduced PrP forms oligomers either through association with 
other disulphide-reduced PrP or with oxidised, normally folded PrP. I have shown 
that disulphide-reduced recPrP can oligomerise with oxidised recPrP, and that as 
little as 5 % disulphide-reduced recPrP can drive the formation of large highly toxic 
oligomers. If the disulphide-reduced PrP did go on to form oligomers in the cytosol, 
then it is yet to be established how these might cause toxicity. One explanation is 
that they may insert into the cell membrane, causing disruption to the calcium 
homeostasis of the cell. It has been demonstrated that when PrP has been disulphide 
reduced, it binds strongly to membranes (Kazlauskaite et al., 2003, Kazlauskaite et 
al., 2005) and causes disruption potentially by membrane insertion (Shin et al., 2008, 
Shin et al., 2009, Caughey and Lansbury, 2003). Therefore, this may be a potential 
pathway for how toxicity may occur in disease (Kazlauskaite et al., 2005, Caughey 
and Lansbury, 2003).  
The diagram in figure 5.14A illustrates how the disulphide-reduced oligomers may 
cause toxicity in the primary cell experiments. The model demonstrates that the 
oligomers may cause toxicity through membrane insertion externally, or after being 
taken up by the cell, and that the larger oligomers may insert deeper into the 
membrane and cause greater toxicity. The model in figure 5.14B shows how 
disulphide-reduced PrP may cause toxicity during disease in vivo. The model 
proposes that if during infection PrPSc causes ER stress and the up-regulation of 
PrPCTM, then the PrPCTM could be translocated to the cytosol where it could 
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oligomerise. These oligomers could then insert into the cell membrane and cause 
cellular disruption and death, or go on to form fibrils. Alternatively, under ER stress 
disulphide-reduced PrP could remain in the ER and potentially oligomerise and 
insert into the ER membrane causing apoptosis. If PrPCTM is directly involved in 
causing cellular toxicity during prion infection, then this may account for why the 
PrPSc titre does not always correlate with cell death and why PrPSc itself is not 
thought to be the toxic entity (Hill et al., 2000, Sandberg et al., 2014, Krasemann et 
al., 2013).  
In summary, I have shown that the oxidation state of PrP is crucial in determining 
the size and potential toxicity of oligomers which will form. I have shown that 
disulphide-reduced recPrP forms oligomers at pH 5.5 and pH 3.4, and that these 
oligomers have different structures and confer different levels of toxicity. 
Disulphide-reduced PrP does exist in vivo and may be involved in instigating 





Figure 5.14 Toxicity models. 
A) Representation of a mammalian cell exposed to recPrP oligomers in vitro, the 
image shows how oligomers may cause cellular toxicity which leads to apoptosis. B) 
Representation of a mammalian cell in vivo which is under ER stress, potentially 
from a neurodegenerative disease. The image illustrates how under ER stress 
recPrP lacking a disulphide bond can form, and potentially be given the chance to 





Chapter 6: Mechanisms leading to cell death associated with misfolded isoforms of recPrP and recAβ 
Mechanisms leading to cell death 
associated with misfolded isoforms 

















In order to better understand the pathology of PMDs, it is important to investigate 
mechanisms and pathways leading to cell death caused by the misfolded proteins 
implicated in these diseases. A better understanding of the pathways leading to cell 
death may help in the development of drugs or therapies for these diseases, which 
are not presently available. The hypothesis that there may be common mechanisms 
leading to cellular toxicity across PMDs has been widely debated (Glabe, 2006, 
Kayed et al., 2003, Haass and Selkoe, 2007, Quist et al., 2005). It is thought that small 
oligomeric forms of the misfolded proteins may activate common pathways leading 
to cell death (Glabe, 2006, Kayed et al., 2003, Haass and Selkoe, 2007, Quist et al., 
2005). If this was the case, then therapies could be developed which target these 
pathways meaning they could be effective in multiple PMDs. 
Previous studies have shown that both PrP and Aβ oligomers can induce apoptotic 
cell death (Novitskaya et al., 2006, Simoneau et al., 2007, Youssef et al., 2008, Yang et 
al., 2009). Additionally, apoptotic cells have been found around lesions in the brains 
of those affected with CJD (Jesionek-Kupnicka et al., 1997). Apoptosis is an energy 
dependent form of programmed cell death in which cellular organelles break down 
and the DNA in the nucleus fragments (Elmore, 2007). Apoptotic cells have 
shrunken nuclei and can undergo blebbing, where small portions of the cellular 
membrane containing cytoplasm can break off from the cell body (Elmore, 2007). 
The process of apoptosis is normal within an organism and the balance between cell 
division and apoptosis is integral to maintaining properly functioning tissues. 
However, during disease the balance between cell division and cell death can be 
altered. In cancer the rate of apoptosis is less than that of cell division, which is 
thought to be vitally important in the process of tumour growth (Elmore, 2007). In 
neurodegenerative diseases such as AD, Huntington’s and prion disease misfolded 
proteins are thought to instigate apoptosis (Elmore, 2007, Hickey and Chesselet, 
2003, Shimohama, 2000, Rohn, 2010, Jesionek-Kupnicka et al., 1997), which results in 
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the death of large numbers of cells. This process results in the loss of neurons and 
atrophy of the brain, which ultimately causes the symptoms seen in these diseases 
(Hickey and Chesselet, 2003, Shimohama, 2000, Rohn, 2010).  
In addition to apoptosis, excitotoxic cell death has previously been implicated in 
several PMDs, including AD (Molinuevo et al., 2005, Esposito et al., 2013, Di et al., 
2010, Dong et al., 2009), ALS (Van Damme et al., 2005) and Huntington’s disease 
(Tabrizi et al., 1999, Chiarlone et al., 2014, Dong et al., 2009). Excitotoxic cell death 
occurs when NMDA receptors, which are calcium gated ion channels activated by 
glutamate, are overly stimulated (Dong et al., 2009). This results in excessive 
calcium influx, which downstream causes cell death (Dong et al., 2009). Previously, 
Aβ oligomers have been shown to activate NMDA receptors leading to excitotoxic 
cell death (Dong et al., 2009, Li et al., 2009, Alberdi et al., 2010, Li et al., 2011, 
Rammes et al., 2011, Rönicke et al., 2011). Fewer studies have been published which 
have found this to be the case for PrP induced cell death (Muller et al., 1993, Sassoon 
et al., 2004, Thellung et al., 2013).  
As outlined in chapter 5, the ER is the site within a cell where secreted proteins 
undergo post-translational modifications and are correctly folded with the aid of 
chaperones (Kleizen and Braakman, 2004). When proteins are folded incorrectly 
they are transported to the cytosol and degraded by the proteasome (Dobson, 2003, 
Wickner et al., 1999). Under certain circumstances the proteasome can become 
overloaded, such as in aged individuals or during infection (Dobson, 2003, Wickner 
et al., 1999, Kristiansen et al., 2007). This can mean that the production of incorrectly 
folded proteins can overtake their degradation, which can be toxic to the cell 
(Dobson, 2003, Wickner et al., 1999, Kristiansen et al., 2007). The presence of 
unfolded proteins in the ER causes the unfolded protein response (UPR) to be 
activated (Bukau et al., 2006). This causes a cascade of proteins to be up-regulated, 
which in the first instance will try to re-establish the balance between protein 
formation and degradation by the production of chaperones (Bukau et al., 2006, 
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Voisine et al., 2010). In addition the ER-associated degradation pathway (ERAD) is 
activated, which translocates misfolded proteins to the cytosol for degradation 
(Bukau et al., 2006). However, if the balance between protein production and 
degradation cannot be corrected then the cell will undergo apoptosis (Bukau et al., 
2006). It has been shown previously that misfolded proteins found in 
neurodegenerative conditions such as AD or prion diseases can cause ER stress 
(Lindholm et al., 2006, Yoshida, 2007) which, when unresolved, can lead to cell 
death (Lindholm et al., 2006, Yoshida, 2007).  
I chose to explore apoptosis, excitotoxicity and ER stress as potential mechanisms 
leading to cell death caused by the recPrP and recAβ isoforms. I chose these 
pathways since they had all been previously implicated in PMDs. Additionally 
there were reagents available to investigate these pathways, such as inhibitors or 
specific proteins which could be probed for in the case of ER stress. There are many 
other pathways which may be involved in causing cell death when cells come into 
contact with misfolded proteins. These include both autophagy (Mizushima et al., 
2008, Martinez-Vicente and Cuervo, 2007) and oxidative stress (Nakamura and 
Lipton, 2010, Youssef et al., 2008). 
In chapter 4, I described work that investigated the toxicity caused by misfolded 
isoforms of recPrP and recAβ. I found that both recPrP oligomers and fibrils caused 
significant toxicity to primary cortical cells, while α-helical recPrP at the same 
concentration did not. Additionally, I discovered that while recAβ 1-42 oligomers 
cause significant toxicity, all recAβ 1-40 isoforms caused low toxicity and both 
recAβ 1-40 and recAβ 1-42 fibrils were found to be non-toxic. In light of this, I 
wanted to investigate how recPrP oligomers and fibrils and recAβ 1-42 oligomers 
were causing toxicity. In this chapter, I will explore the mechanisms which are 
activated in the cells when they are incubated with these misfolded proteins.  
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6.2 Misfolded isoforms of recPrP and recAβ cause apoptosis 
Both recPrP oligomers and fibrils caused significant toxicity to the cells, with the 
recPrP fibrils eliciting the greatest toxic response. By contrast, both recAβ 1-40 and 
recAβ 1-42 fibrils caused no significant toxicity. However, the recAβ 1-42 oligomers 
did cause significant toxicity when compared to the buffer control or the recAβ 1-42 
fibrils. In this chapter, I will explore the pathways and mechanisms which are 
activated by these misfolded proteins, which ultimately lead to cell death.  
Firstly, I wanted investigate whether recPrP oligomers or fibrils could be causing 
cell death via apoptosis. To do this, I used a pan-caspase inhibitor which blocks 
apoptosis by inhibiting the three major caspase pathways (caspases 9/3, 8/10 and 
12)(Caserta et al., 2003). The toxin staurosporine is known to cause 
apoptosis(Léveillé et al., 2010), however, when cells are treated with the pan-caspase 
inhibitor prior to exposure to staurosporine, cell viability is dramatically and 
significantly increased (figure 6.1A). Therefore, staurosporine was used as a positive 
control for these assays. Subsequently, I compared cell death between those treated 
with recPrP oligomers or fibrils alone, and those treated with oligomers or fibrils 
and the caspase inhibiter. The cells were incubated with the caspase inhibitor for 1 
hour prior to the addition of recPrP, once the recPrP isoforms had been added, the 
cells were incubated at 37 °C for 24 hours. Interestingly, I found a significant 
recovery in cell viability when cells were treated with recPrP oligomers and the 
caspase inhibitor (paired t-test; p value <0.05, figure 6.1A), suggesting that recPrP 
oligomers activate the programmed cell death pathway and cause apoptosis. By 
contrast, no significant difference was seen in cell viability between cells treated 
with fibrils alone and those treated with fibrils and the caspase inhibiter (figure 
6.1A). This suggests that recPrP fibrils do not cause cell death by apoptosis. 
Importantly, this also indicates that recPrP oligomers and fibrils are activating 
different cellular pathways to cause toxicity. 
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To further analyse the role of apoptosis in oligomer induced cell death, I probed for 
the presence of activated caspase 3. Caspase 3 is an executioner caspase and, once 
cleaved, it becomes active and causes the cell to undergo programmed cell 
death(Brentnall et al., 2013). I detected activated caspase 3 by western blotting. I 
found there was an up-regulation of activated caspase 3 in cells treated with recPrP 
oligomers (figure 6.1B+C), which confirms that recPrP oligomers induce apoptosis. 
The western blot shown in figure 6.1B is a representative example of 4 western blots, 
in which activated caspase 3 was detected. All of the western blots were analysed by 
densitometry for activated caspase 3 protein expression. β-actin was used as a 
control for the amount of protein loaded, hence the activated caspase 3 expression 
was normalised to β-actin expression. The data presented in figure 6.1C is the 
average western blot data expressed as a percentage of the high and low controls. 
The untreated cells acted as a low control and staurosporine treated cells acted as a 
high control. By presenting the data this way, it takes into account background cell 
death (untreated low control) and the maximum amount of activated caspase 3 that 
could be produced in this assay (staurosporine, high control). The oligomer treated 
cells at 1.3 µM show the greatest expression of activated caspase 3 (figure 6.1C). 
However, the fibril treated cells also showed activated caspase 3 expression (figure 
6.1B+C). This was surprising, since there was no recovery with the caspase inhibitor. 
The activated caspase 3 expression seen in the fibril treated cells is lower than that 
seen for oligomer treated cells. Therefore, perhaps there was a subset of fibril 
treated cells which were dying by apoptosis. The small soluble protofibrils found in 
the fibril preparations could be causing apoptosis in these cells. However, the main 
fibril population may be causing cell death by a different pathway, which is why no 
recovery was seen with the caspase inhibitor. Further studies would be needed to 
test this hypothesis. Nevertheless, the data strongly suggests that recPrP oligomers 







Figure 6.1 RecPrP oligomers cause apoptosis. 
A) Bar chart to show viability of the primary cells when treated with recPrP oligomers 
(mid grey) or fibrils (white) at 1.3 µM alone or in addition to the caspase inhibitor Q-
VD-OPh (50 µM), the cells were also treated with recPrP monomers (dark grey) at 
1.3 µM as a negative control and staurosporine (200 nM) as a positive control. Cell 
viability is shown as a percentage of the buffer control, a minimum of 6 readings (3- 
4 pictures per well with 2 wells for each) were taken for each experiment (n=4) ± 
standard error (SE). * indicates a significant recovery in cell viability for cells treated 
with oligomers and the caspase inhibitor when compared to oligomers alone (paired 
t-test; p value <0.05). B) Western blot to show the presence of activated caspase 3 
in the cells, the blot is representative of 4 blots. Top: shows β-actin loading control, 
bottom: shows activated caspase 3. Lanes 1-12 show cells treated with: lane 1: 
untreated, lane 2:, oligomer buffer control, lane 3: monomer and fibril buffer control, 
lane 4: monomer at 0.65 µM, lane 5: monomer at 1.3 µM, lane 6: α-helical PrP at 
0.65 µM, lane 7: oligomers at 0.65 µM, lane 8: oligomers at 1.3 µM, lane 9: fibrils at 
0.65 µM, lane 10: fibrils at 1.3 µM, lane 11: blank, lane 12: staurosporine (positive 
control) at 200 nM. C) Bar chart to show the average western blot results for 
activated caspase 3 (for 2 independent experiments with 2 wells of cells and 2 blots 
in each experiment), blots were analysed by image J and normalised to the β-actin 
control. Results were then expressed as a percentage of the high control 
(staurosporine) and low control (untreated).  
When the primary cells were visualised under a microscope following incubation 
with the recPrP isoforms, the cells appeared morphologically different from each 
other. Bright-field microscopy images of the primary cells after a 24 hour incubation 
with either α-helical recPrP, recPrP oligomers or recPrP fibrils are shown in figure 
6.2. Cells treated with α-helical recPrP appear similar to untreated cells, however, 
cells treated with oligomers or fibrils do not share the same morphology as the 
untreated cells. The cells treated with the oligomers are more spread out across the 
plate, with obvious neurite loss. Conversely, the fibril treated cells are clumped 
together, with large areas of the plate showing no cells. These morphological 
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differences further suggest that the recPrP oligomers and fibrils are activating 
different cellular pathways leading to cell death.  
 
 
Figure 6.2 Bright-field images of recPrP treated cells 
Bright-field microscopy images of murine primary cortical cells treated with different 
isoforms of recPrP. Top left image shows untreated cells. Top right image shows 
cells treated with α-helical recPrP at 1.3 µM. Bottom left image shows cells treated 
with recPrP oligomers at 1.3 µM and the bottom right image shows cells treated with 
recPrP fibrils at 1.3 µM. All images are shown at 10x magnification.  
In chapter 4, I showed that both the recAβ 1-42 monomers and oligomers caused 
significantly more toxicity that the recAβ 1-42 fibrils. Therefore, I investigated the 
mechanisms leading to cell death for both recAβ 1-42 monomers and oligomers. 
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After establishing that recPrP oligomers cause apoptosis to primary cortical cells 
(figure 6.1), I wanted to investigate whether toxic isoforms of recAβ 1-42 also induce 
apoptosis. I again investigated this using a pan-caspase inhibiter to block apoptosis. 
The average cell viability results are shown in figure 6.3A. There was some recovery 
in the cells treated with the caspase inhibitor and the Aβ 1-42 oligomers (figure 
6.3A). However, the recovery was not significant (paired t-test p value = 0.089). It is 
likely that the difference was not significant because in one of the three repeats the 
cell density was very high, which meant that the oligomer toxicity was reduced 
(figure 6.3D). The three independent repeats are shown in figure 6.3 B-D, the 
caspase inhibitor seemed to reduce toxicity in the oligomer treated cells in B and C. 
However, further repeats would be needed in order to see if the recovery with the 
caspase inhibitor would reach statistical significance. If the recAβ oligomers were 
found to also cause apoptosis this would be very interesting when put in context 
with the recPrP oligomer data, and could suggest a common mechanism leading to 
cell death caused by oligomers. The recAβ 1-42 monomer treated cells showed no 
significant recovery when treated with the caspase inhibitor. This is likely due to the 
recAβ 1-42 monomer not causing high enough levels of toxicity to be significantly 




Figure 6.3 RecAβ 1-42 oligomers cause apoptosis. 
A-D) Bar charts to show viability of the primary cells when treated with recAβ 1-42 
oligomers at 0.87 µM (dark pink) or recAβ 1-42 monomers at 0.43 µM (pale pink) 
alone or in addition to the caspase inhibitor Q-VD-OPh (50 µM, blue). Staurosporine 
(200 nM) acted as a positive control. Cell viability is shown as a percentage of the 
buffer control, a minimum of 6 readings (3- 4 pictures per well with 2 wells for each) 
were taken for each experiment ± standard error (SE). A) Average cell viability data 
for 3 independent experiments (shown separately B-D) B-D) Independent cell 
viability experiments, M: recAβ 1-42 monomers, O: recAβ 1-42 oligomers, Stauro: 
staurosporine.   
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6.3 The role of excitotoxicity in oligomer induced cell death 
I have demonstrated that recPrP oligomers induce apoptosis in primary cortical 
cells. Additionally, I have shown that recAβ 1-42 oligomers may also induce 
apoptosis. I wanted to further investigate the mechanisms leading to apoptosis, 
instigated by the oligomers. It has been shown that over stimulation of NMDA 
receptors can lead to excitotoxicity, which causes an influx of calcium into the cell 
and can lead to apoptosis. Excitotoxic cell death has been implicated in many PMDs 
(Molinuevo et al., 2005, Esposito et al., 2013, Di et al., 2010, Dong et al., 2009, Tabrizi 
et al., 1999, Chiarlone et al., 2014, Muller et al., 1993, Sassoon et al., 2004, Thellung et 
al., 2013, Alberdi et al., 2010). Therefore, I wanted to investigate whether the 
apoptosis induced by the oligomers could be caused by excitotoxicity. To investigate 
this, I used an NMDA receptor antagonist which blocks excitotoxicity. I first 
investigated the role of excitotoxicity in recPrP induced cell death. The cells were 
incubated with the NMDA receptor antagonist for 1 hour prior to the recPrP 
isoforms being added to the cell culture media. Cells were also treated with the 
recPrP isoforms alone, so that cell viability could be compared. There was no 
recovery seen in cells treated with the NMDA receptor antagonist and either recPrP 
oligomers or recPrP fibrils (figure 6.4). I repeated the experiment, and again no 
recovery was seen for cells treated with the NMDA receptor antagonist and 
oligomers or fibrils. Therefore, I decided not to carry out further repeats since even 
with an n =2 the result seemed conclusive. I think that since no recovery was seen 
with the NMDA receptor antagonist it is very unlikely that the oligomers cause 
excitotoxicity. Therefore, the oligomers must be activating a different pathway, 
which is leading to apoptosis. The data also suggests that recPrP fibrils do not cause 
excitotoxicity, therefore, the mechanisms causing fibril induced cell death are still 
unknown. NMDA was used as a positive control, which causes excitotoxicity and is 




Figure 6.4 RecPrP oligomers and fibrils are not inducing excitotoxicity. 
Bar chart to show viability of the primary cells when treated with recPrP oligomers 
(mid grey) or fibrils (white) at 1.3 µM alone or in addition to the NMDA receptor 
antagonist MK-801. The cells were also treated with monomers (dark grey) at 1.3 
µM as a negative control and NMDA (50 µM) as a positive control. Cell viability is 
shown as a percentage of the buffer control, a minimum of 6 readings (3- 4 pictures 






Having established that recPrP oligomers do not cause excitotoxicity, I wanted to 
investigate whether recAβ 1-42 oligomers induce excitotoxic cell death. I used a 
NMDA receptor antagonist to block excitotoxicity, as I did for the recPrP assays. 
The average cell viability results can be seen in figure 6.5A. The cells treated with 
the NMDA receptor antagonist and the recAβ 1-42 oligomers show an increase in 
viability, however, this increase was not significant (figure 6.5A). This was again 
likely due to the cells being highly confluent in one of the repeats, so that the 
oligomers caused less toxicity (figure 6.5D). The three independent repeats are 
shown in figure 6.5 B-D. The NMDA receptor antagonist seemed to increase cell 
viability in the oligomer treated cells in B and C, however, overall the recovery was 
not significant for the average data. It is possible that with further repeats the 
recovery with the NMDA receptor antagonist may reach statistical significance. If 
this was found to be the case then this could indicate that the recAβ 1-42 oligomers 
cause excitotoxicity, which then leads to apoptosis. If the recAβ 1-42 oligomers 
cause excitotoxicity, then this would suggest that recPrP oligomers and recAβ 




Figure 6.5 RecAβ 1-42 oligomers may induce excitotoxicity.  
A-D) Bar charts to show viability of the primary cells when treated with recAβ 1-42 
oligomers at 0.87 µM (dark pink) or recAβ 1-42 monomers at 0.43 µM (pale pink) 
alone or in addition to the NMDA receptor antagonist MK801 (blue). NMDA (50 µM) 
acted as a positive control. Cell viability is shown as a percentage of the buffer 
control, a minimum of 6 readings (3- 4 pictures per well with 2 wells for each) were 
taken for each experiment ± standard error (SE). A) Average cell viability data for 3 
independent experiments (shown separately B-D) B-D) Independent cell viability 
experiments, M: recAβ 1-42 monomers, O: recAβ 1-42 oligomers.  
6.4 Investigating the role of ER stress in recPrP induced toxicity 
The endoplasmic reticulum (ER) is the site within a cell where secreted proteins 
undergo post-translational modifications and are correctly folded. The process 
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within a cell of translating proteins and then folding them correctly, so they are 
functional, is based on a fine balance of protein production and protein degradation. 
Misfolded proteins in the ER cause the UPR and ERAD systems to be activated. The 
ERAD pathway translocates misfolded proteins to the cytosol for degradation by 
the proteasome. The UPR pathway causes the upregulation of chaperones to aid in 
protein folding. However, certain conditions such as aging or disease can put the ER 
under stress and cause the amount of incorrectly folded proteins to rise, this can 
lead to apoptosis through an ER stress related pathway. Additionally, a rise in the 
concentration of misfolded proteins can put a greater burden on the proteasome and 
lead to cell death potentially through autophagy. ER stress is thought to be involved 
in some PMDs, where the misfolded protein assemblies can cause ER stress leading 
to cellular toxicity and death. In light of this, I wanted to investigate if the recPrP 
oligomers could be causing ER stress. To investigate the involvement of ER stress in 
oligomer induced toxicity, I probed for the up-regulation of proteins associated with 





Figure 6.6 ER stress illustration 
Illustration showing the unfolded protein response (UPR) pathways downstream of 
ER stress.  
 
The cells were incubated with the different recPrP isoforms, lysed, and the cell 
lysates were used for western blotting. Initially I incubated the cells with recPrP for 
24 hours prior to lysis, since this was the length of incubation used in all cell 
viability assays. I first probed for the ER chaperone BiP, which is upstream of the 
other ER stress related proteins and is produced at the early stages of ER stress(Lee, 
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2005) (figure 6.6). I found no significant up-regulation of BiP at the 24 hour time 
point in cells treated with any of the recPrP isoforms (figure 6.7). I also incubated 
the cells with tunicamycin, which causes ER stress and acted as a positive control. 
Cells treated with tunicamycin showed an up-regulation in BiP expression. I 
decided to also probe for the presence of CHOP which is downstream of BiP and 
promotes apoptosis(Moreno et al., 2013). I found no CHOP expression for cells 
treated with any of the recPrP isoforms (figure 6.8, lane 11 shows the positive 
control). Additionally, I tested for the presence of phosphorylated EIF2α. EIF2α, as 
shown in figure 6.6 is downstream of BiP and upstream of CHOP. During ER stress 
EIF2α is phosphorylated, so the presence of the phosphorylated form is indicative of 
ER stress. I probed for the presence of phosphorylated EIF2α and normalised this to 
total EIF2α expression. I saw no up-regulation of phosphorylated EIF2α in cells 
treated with any of the recPrP isoforms (figure 6.9). Figure 6.6 depicts the various 
ER stress related pathways; caspase 12 is shown to be separate from the other UPR 
pathways and can cause apoptosis independently of CHOP. With this is mind, I 
decided to probe for the presence of caspase 12 to see if oligomer induced apoptosis 
could be triggered through this pathway. There was an up-regulation of caspase 12 





Figure 6.7 ER stress data for BiP after 24 hour incubation with recPrP 
isoforms  
A) Bar chart to show the average BiP western blot data for cells treated with recPrP 
isoforms for 24 hours (for 2 independent experiments with 2 wells of cells in each 
experiment), blots were analysed by image J and normalised to the β-actin control. 
The data is expressed as fold change over the buffer controls (the buffer controls 
would be 1). B+C western blots are from the same experiment but different wells of 
cells, D shows an independent experiment (all after 24 hour incubation). B+C) Lane 
1: untreated, lane 2: oligomer buffer control, lane 3: monomer and fibril buffer 
control, lane 4: monomer at 0.65 µM, lane 5: monomer at 1.3 µM, lane 6: α-helical 
control at 0.65 µM, lane 7: oligomers at 0.65 µM, lane 8: oligomers at 1.3 µM, lane 
9: fibrils at 0.65 µM, lane 10: fibrils at 1.3 µM, lane 11: tunicamycin (2.5 µg/ml). D) 
Lane 1: untreated, lane 2: oligomer buffer control, lane 3: monomer and fibril buffer 
control, lane 4: monomer at 0.65 µM, lane 5: monomer at 1.3 µM, lane 6: oligomers 
at 0.65 µM, lane 7: oligomers at 1.3 µM, lane 8: fibrils at 0.65 µM, lane 9: fibrils at 






Figure 6.8 ER stress data for CHOP after 24 hour incubation with recPrP 
isoforms 
Western blot from cell lysates after a 24 hour incubation with recPrP isoforms. Lane 
1: untreated, lane 2: oligomer buffer control, lane 3: monomer and fibril buffer 
control, lane 4: monomer at 0.65 µM, lane 5: monomer at 1.3 µM, lane 6: α-helical 
control at 0.65 µM, lane 7: oligomers at 0.65 µM, lane 8: oligomers at 1.3 µM, lane 
9: fibrils at 0.65 µM, lane 10: fibrils at 1.3 µM, lane 11: tunicamycin (2.5 µg/ml). The 






Figure 6.9 ER stress data for phosphorylated EIF2α after 24 hour incubation 
with recPrP isoforms 
A) Bar chart to show the average phosphorylated EIF2α western blot data for cells 
treated with PrP isoforms for 24 hours (for 2 independent experiments with 2 wells 
of cells in each experiment), blots were analysed by image J and normalised first to 
the β-actin control and then phosphorylated EIF2α was normalised to total EIF2α 
expression. The data is expressed as fold change over the buffer controls (the buffer 
controls would be 1). C+D show western blots from the same experiment but 
different wells of cells, B shows an independent experiment (all after 24 hour 
incubation). B) Lane 1: untreated, lane 2: oligomer buffer control, lane 3: monomer 
and fibril buffer control, lane 4: monomer at 0.65 µM, lane 5: monomer at 1.3 µM, 
lane 6: α-helical control at 0.65 µM, lane 7: oligomers at 0.65 µM, lane 8: oligomers 
at 1.3 µM, lane 9: fibrils at 0.65 µM, lane 10: fibrils at 1.3 µM, lane 11: tunicamycin 
(2.5 µg/ml). C+D) Lane 1: untreated, lane 2: oligomer buffer control, lane 3: 
monomer and fibril buffer control, lane 4: monomer at 0.65 µM, lane 5: monomer at 
1.3 µM, lane 6: oligomers at 0.65 µM, lane 7: oligomers at 1.3 µM, lane 8: fibrils at 
0.65 µM, lane 9: fibrils at 1.3 µM, lane 10: staurosporine (200 nM), lane 11: 






Figure 6.10 ER stress data for caspase 12 after 24 hour incubation with recPrP 
isoforms 
A) Bar chart to show the average caspase 12 western blot data for cells treated with 
recPrP isoforms for 24 hours (for 2 independent experiments with 2 wells of cells in 
each experiment), blots were analysed by image J and normalised to the β-actin 
control. The data is expressed as fold change over the buffer controls (the buffer 
controls would be 1). B+C show western blots from the same experiment but 
different wells of cells, D+E show western blots from the same experiment but 
different wells of cells (all after 24 hour incubation). B+C) Lane 1: untreated, lane 2: 
oligomer buffer control, lane 3: monomer and fibril buffer control, lane 4: monomer at 
0.65 µM, lane 5: monomer at 1.3 µM, lane 6: α-helical control at 0.65 µM, lane 7: 
oligomers at 0.65 µM, lane 8: oligomers at 1.3 µM, lane 9: fibrils at 0.65 µM, lane 10: 
fibrils at 1.3 µM, lane 11: staurosporine (200 nM). C+D) Lane 1: untreated, lane 2: 
oligomer buffer control, lane 3: monomer and fibril buffer control, lane 4: monomer at 
0.65 µM, lane 5: monomer at 1.3 µM, lane 6: oligomers at 0.65 µM, lane 7: 
oligomers at 1.3 µM, lane 8: fibrils at 0.65 µM, lane 9: fibrils at 1.3 µM, lane 10: 




I hypothesised that the lack of ER stress related markers at the 24 hour time point 
could be due to a high proportion of the cells being dead. Therefore, I decided to 
investigate the expression of ER stress related proteins in the cells after a six hour 
incubation with the recPrP isoforms. I hypothesised that an earlier time point may 
show early stages of toxicity and increased expression of ER stress proteins, if ER 
stress was being induced.  
After a six hour incubation, cells treated with the recPrP oligomers did show an up-
regulation of BiP above the buffer control (figure 6.11). Although this up-regulation 
was not significant (t-test, p = 0.07). BiP was also not significantly upregulated in 
cells treated with α-helical recPrP or recPrP fibrils, showing that neither were 
causing ER stress.  
In addition to BiP, I also probed for the presence of CHOP (figure 6.12). After a six 
hour incubation, no CHOP expression was seen in cells treated with any of the 
recPrP isoforms (figure 6.12). CHOP can be seen in the tunicamycin treated cells in 
lane 10 (27 kDa), showing that the CHOP antibody was working. There was some 
up-regulation of caspase 12 seen at the 24 hour time point in oligomer and fibril 
treated cells. Therefore, I wanted to see if there was greater caspase 12 expression at 
an earlier time point when the level of cell death would be lower. However, after a 
six hour incubation I saw no up-regulation of caspase 12 in any of the recPrP treated 
cells when compared to the buffer control cells (figure 6.13).  
Taken together, it seems that the recPrP oligomers and fibrils are not causing ER 
stress through an EIF2α/ CHOP related pathway or through the caspase 12 ER stress 
pathway. The recPrP oligomers must be causing apoptosis independently of ER 






Figure 6.11 ER stress data for BiP after six hour incubation with PrP isoforms  
A) Bar chart to show the average BiP western blot data for cells treated with PrP 
isoforms for six hours (for 2 independent experiments with 2 wells of cells in each 
experiment), blots were analysed by image J and normalised to the β-actin control. 
The data is expressed as fold change over the buffer controls (the buffer controls 
would be 1, t-test showed a p value of 0.07 for oligomers at 0.65 µM compared to 
the buffer control). B + C western blots are from the same experiment but different 
wells of cells, D shows an independent experiment (all after 6 hour incubation). B) 
Lane 1: untreated, lane 2: oligomer buffer control, lane 3: monomer and fibril buffer 
control, lane 4: monomer at 0.65 µM, lane 5: monomer at 1.3 µM, lane 6: oligomers 
at 0.65 µM, lane 7: oligomers at 1.3 µM, lane 8: fibrils at 0.65 µM, lane 9: fibrils at 
1.3 µM, lane 10: tunicamycin (2.5 µg/ml). C) Lane 1: oligomer buffer control, lane 2: 
monomer and fibril buffer control, lane 3: monomer at 0.65 µM, lane 4: monomer at 
1.3 µM, lane 5: oligomers at 0.65 µM, lane 6: oligomers at 1.3 µM, lane 7: fibrils at 
0.65 µM, lane 8: fibrils at 1.3 µM, lane 9: tunicamycin (2.5 µg/ml). D) Lane 1: 
untreated, lane 2: oligomer buffer control, lane 3: monomer and fibril buffer control, 
lane 4: monomer at 0.65 µM, lane 5: monomer at 1.3 µM, lane 6: α-helical control at 
0.65 µM, lane 7: oligomers at 0.65 µM, lane 8: oligomers at 1.3 µM, lane 9: fibrils at 






Figure 6.12 ER stress data for CHOP after six hour incubation with recPrP 
isoforms 
Western blot for cell lysates after a six hour incubation with recPrP isoforms. Lane 1: 
untreated, lane 2: oligomer buffer control, lane 3: monomer and fibril buffer control, 
lane 4: monomer at 0.65 µM, lane 5: monomer at 1.3 µM, lane 6: oligomers at 0.65 
µM, lane 7: oligomers at 1.3 µM, lane 8: fibrils at 0.65 µM, lane 9: fibrils at 1.3 µM, 
lane 10: tunicamycin (2.5 µg/ml). CHOP can be seen as a faint band at 27 kDa in 






Figure 6.13 ER stress data for caspase 12 after six hour incubation with 
recPrP isoforms 
A) Bar chart to show the average caspase 12 western blot data for cells treated with 
recPrP isoforms for six hours (for 2 independent experiments with 2 wells of cells in 
each experiment), blots were analysed by image J and normalised to the β-actin 
control. The data is expressed as fold change over the buffer controls (the buffer 
controls would be 1). C+D blots are from the same experiment but different wells of 
cells, B shows an independent experiment (all after 6 hour incubation). B) Lane 1: 
untreated, lane 2: oligomer buffer control, lane 3: monomer and fibril buffer control, 
lane 4: monomer at 0.65 µM, lane 5: monomer at 1.3 µM, lane 6: α-helical control at 
0.65 µM, lane 7: oligomers at 0.65 µM, lane 8: oligomers at 1.3 µM, lane 9: fibrils at 
0.65 µM, lane 10: fibrils at 1.3 µM, lane 11: tunicamycin (2.5 µg/ml). C+D) Lane 1: 
untreated, lane 2: oligomer buffer control, lane 3: monomer and fibril buffer control, 
lane 4: monomer at 0.65 µM, lane 5: monomer at 1.3 µM, lane 6: oligomers at 0.65 
µM, lane 7: oligomers at 1.3 µM, lane 8: fibrils at 0.65 µM, lane 9: fibrils at 1.3 µM, 





Methods for studying pathways and mechanisms associated with cell death often 
involve the use of inhibitors to block specific pathways, or the detection of specific 
markers associated with a cellular pathway (Oslowski and Urano, 2011, Moreno et 
al., 2013, Hetz et al., 2003, Léveillé et al., 2010). In this chapter, when investigating 
the mechanisms associated with recPrP and recAβ induced cell death, I have 
employed the use of both methods. I have used inhibitors to test for apoptosis and 
excitotoxicity induced by the misfolded proteins. Additionally, I have detected the 
presence of activated proteins associated with ER stress. I also probed for the up-
regulation of activated caspase 3 to complement the apoptosis inhibitor data. In all 
of these experiments it was very important to have the correct controls. For the 
inhibitor experiments a positive control was needed, which was recovered by the 
inhibitor. Without this, it would be impossible to know whether the inhibitor was 
effectively blocking the pathway under investigation.  
In this chapter, I have investigated potential pathways which may be involved in 
recPrP or recAβ induced cell death. I found that recPrP oligomers cause apoptosis, 
which is not mediated through excitotoxic mechanisms or ER stress. I have shown 
that recPrP oligomers and fibrils activate different pathways and the mechanisms 
leading to fibril induced cell death are still to be determined. Interestingly, I found 
that recAβ 1-42 oligomers may also induce apoptosis. However, by contrast, this 
could be caused by excitotoxicity. These potential differences are intriguing, and 
may be important when developing therapies which target PMDs.  
Previous studies have shown many pathways to be activated in cells treated with 
misfolded forms of PrP including apoptosis (Simoneau et al., 2007, Novitskaya et al., 
2006), excitotoxicity (Muller et al., 1993, Sassoon et al., 2004, Thellung et al., 2013), 
ER stress(Lindholm et al., 2006, Yoshida, 2007) and autophagy (Wong and Cuervo, 
2010, Heiseke et al., 2010). My data show that primary cells treated with recPrP 
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oligomers were recovered by a caspase inhibitor, indicating apoptotic cell death. By 
contrast, while recPrP fibrils elicited a strong toxic response from the cells and were 
shown to cause some up-regulation of activated caspase 3, fibril treated cells were 
not recovered by a caspase inhibitor. This indicated that the majority of fibril treated 
cells were not dying by apoptosis. These differences between fibril and oligomer 
treated cells may have important implications for the pathology of prion diseases, 
and for targeting certain pathways for therapeutic purposes.  
Relatively few papers have demonstrated that misfolded forms of PrP induce 
excitotoxicity (Muller et al., 1993, Sassoon et al., 2004, Thellung et al., 2013). The 
recPrP treated cells in this study were not recovered by a NMDA receptor 
antagonist, demonstrating that neither the oligomers nor fibrils were inducing 
excitotoxicity. Studies which have found excitotoxicity in PrP treated cells used 
fragments of PrP (Thellung et al., 2013, Sassoon et al., 2004), which may behave 
differently to full length PrP. In addition, one study showed excitotoxicity in cells 
treated with PrPSc (Muller et al., 1993). PrPSc, isolated from hamster brain, was 
incubated with liposomes and it was this PrPSc/ liposome material that was used to 
dose the cells (Muller et al., 1993). No structural information for the PrPSc/ liposome 
mixture is available, which makes it difficult to determine the toxic species and how 
this might stimulate excitotoxicity. Taken together, it is unclear from these studies 
how much of a role excitotoxicity would play in vivo. When undertaking in vitro 
experiments, it is important to remember that the conditions are artificial and, 
therefore, not a direct comparison for prion disease mechanisms in vivo. Evidence 
for excitotoxicity acting as a mechanism of disease in prion diseases, in vivo, is 
tentative (Marandi et al., 2012). Further investigations will be needed to understand 
whether excitotoxicity does play a role in prion related pathology, as it seems to in 
other PMDs (Molinuevo et al., 2005, Esposito et al., 2013, Di et al., 2010, Dong et al., 
2009, Tabrizi et al., 1999, Chiarlone et al., 2014).  
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ER stress is associated with many neurodegenerative conditions with misfolded 
proteins causing the UPR and ERAD systems to be activated (Bukau et al., 2006, 
Voisine et al., 2010, Lindholm et al., 2006, Yoshida, 2007), leading to apoptosis if 
balance is not resumed (Bukau et al., 2006, Voisine et al., 2010, Lindholm et al., 2006, 
Yoshida, 2007). Therefore, I hypothesised that the recPrP oligomers may be causing 
ER stress which was leading to apoptosis. However, I found no significant up-
regulation of ER stress related proteins in cells treated with recPrP oligomers. 
Therefore, in this in vitro system, ER stress was not the mechanism of cell death. For 
ER stress to be activated by misfolded exogenous protein, such as in this in vitro 
system, the recPrP oligomers would have had to be endocytosed and trafficked to 
the ER. I found no evidence for this, since no ER stress proteins were up-regulated. 
This may mean that in vivo, extracellular oligomers may also not be endocytosed, 
however, if oligomers were formed within a cell then this may lead to ER stress. For 
example, PrPCTM as discussed in chapter 5 could oligomerise within a cell and cause 
ER stress. Therefore, in vivo ER stress could be involved in toxicity and disease 
pathology.  
In chapter 5, I discussed the possibility that the oligomers may be causing cell death 
by membrane insertion. It has been shown previously that oligomers can insert into 
phospholipid membranes (Kayed et al., 2004, Demuro et al., 2005), causing 
membrane disruption and affecting the calcium homeostasis of the cell (Demuro et 
al., 2005), which can lead to apoptosis. If the recPrP oligomers in this study are 
causing apoptosis independently of ER stress or excitotoxicity, then it is perhaps 
plausible that the oligomers may be inducing apoptosis through membrane 
insertion. Further study would be needed to explore this pathway.  
 
The toxicity of fibrils in prion diseases and also other PMDs has long been debated 
(Novitskaya et al., 2006, Novitskaya et al., 2007, Simoneau et al., 2007, Kuo et al., 
1996, Naslund et al., 2000, McLean et al., 1999, Mucke et al., 2000a, Walsh et al., 2002, 
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Quist et al., 2005, Kristiansen et al., 2007, Volles et al., 2001, Lue et al., 1999). 
Whether fibrillar plaques are a non-toxic endpoint or a toxic species important in 
disease pathology is yet to be proved. The toxicity data for recPrP fibrils has been 
variable, with some studies showing high levels of toxicity (Novitskaya et al., 2006, 
Novitskaya et al., 2007) while others show them to cause relatively low levels of 
toxicity (Simoneau et al., 2007, Kuo et al., 1996, Naslund et al., 2000, McLean et al., 
1999, Mucke et al., 2000a, Walsh et al., 2002, Quist et al., 2005, Kristiansen et al., 
2007, Volles et al., 2001, Lue et al., 1999). As mentioned in chapter 4, some of the 
variability in toxicity associated with fibrils may be due to the variable structure of 
fibrils and amyloid plaques. Additionally, since fibrils are insoluble their availability 
in vivo to cause toxicity to neurons may be substantially less than soluble oligomers. 
These are important limitations to keep in mind when interpreting in vitro data, 
since in vivo only a subset of neurons would be in close proximity with fibrillar 
plaques. Therefore, other misfolded protein species such as oligomers are likely 
responsible for cell death seen in the wider population of cells. In this study, I was 
not able to identify how the fibrils were causing toxicity. Previous studies have 
shown that autophagy may be involved (Levine and Kroemer, 2008, Martinez-
Vicente and Cuervo, 2007, Wong and Cuervo, 2010, Heiseke et al., 2010), since large 
aggregated proteins cannot pass through the narrow pore of the proteasomal barrel 
making them good candidates for lysosomal degradation (Levine and Kroemer, 
2008). Therefore, the fibrils may be causing cell death by activating lysosomal 
degradation and autophagy. Further work would be required to explore these 
pathways and determine their involvement.  
Aβ oligomers and their involvement in AD is widely accepted (Haass and Selkoe, 
2007, El-Agnaf et al., 2000, Cleary et al., 2005, Texido et al., 2011). Aβ fibrils are 
thought to be relatively non-toxic (Dahlgren et al., 2002, Ahmed et al., 2010, Lesné et 
al., 2008) but potentially act as a reservoir of smaller oligomeric forms of Aβ, which 
can form a halo around the fibrillar plaque (Koffie et al., 2009). Many in vitro studies 
have shown Aβ 1-42 oligomers to be cytotoxic (Manzoni et al., 2011, El-Agnaf et al., 
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2000, Texido et al., 2011). Therefore, it is likely that oligomers play an important role 
in causing neuronal loss during disease. In vivo studies have complemented the in 
vitro work and also show an important role for Aβ oligomers in causing toxicity 
(Walsh et al., 2002, Klyubin et al., 2005, Cleary et al., 2005, Oddo et al., 2006). My 
data show that recAβ 1-42 oligomers caused a significant level of toxicity in primary 
cortical cells. Caspase inhibitor and NMDA receptor antagonist experiments 
showed that this toxicity was likely mediated through excitotoxic induced 
apoptosis, since the cells showed some recovery with both inhibitors. However, as I 
have shown in sections 6.2 and 6.3, in one of the inhibitor recovery experiments the 
recAβ 1-42 oligomers did not cause a significant level of toxicity due to the cells 
being highly confluent. Therefore, in that one experiment there was not a significant 
recovery with the inhibitor or receptor antagonist. This meant that the average 
recovery data was not significant. However, in the other two experiments recovery 
with both inhibitors was seen. Therefore, the data suggests that both apoptosis and 
excitotoxicity are likely activated in cells treated with recAβ 1-42 oligomers, but 
further experiments are needed to confirm this. The mechanism data I have 
presented for recAβ 1-42 oligomers is substantiated by previous work (Yang et al., 
2009, Youssef et al., 2008, Molinuevo et al., 2005, Esposito et al., 2013, Di et al., 2010, 
Dong et al., 2009, Alberdi et al., 2010). Studies have shown that Aβ 1-42 oligomers 
induce both apoptosis and excitotoxicity both in vitro and in vivo (Yang et al., 2009, 
Youssef et al., 2008, Molinuevo et al., 2005, Esposito et al., 2013, Di et al., 2010, Dong 
et al., 2009, Alberdi et al., 2010). These previous findings strengthen the validity of 
my data.  
While there are similarities in potential toxic species between PMDs and, therefore, 
some potential shared mechanisms leading to cell death such as apoptosis, during 
disease it is likely to be a lot more complicated with multiple pathways and 
mechanisms being activated. It is likely that toxicity in these diseases is caused by a 
multitude of toxic misfolded protein species. It is unlikely that oligomers occur as 
one species, and instead are probably a heterogeneous mixture of isoforms that are 
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different sizes and have different abilities to induce toxicity. With this in mind, it is 
plausible that they would stimulate different pathways. In prion disease the 
majority of oligomers may cause apoptosis by membrane insertion, but in some 
instances they may cause ER stress (Lindholm et al., 2006, Yoshida, 2007) or 
autophagy(Levine and Kroemer, 2008, Mizushima et al., 2008, Wong and Cuervo, 
2010, Heiseke et al., 2010). Therefore, it is too simplistic to identify one pathway 
which is causing cell death in PMDs. It is much more likely that an array of 
pathways are activated and lead to cellular toxicity.  
In this study, the oligomers which were formed from recPrP and recAβ likely 
represent one set of oligomeric isoforms that could potentially form during disease. 
Therefore, the pathways that I have shown to be activated would correspond to 
potential pathways that could be important during neurodegeneration. However, 
due to the in vitro conditions in which this study was conducted, it is hard to 
determine the relevance of these findings for disease. Conclusions which can be 
drawn are that if oligomers or fibrils were to occur in disease with structures similar 
to those demonstrated, then they would likely cause cell death by the mechanisms I 




Chapter 7: Conclusions and future directions 




Protein misfolding diseases (PMDs) are thought to be caused by misfolded, 
aggregated proteins which accumulate in the brain. These misfolded proteins can 
exist as small soluble assemblies or large insoluble fibrillar deposits. There is still 
some debate surrounding whether fibrils are involved in causing toxicity in these 
diseases(Soto, 2003, Ross and Poirier, 2004, Dobson, 2003, Haass and Selkoe, 2007, 
Treusch et al., 2009), or whether they may be protective (Haass and Selkoe, 2007, 
Treusch et al., 2009). However, there is a general consensus that smaller assemblies 
of misfolded proteins, such as oligomers or protofibrils, are more toxic than fibrils 
and, consequently, more important in disease (Kuo et al., 1996, Lue et al., 1999, 
Naslund et al., 2000, McLean et al., 1999, Mucke et al., 2000a, Walsh et al., 2002, 
Quist et al., 2005, Kristiansen et al., 2007, Simoneau et al., 2007, Volles et al., 2001). 
Therefore, it is possible there may be a common pathological protein species which 
underpins multiple PMDs.  
Although similarities between PrP and Aβ have been previously demonstrated, 
their toxicity and mechanisms of their pathogenicity have not previously been 
compared. PrPSc is known to spread and replicate by a templating process, 
converting normal PrPC to PrPSc (Collinge and Clarke, 2007). It has now been shown 
that Aβ behaves in a similar manner during disease (Jucker and Walker, 2011). Aβ 
injected into the brains of transgenic APP mice, which overexpress the amyloid 
precursor protein, spreads to other axonally connected areas of the brain in a 
manner reminiscent of PrPSc (Jucker and Walker, 2011, Walker et al., 2002). 
Interestingly, it has also been shown that intraperitoneal (IP) injection of Aβ can 
cause Aβ pathology in the brains of transgenic mice after a prolonged incubation 
(Eisele et al., 2010). This is very similar to how PrPSc behaves after peripheral 
inoculation, through IP, subcutaneous, or intravenous injection (Eklund et al., 1967, 
Kimberlin and Walker, 1979). Additionally, oligomers of the two proteins are 
thought be important in causing toxicity during disease. Therefore, this led to the 
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hypothesis that these two proteins may be eliciting cell death by the same 
mechanisms.  
In this thesis I have demonstrated the production of two disease associated proteins 
and their subsequent misfolding into disease associated conformations. These 
misfolded isoforms were extensively characterised before toxicity experiments were 
carried out using primary cortical cells. The toxicity of the different misfolded 
protein species were robustly analysed and compared. The mechanisms underlying 
the toxicity caused by these misfolded proteins were then investigated. 
Additionally, I have shown that the oxidative state of recPrP, whether it has an 
intact disulphide bond, is crucially important in determining the size of oligomers 
which will form and how this impacts on toxicity. This work has built upon the 
existing body of research which has investigated the molecular mechanisms 
underlying PMDs.  
Previous studies that have sought to investigate the mechanisms underlying PMDs 
have often analysed the toxicity and associated mechanisms of partially-
uncharacterised misfolded proteins (Alberdi et al., 2010, El-Agnaf et al., 2000, Li et 
al., 2011, Rammes et al., 2011, Muller et al., 1993). This has made it difficult to link 
specific protein species with toxicity and define the mechanisms which lead to cell 
death in these diseases. To address these limitations, I have produced misfolded 
protein species for both recPrP and recAβ and extensively characterised them prior 
to any toxicity experiments. By producing well characterised misfolded protein 
species, it is possible to have confidence in the resulting experimental data and this 
allows us to directly correlate specific protein species with toxicity.  
I have shown that while oligomers of recPrP and recAβ are both toxic to murine 
cortical cells, there are distinct differences in the toxicity of the fibrils composed of 
each protein. The data in chapter 4 shows that recPrP fibrils are not only 
significantly more toxic than recPrP oligomers, they are also significantly more toxic 
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than all of the recAβ isoforms. By contrast, the recAβ fibrils do not cause significant 
toxicity to the cells. These differences may be due to the structure of the fibrils 
formed in vitro, the differences in toxicity caused by these fibrils could be an artefact 
of the fact they were formed in the laboratory under artificial conditions. However, I 
do not believe this is the case, since the fibrils I have formed in vitro have properties 
similar to those found in disease. These include an amyloid structure as shown by 
Congo red staining, resistance to PK digestion and they bind to thioflavin T. 
Therefore, the differences in toxicity may instead indicate that PrP fibrils are toxic 
and important in the pathology of prion disease. The size distribution of PrP fibrils 
in vivo is not well studied, making it difficult to compare to the proteins produced in 
vitro, but it is thought that PrPSc exists as a heterogeneous mixture of sizes (Silveira 
et al., 2005, Prusiner et al., 1983). These likely range from hundreds to thousands of 
PrP molecules (Silveira et al., 2005, Prusiner et al., 1983). The toxicity I have shown 
for the recAβ fibrils fits with the general consensus that fibrils are not toxic and may 
be protective; sequestering small toxic oligomers into a less toxic form. The size of 
Aβ fibrils in disease are not well defined, but seem to be very heterogeneous and 
vary from small protofibrils up to large plaques ranging in size from 100- 1500 µm2 
(Hyman et al., 1995).  
Furthermore, at higher concentrations, the recPrP oligomers are significantly more 
toxic than the recAβ oligomers. If this were the case in vivo, then it is possible that 
these differences in toxicity may impact on how quickly neurons are killed and, 
therefore, how quickly the disease progresses. It is possible that this could explain 
why prion diseases have a much shorter clinical phase than AD. These data suggest 
that there may be significant differences in which protein species are important in 
different PMDs.  
Previous studies have highlighted a variety of pathways and mechanisms which 
may be activated by misfolded proteins (Elmore, 2007, Lindholm et al., 2006, 
Martinez-Vicente and Cuervo, 2007, Youssef et al., 2008). However, in many of these 
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studies the misfolded proteins were not characterised prior to investigating toxicity 
and associated mechanisms (Elmore, 2007, Lindholm et al., 2006, Martinez-Vicente 
and Cuervo, 2007, Youssef et al., 2008). Therefore, it is difficult to interpret the 
resulting data and to correlate specific protein species with particular mechanisms 
of toxicity. In this study, I sought to address many of these issues by producing and 
characterising misfolded forms of recPrP and recAβ before investigating their 
toxicity and associated mechanisms. Previous studies have indicated many 
pathways that may be involved in cell death associated with misfolded proteins 
including apoptosis, excitotoxicity, ER stress, autophagy and oxidative stress 
(Elmore, 2007, Hickey and Chesselet, 2003, Shimohama, 2000, Rohn, 2010, Jesionek-
Kupnicka et al., 1997, Dong et al., 2009, Li et al., 2009, Alberdi et al., 2010, Li et al., 
2011, Rammes et al., 2011, Rönicke et al., 2011, Lindholm et al., 2006, Yoshida, 2007, 
Mizushima et al., 2008, Martinez-Vicente and Cuervo, 2007, Nakamura and Lipton, 
2010, Youssef et al., 2008). My data indicates that recPrP oligomers cause apoptosis 
and recAβ oligomers may cause apoptosis but more repeats are needed to confirm 
this. These findings are supported by many studies that have shown apoptosis to be 
important in these diseases (Elmore, 2007, Hickey and Chesselet, 2003, Shimohama, 
2000, Rohn, 2010, Jesionek-Kupnicka et al., 1997, Youssef et al., 2008, Yang et al., 
2009, Novitskaya et al., 2006, Simoneau et al., 2007). However, the data in chapter 6 
indicates that recPrP oligomers are not inducing apoptosis through an excitotoxic 
pathway, therefore, they must be causing apoptosis through an independent and, as 
yet, undefined pathway. The recAβ oligomer data suggested that the oligomers may 
be causing excitotoxicity but, like the apoptosis data, more repeats are needed to 
confirm this. If this was found to be the case, then this would suggest that recPrP 
and recAβ oligomers potentially activate different pathways. These findings may 
further highlight that recAβ and recPrP oligomers have different structures, which 
not only confer different abilities to cause toxicity but also potentially affect how 
they interact with the cells, activating different pathways. These differences may be 
fundamental to understanding the pathogenesis of PMDs, and how assemblies of 
different proteins may cause toxicity by activating different mechanisms.  
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At the highest concentration tested, recPrP oligomers were found to be significantly 
more toxic than recAβ oligomers this may be due to differences in the structure of 
these protein assemblies. However, as I demonstrated in chapter 5, there is 
considerable variation in the structure and size of oligomers which can form from 
recPrP. These differences were shown to be caused by the presence or absence of the 
disulphide bond, with disulphide-reduced recPrP forming larger oligomers than 
those formed from oxidised recPrP (with an intact disulphide bond). The 
disulphide-reduced recPrP oligomers were also significantly more toxic than 
oligomers formed from oxidised recPrP. It is possible that other post-translational 
modifications could also affect the structure and toxicity of recPrP oligomers. This 
adds another layer of complexity, since it means that during disease the oligomers 
formed from PrP may vary considerably in their structure and toxicity.  
Aβ fibrillises more readily than PrP, therefore, Aβ oligomers may be more transient 
than PrP oligomers. However, Aβ does vary in its length, according to where the γ-
secretase complex cleaves the APP, which affects its readiness to fibrillise. I found 
that recAβ 1-40 oligomers were not toxic; only the recAβ 1-42 oligomers elicited a 
toxic response from the cells. The ratio of the different forms of Aβ varies in the 
brain, with Aβ 1-42 found at lower concentrations than Aβ 1-40, although it is often 
upregulated in LOAD and in certain types of FAD (Thinakaran and Koo, 2008, 
Hansson et al., 2007). The lower concentration of the toxic Aβ 1-42 form may impact 
on how long it takes for harmful oligomers to cause cell death and may suggest why 
AD has such a long clinical phase.  
As previously suggested, the extreme toxic effect of the recPrP fibrils may be due to 
the structure of the fibrils formed from this method (Breydo et al., 2008), or it may 
be that fibrils formed from different proteins may have different abilities to cause 
toxicity. However, whilst in some cases fibrils may be toxic, the large insoluble 
plaques seen in many PMDs are insoluble and, therefore, not able to diffuse 
throughout the brain in the same way as oligomers or soluble protofibrils. This 
209 
 
would mean that only cells within the vicinity of a fibrillar plaque would likely be 
damaged. In AD it has been suggested that fibrils can act as a reservoir of small 
soluble oligomers and that oligomers can form a halo around a plaque (Koffie et al., 
2009). This would likely be more of a chronic effect caused by fibrils which would 
not be detected during a 24 hour incubation period with the cells. Further 
experiments with longer incubation periods, which could assess more chronic 
damage, may be useful in investigating this. Therefore, while I have demonstrated 
that recPrP fibrils elicit a very strong toxic response in vitro, it is still difficult to 
determine how important fibrils are in causing cell death in disease.  
In this study, I have sought to investigate how the structure and conformation of the 
PrP and Aβ proteins are related to toxicity, and the subsequent mechanisms that 
lead to cell death. To do this an in vitro approach was needed, since this allows 
controlled misfolding and extensive characterisation of the proteins. Toxicity can 
then be tested in a controlled manner eliminating many other variables, which 
allows direct links to be made between protein conformation and toxicity. However, 
while an in vitro approach allows these direct links to be made between 
conformation and toxicity, there are several limitations to this type of experimental 
approach. 
Firstly, producing proteins recombinantly in bacteria has limitations which may 
affect the ability to extrapolate results to native proteins. Proteins which are 
produced in bacteria may not have the same post-translational modifications as 
those produced natively in mammalian cells, for example, recPrP lacks the N-
terminal signal peptide which is present in native PrP (murine recPrP starts at 
residue 23 leaving out the signal peptide residues). This signal peptide is necessary 
for the translocation of the protein into the ER prior to secretion into the cellular 
membrane, therefore, this effect may not impact my study since I did not address 
the cellular processing of PrP.  However, as discussed in chapter 5, it is possible that 
PrP may misfold spontaneously before entering the ER, preventing the signal 
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peptide from being cleaved. In this case, the conformation of the resultant oligomers 
or fibrils could be affected by the presence of the signal peptide. Therefore, the 
conformation of oligomers and fibrils produced from recombinant PrP may not be 
the same as those containing the signal peptide.  
Furthermore, there are limitations to testing the toxicity of proteins by incubating 
cells with exogenously added conformations. The main criticism of this type of 
study is that it is not representative of real physiological conditions or that there 
may be some kind of toxic response caused by adding any exogenous protein to 
cells. While these points are valid, it is possible to try and control for some of these 
variables by using control proteins such as α- helical recPrP. If the control protein 
causes no toxicity at the same concentration as the misfolded proteins, then the 
toxicity seen in the cells treated with misfolded proteins is likely conformation 
specific. This type of study will never be as physiologically relevant as an in vivo 
study, however, by using primary cells the biological model is as close to cells in 
vivo as possible.  
Other approaches such as transfecting mammalian cells with plasmids encoding 
specific protein fragments, which are more likely to form oligomers or fibrils, may 
be useful. Toxicity can then be monitored in the transfected cells. However, this also 
has limitations since it is difficult to control the amount of misfolded protein 
produced in the cells, or how this is processed or degraded. It would also be 
difficult to analyse the conformation of the proteins which were produced in the 
cells, making it harder to directly link conformation with toxicity. 
Using animal models is another valuable approach. Transgenic animals which 
overexpress a protein, or animals which are injected with misfolded protein such as 
PrPSc, can be used to investigate neurodegeneration and various aspects of the 
disease process. However, as I have mentioned in previous chapters, in vivo animal 
experiments make it very difficult to directly link protein conformation and toxicity. 
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Studies using animal models can cull the animals at set time points (pre-
symptomatic, symptomatic etc.) and then analyse pathology, protein deposition etc. 
however, if pathological changes have already occurred it is hard to define which 
protein species may be important in causing toxicity. 
Natural disease models also have advantages and disadvantages, patients with 
PMDs or animals with natural scrapie, BSE etc. present an opportunity to study the 
disease process is in its most natural form. However, even with more advanced 
imaging techniques, which are now available, tissue from patients is not available 
until post-mortem. This means that the disease has already run its course, and 
makes it impossible to understand the disease mechanisms which occurred prior to 
cell death. There are still limitations even with animals with naturally occurring 
disease. While the animal can be culled and tissues taken as soon as symptoms are 
observed, it may still be too late to investigate how misfolded protein species are 
causing cell death since once the onset of symptoms has occurred, cellular toxicity 
and pathological changes in the brain have already started to happen. 
In light of this, it is likely that both in vivo and in vitro studies will be needed to fully 
elucidate the disease processes in PMDs. In vivo studies are needed to investigate 
the more complex chronic effects of neurodegeneration caused by the presence 
misfolded proteins, whilst in vitro studies allow us to directly investigate the toxicity 
of certain protein conformations. If the data from both types of studies are 
combined, then this will give us a better understanding of these diseases.   
There are limitations to all of these experimental approaches. In this study, I set out 
to try and understand how the conformation of a misfolded protein can affect 
toxicity and to try and compare the toxicity of different disease associated proteins. 
Therefore, I think the in vitro model which I have used, whilst it has limitations, was 
the most appropriate approach for the questions I wanted to investigate.   
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7.2 Possible future directions 
The are many areas of this thesis which could be developed and explored further, to 
possibly lead to a more complete picture of the mechanisms underlying 
neurodegeneration in AD and prion disease. Potential areas to investigate further 
would include: 
Further investigations of how the recPrP oligomers are causing apoptosis, since they 
were shown to cause apoptosis by a pathway independent of ER stress and 
excitotoxicity. A potential candidate could be membrane insertion. Further 
experiments could include fluorescently tagging the recPrP oligomers and 
investigating how the oligomers interact with the cells by confocal microscopy. This 
may show whether the oligomers are inserting into the cell membrane. 
Furthermore, experiments could be carried out to investigate whether the 
membrane potential of the cells is affected by the oligomers.  
Whilst my data suggest that recAβ oligomers are causing both apoptosis and 
excitotoxicity, more repeats are needed in order to confirm this observation. Further 
repeats are needed for both the caspase inhibitor and NMDA receptor antagonist 
experiments, in order to see if the recovery of cells treated with recAβ oligomers 
and the inhibitors is significant. If the caspase inhibitor and NMDA receptor 
antagonist data was confirmed for the recAβ oligomers, then it would be interesting 
to explore these pathways further. How the oligomers are interacting with the cells 
and causing excitotoxicity could be investigated. Firstly it would be important to 
understand if the recAβ oligomers are endocytosed. If they are taken up by the cell 
then it would be interesting to see how this may be mediated. Furthermore, it 
would be important to understand if the recAβ oligomers cause excitotoxicity 
directly by interacting with the NMDA receptors or if they instigate a cascade which 
indirectly causes excitotoxicity. 
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The recAβ fibrils did not cause toxicity to the cells over a 24 hour incubation period. 
It would be interesting to investigate more chronic effects which the fibrils may 
cause by incubating the fibrils with the cells for longer incubation periods. Previous 
studies have demonstrated that Aβ fibrils can be a reservoir for Aβ oligomers 
suggesting that the fibrils might cause toxicity if the incubation time was longer.  
Further investigations could be carried out to look at how the recAβ monomer 
fibrillises in the cell culture media. I demonstrated in chapter 4 that the recAβ 
monomer fibrillises in a concentration and time dependent manner in cell culture 
media. It would be valuable to understand the process that the recAβ monomer 
goes through to become a fibril. Different time points could be taken during the 24 
hour period in which the fibrillisation takes place and experiments could be done to 
assess the size of the assemblies which have formed. This could be done using DLS 
and native gels. This may help us understand the process of plaque formation in AD 
and how smaller assemblies which are more toxic can form.  
Additionally, it would be important to try and elucidate how the recPrP fibrils are 
causing toxicity. Pathways which may potentially be involved include autophagy 
and oxidative stress. To fully understand the importance of the different misfolded 
PrP species in disease, it would be important to reveal how the fibrils cause toxicity.  
Furthermore, it would be interesting to try and determine the physiological 
relevance of the data I have presented. One approach would be to purify PrPSc 
oligomers and fibrils from infected tissue, and test their toxicity using the same 
primary cell culture model I have used in this study. This would identify what the 
toxic species of PrPSc are, and show if they are the same as for misfolded recPrP. 
The work I have presented concerning the importance of the disulphide bond in 
oligomerisation and toxicity could be developed further. Transgenic mice could be 
engineered, which have PrP with no disulphide bond (one of the cysteine residues 
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could be mutated to a methionine). The mice could then be analysed for any build-
up of oligomeric protein, reduction in lifespan and potentially the development of 
any neurological disease. 
In this study, I have investigated the toxicity and associated mechanisms of 
misfolded forms of recPrP and recAβ. It would be interesting to explore this further 
with other disease associated proteins such as α-synuclein, associated with 
Parkinson’s, or huntingtin, associated with Huntington’s disease. This would 
provide a more comprehensive picture of whether there are common toxic species 
between PMDs and if they activate the same pathways.  
In conclusion, I have shown that both recPrP and recAβ oligomers cause toxicity but 
potentially by activating independent pathways. Additionally, I have demonstrated 
differences in the toxicity of fibrils formed from recPrP and recAβ. I have also 
shown that the presence or absence of the disulphide-bond in recPrP is critically 
important in determining the size of oligomers which will form and their toxicity. 
This demonstrates how important post-translational modifications can be in 
modifying the misfolding of a protein and how this may have important 
implications during disease. The differences I have presented between these two 
important disease associated proteins may indicate that the molecular mechanisms 
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Supplementary figure 1 RecPrP purification 
 
A+B) recPrP purification. A) Reverse phase chromatogram for recPrP purification, 
eluting peaks show separation of different oxidised forms of recPrP. B) SDS-PAGE 
with coomassie staining of the fractions collected from A. Lanes 9-14 correspond 
with the eluting peaks from A.  
 
